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ABSTRACT
Background
Hyperemesis gravidarum is a severe form of nausea and vomiting in pregnancy affecting 0.3% to 1.0% of pregnancies, and is one of the
most common indications for hospitalization during pregnancy. While a previous Cochrane review examined interventions for nausea
and vomiting in pregnancy, there has not yet been a review examining the interventions for the more severe condition of hyperemesis
gravidarum.
Objectives
To assess the effectiveness and safety, of all interventions for hyperemesis gravidarum in pregnancy up to 20 weeks’ gestation.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register and the Cochrane Complementary Medicine Field’s Trials
Register (20 December 2015) and reference lists of retrieved studies.
Selection criteria
Randomized controlled trials of any intervention for hyperemesis gravidarum. Quasi-randomized trials and trials using a cross-over
design were not eligible for inclusion.
We excluded trials on nausea and vomiting of pregnancy that were not specifically studying the more severe condition of hyperemesis
gravidarum.
Data collection and analysis
Two review authors independently reviewed the eligibility of trials, extracted data and evaluated the risk of bias. Data were checked for
accuracy.
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Main results
Twenty-five trials (involving 2052 women) met the inclusion criteria but the majority of 18 different comparisons described in the
review include data from single studies with small numbers of participants. The comparisons covered a range of interventions including
acupressure/acupuncture, outpatient care, intravenous fluids, and various pharmaceutical interventions. The methodological quality
of included studies was mixed. For selected important comparisons and outcomes, we graded the quality of the evidence and created
’Summary of findings’ tables. For most outcomes the evidence was graded as low or very low quality mainly due to the imprecision
of effect estimates. Comparisons included in the ’Summary of findings’ tables are described below, the remaining comparisons are
described in detail in the main text.
No primary outcome data were available when acupuncture was compared with placebo, There was no clear evidence of differences
between groups for anxiodepressive symptoms (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.73 to 1.40; one study, 36 women,
very low-quality evidence), spontaneous abortion (RR 0.48, 95% CI 0.05 to 5.03; one study, 57 women, low-quality evidence), preterm
birth (RR 0.12, 95% CI 0.01 to 2.26; one study, 36 women, low-quality evidence), or perinatal death (RR 0.57, 95% CI 0.04 to 8.30;
one study, 36 women, low-quality evidence).
There was insufficient evidence to identify clear differences between acupuncture and metoclopramide in a study with 81 participants
regarding reduction/cessation in nausea or vomiting (RR 1.40, 95% CI 0.79 to 2.49 and RR 1.51, 95% CI 0.92 to 2.48, respectively;
very low-quality evidence).
In a study with 92 participants, women taking vitamin B6 had a slightly longer hospital stay compared with placebo (mean difference
(MD) 0.80 days, 95% CI 0.08 to 1.52, moderate-quality evidence). There was insufficient evidence to demonstrate a difference in other
outcomes including mean number of episodes of emesis (MD 0.50, 95% CI -0.40 to 1.40, low-quality evidence) or side effects.
A comparison between metoclopramide and ondansetron identified no clear difference in the severity of nausea or vomiting (MD 1.70,
95% CI -0.15 to 3.55, and MD -0.10, 95% CI -1.63 to 1.43; one study, 83 women, respectively, very low-quality evidence). However,
more women taking metoclopramide complained of drowsiness and dry mouth (RR 2.40, 95% CI 1.23 to 4.69, and RR 2.38, 95%
CI 1.10 to 5.11, respectively; moderate-quality evidence). There were no clear differences between groups for other side effects.
In a single study with 146 participants comparing metoclopramide with promethazine, more women taking promethazine reported
drowsiness, dizziness, and dystonia (RR 0.70, 95% CI 0.56 to 0.87, RR 0.48, 95% CI 0.34 to 0.69, and RR 0.31, 95% CI 0.11 to
0.90, respectively, moderate-quality evidence). There were no clear differences between groups for other important outcomes including
quality of life and other side effects.
In a single trial with 30 women, those receiving ondansetron had no difference in duration of hospital admission compared to those
receiving promethazine (MD 0.00, 95% CI -1.39 to 1.39, very low-quality evidence), although there was increased sedation with
promethazine (RR 0.06, 95% CI 0.00 to 0.94, low-quality evidence) .
Regarding corticosteroids, in a study with 110 participants there was no difference in days of hospital admission compared to placebo
(MD -0.30, 95% CI -0.70 to 0.10; very low-quality evidence), but there was a decreased readmission rate (RR 0.69, 95% CI 0.50 to
0.94; four studies, 269 women). For other important outcomes including pregnancy complications, spontaneous abortion, stillbirth
and congenital abnormalities, there was insufficient evidence to identify differences between groups (very low-quality evidence for all
outcomes). In other single studies there were no clear differences between groups for preterm birth or side effects (very low-quality
evidence).
For hydrocortisone compared with metoclopramide, no data were available for primary outcomes and there was no difference in the
readmission rate (RR 0.08, 95% CI 0.00 to 1.28;one study, 40 women).
In a study with 80 women, compared to promethazine, those receiving prednisolone had increased nausea at 48 hours (RR 2.00, 95%
CI 1.08 to 3.72; low-quality evidence), but not at 17 days (RR 0.81, 95% CI 0.58 to 1.15, very low-quality evidence). There was no
clear difference in the number of episodes of emesis or subjective improvement in nausea/vomiting. There was insufficient evidence to
identify differences between groups for stillbirth and neonatal death and preterm birth.
Authors’ conclusions
On the basis of this review, there is little high-quality and consistent evidence supporting any one intervention, which should be taken
into account when making management decisions. There was also very limited reporting on the economic impact of hyperemesis
gravidarum and the impact that interventions may have.
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The limitations in interpreting the results of the included studies highlights the importance of consistency in the definition of hyperemesis
gravidarum, the use of validated outcome measures, and the need for larger placebo-controlled trials.

PLAIN LANGUAGE SUMMARY
Interventions for treating severe nausea and vomiting during pregnancy (hyperemesis gravidarum)
What is the issue and why is it important?
Although severe nausea and vomiting in pregnancy (hyperemesis gravidarum) rarely causes death, it is an important cause of ill
health with emotional, physical, and economic consequences. Women may need hospital treatment and may not be able to work
and it occasionally causes pregnancy complications and adverse outcomes for babies such as low birthweight. Many pharmaceutical,
complementary, and alternative therapies are available and the objective of this review was to examine the effectiveness and safety of
interventions for hyperemesis gravidarum.
What evidence did we find?
Twenty-five trials (involving 2052 women) were included examining 18 different comparisons covering a range of interventions
including acupressure/acupuncture, outpatient care, intravenous fluids, and various commonly used anti-sickness drugs. The quality
of included studies was mixed and for most outcomes findings were from single studies with low numbers of women taking part and
the evidence was assessed as being of low or very low quality. We have described findings for selected important comparisons below,
the remaining comparisons are described in detail in the main text.
There was no clear evidence of differences between acupuncture and placebo for symptoms of anxiety or depression, spontaneous
abortion, preterm birth or perinatal death.
There was insufficient evidence to identify clear differences between acupuncture and metoclopramide (an anti-nausea medication) for
reduction or cessation in nausea or vomiting.
Women taking vitamin B6 had a slightly longer hospital stay compared with placebo but there was no clear evidence of differences in
other outcomes including the average number of episodes of vomiting, hospital readmission rate, or side effects.
A comparison between two anti-nausea medications, metoclopramide and ondansetron, identified no clear difference in the severity
of nausea or vomiting, but more women taking metoclopramide complained of drowsiness and dry mouth. In a study comparing
metoclopramide with promethazine, more women taking promethazine reported drowsiness and dizziness but there were no clear
differences between groups for other important outcomes including quality of life and other side effects. In a study looking at ondansetron
versus promethazine women spent similar lengths of time in hospital but there was increased sedation with promethazine.
Regarding corticosteroids, there was no difference in days of hospital admission compared to placebo, but there was a decreased
readmission rate. For other important outcomes including pregnancy complications, spontaneous abortion, stillbirth and congenital
abnormalities, preterm birth and side effects, there was insufficient evidence to identify differences between groups.
In a study comparing hydrocortisone (a corticosteroid) with metoclopramide, no data were available for primary outcomes, but there
was no difference in hospital readmission rate.
In a study comparing promethazine and prednisolone (a corticosteroid) those receiving prednisolone had increased nausea at 48 hours
but not at 17 days. There was no clear difference in the number of episodes of vomiting. There was insufficient evidence to identify
differences between groups for stillbirth and neonatal death and preterm birth
What does this mean?
Given that there was little evidence to support the superiority of one intervention over another in the treatment of hyperemesis, larger
controlled trials are needed on these therapies. More research should be done comparing the side effects and safety, as well as the
economic costs and benefits of these interventions to aid in the selection of the optimal treatment.
Reporting on adverse maternal and infant outcomes was limited and we did not find any studies on dietary or other lifestyle interventions.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]

Acupuncture versus placebo
[Note: This table relates to the first comparison described in the abstract rather than the ’main’ or most important comparison presented in the review]
Patient or population: pregnant wom en with hyperem esis gravidarum
Setting: Studies in Croatia (1) and UK (1)
Intervention: Acupuncture and acupressure
Comparison: Placebo
Outcomes

Anticipated absolute effects∗ (95% CI)

Risk with placebo

Quality of lif e: anxiode- Study population
pressive sym ptom atol800 per 1000
ogy

Spontaneous abortion

Preterm birth less than Study population
37 weeks
154 per 1000

Stillbirth and neonatal Study population
death
77 per 1000

of participants
(studies)

Quality of the evidence Comments
(GRADE)

RR 1.01
(0.73 to 1.40)

36
(1 RCT)

⊕
VERY LOW 12

Absolute ef f ects calculated f rom results of
single study.

RR 0.48
(0.05 to 5.03)

57
(1 RCT)

⊕⊕
LOW 3

Absolute ef f ects calculated f rom results of
single study.

RR 0.12
(0.01 to 2.26)

36
(1 RCT)

⊕⊕
LOW 3

Absolute ef f ects calculated f rom results of
single study.

RR 0.57
(0.04 to 8.30)

36
(1 RCT)

⊕⊕
LOW 3

Absolute ef f ects calculated f rom results of
single study.

Risk with Acupuncture
and acupressure

808 per 1000
(584 to 1000)

Study population
71 per 1000

Relative effect
(95% CI)

34 per 1000
(4 to 359)

18 per 1000
(2 to 348)

44 per 1000
(3 to 638)

4

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1. Severity, reduction Not reported
or cessation in nausea/
vom iting
2. Num ber of episodes
of em esis
3. Days of hospital adm ission
4. Intervention side ef f ects

Not estim able

Studies included in this
com parison did not report these review outcom es

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1

Single study with design lim itations contributing data
Sm all sam ple size and wide 95% CIs crossing the line of no ef f ect
3 Sm all sam ple size, low event rate and wide 95% CIs crossing the line of no ef f ect
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BACKGROUND

Description of the condition
While nausea and vomiting in early pregnancy are very common,
affecting approximately 80% of pregnancies, hyperemesis gravidarum is a severe form affecting 0.3% to 1.0% of pregnancies
(Gadsby 1993; Niebyl 2010). The definition of hyperemesis gravidarum varies but generally includes intractable nausea/vomiting,
signs of dehydration such as ketonuria, high urine specific gravity, electrolyte imbalances, and weight loss of at least 5% of prepregnancy weight, excluding other diagnoses (ACOG 2004; Mella
2011). The onset is generally in the first trimester at six to eight
weeks, peaking by 12 weeks, with most women having resolution
of symptoms by 20 weeks’ gestation (Jarvis 2011). The lack of
standard criteria has implications for inclusion criteria and outcome measurements of controlled studies. For example, requirement of at least 5% weight loss is not always used as an inclusion
criteria in studies of interventions for hyperemesis gravidarum,
but one study found that the efficacy of corticosteroids may vary
depending on this criterion (Moran 2002).
It is important to exclude other causes of severe nausea and vomiting before arriving at the diagnosis of hyperemesis gravidarum.
Other causes include gastrointestinal (GI) etiologies such as infection, gastritis, cholecystitis, hepatitis, appendicitis, and pancreatitis. Neurological causes include migraines or other central nervous
system diseases. Genitourinary etiologies include urinary tract infection/pyelonephritis. Metabolic or endocrine disturbances include hypercalcemia, Addisons’s disease, thyrotoxicosis. Psychological disorders include the spectrum of eating disorders. Finally,
other pregnancy-associated conditions such as molar pregnancy
must also be excluded (Ismail 2007; Mella 2011).
The epidemiology of hyperemesis gravidarum is generally young
women, primiparous, non-smokers, and non-Caucasian (Bailit
2005; Klebanoff 1985; Niebyl 2010). Other risk factors include
prior history of hyperemesis, pre-existing diabetes, hyperthyroid
disorder, depression or psychiatric illness, asthma, and GI disorders (Fell 2006). Fetal abnormalities such as triploidy and hydrops
have also been associated with hyperemesis (Kelly 2009). The etiology of hyperemesis gravidarum is poorly understood, although
it is generally thought to be associated with hormonal changes associated with pregnancy. Postulated mechanisms include human
chorionic gonadotropin stimulating secretory processes in the upper GI tract and/or stimulation of the thyroid stimulating hormone receptor. Estrogen levels have also been positively associated with nausea and vomiting in pregnancy, perhaps through delayed GI motility and gastric emptying. Physiological stimulation
of the thyroid gland in early pregnancy causes a transient thyrotoxicosis that may lead to hyperemesis. Several studies have found
a significant increase in Helicobacter pylori (H. pylori) infection
among women with hyperemesis, although whether this is a cause,

risk factor, or consequence of hyperemesis is not well established
(Ismail 2007; Kelly 2009).
Hyperemesis gravidarum has both maternal and fetal complications. Although hyperemesis gravidarum is rarely a source of mortality, it is a significant source of morbidity. It is the most common
indication for hospitalization in early pregnancy, and the second
most common indication for hospitalization in pregnancy (ACOG
2004). Malnutrition and vitamin deficiencies may lead to anemia
and peripheral neuropathies, or more serious, but rare, complications such as Wernicke’s encephalopathy and central pontine
myelinolysis. Prolonged vomiting may lead to esophageal trauma
such as Mallory-Weiss tears. Nausea and vomiting in early pregnancy are associated with psychiatric morbidity. Although a causal
relationship is uncertain, the severity of nausea and vomiting has
been correlated with somatic symptoms, social dysfunction, anxiety, insomnia, and severe depression (Ismail 2007; Kramer 2013;
Mella 2011; Swallow 2004). There may also be significant psychosocial morbidity associated with hyperemesis. Multiple studies have demonstrated an association with decreased psychosocial
well-being, depression, and anxiety (ACOG 2004; Munch 2011;
Poursharif 2008). The physical and psychological/social burden
of hyperemesis gravidarum has also been associated with termination of pregnancy (ACOG 2004; Poursharif 2007). Fetal complications include preterm birth (delivery less than 37 weeks’ gestation), low birthweight (generally less than 2.5 kg), and small-forgestational age (less than the 10th percentile of expected weight for
gestational age). There does not appear to be an increased risk of
spontaneous abortion (usually defined as less than 20 weeks), stillbirth (death of a fetus >= 20 weeks’ gestation or greater than 500
g), or neonatal death (death of a baby born live within 28 days of
birth) (Bailit 2005; Dodds 2006). The socioeconomic costs of hyperemesis are also significant, stemming from individual expense
in paying for treatment, lost job productivity from time off work,
and high healthcare costs related to provision of services and hospital admissions. One study found that the cost of hyperemesis was
about $200,000,000 (USD) per year for the United States (Bailit
2005). Studies in Canada have estimated that severe nausea and
vomiting in pregnancy result in as many as 14 hospitalizations/
1000 births, and has a cost of $653/woman/week (CAD) (Neutel
2000; Piwko 2007).

Description of the interventions and how they
might work
A range of interventions are commonly used for the treatment
of hyperemesis gravidarum. These include dietary and lifestyle
modifications, complementary therapies (i.e. acupuncture, herbal
remedies), pharmaceutical therapies including a variety of classes
of antiemetics and corticosteroids, and enteral/parenteral nutrition. The goals of therapy are generally to reduce nausea and vomiting, minimize hospitalization, prevent progression of symptom
severity, and improve quality of life. Prior studies examining in-
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tervention efficacy have used subjective measures of nausea/vomiting such as visual analogue scales (Sullivan 1996; Tan 2009) and
the Rhodes Index of Nausea, Vomiting, and Retching (Rhodes
1984; Rhodes 1999; Rosen 2003; Shin 2007), quantitative measures such as days of hospital admission and readmission rates,
and quality of life measures such as the General Health Questionnaire (Swallow 2004), and the Edinburgh Postpartum Depression
Screen (Bown 2008; Cox 1987; Kramer 2013). Secondary outcomes often include adverse maternal and fetal outcomes. It can be
difficult to extrapolate safety data from trials designed to examine
efficacy because they may not be powered to detect such outcomes,
and it is difficult to determine whether certain outcomes, such as
preterm delivery, are related to the intervention or the condition
of hyperemesis. However, given that some adverse outcomes, such
as congenital abnormalities, are not associated with hyperemesis,
data on some specific outcomes may be used to draw conclusions
on safety.

Non-pharmacological interventions

Dietary and lifestyle modifications

Dietary modifications include recommendations to have small and
frequent meals, avoid spicy or fatty foods, and drink fluids regularly. Lifestyle modifications include avoiding noxious sensory
stimuli, eating crackers in the morning after waking, and increasing rest. Although these are common recommendations, there are
few published studies evaluating the efficacy of these changes for
prevention or treatment of nausea/vomiting of pregnancy (ACOG
2004; Arsenault 2002; Matthews 2015).

Complementary therapies

There are a number of non-pharmacological therapies that have
been used for the treatment of nausea and vomiting in pregnancy
and hyperemesis gravidarum. Acupressure and electrical stimulation wrist bands have been associated with benefit for nausea/
vomiting of early pregnancy, although the evidence is mixed and
limited (Heazell 2006; Ismail 2007; Matthews 2015; Mella 2011;
Rosen 2003; Shin 2007). Acupuncture has also been shown to
have some benefit in the treatment of nausea and vomiting in
pregnancy although again, the evidence is limited (ACOG 2004;
Carlsson 2000; Mella 2011). A Cochrane review evaluating its efficacy in nausea and vomiting in early pregnancy found one study
that demonstrated an improvement in severity of nausea and vomiting (Matthews 2015). These methods are based on traditional
Chinese medicine that specifies a point PC6 5 cm proximal to the
wrist crease that is associated with decreasing nausea. Acupuncture
and other stimulation at this point has been suggested to reduce
opioid-related post operative nausea as well as chemotherapy-associated nausea (Carlsson 2000).

Ginger

Ginger is another commonly recommended non-pharmacological
intervention for the treatment of nausea and vomiting in pregnancy. The active ingredient in ginger responsible for its therapeutic effect is not well understood but it has long been used as
a herbal medicine in Asian culture for the treatment of nausea
and vomiting in pregnancy. Several randomized controlled trials
have demonstrated a benefit of ginger in nausea and vomiting of
pregnancy without any demonstrable adverse pregnancy outcomes
(Arsenault 2002; Matthews 2015; Mella 2011).
Intravenous fluids/enteral nutrition/parenteral nutrition

Hyperemesis gravidarum is commonly characterized by metabolic
and electrolyte disturbance requiring hospital admission, with the
initial therapy frequently being intravenous rehydration/repletion
of electrolytes. (ACOG 2004).
Both enteral and parenteral nutrition are used in refractory hyperemesis gravidarum. Complications of enteral nutrition can include infection, bleeding, tube dislodgement, preterm labor, and
discomfort for the woman (ACOG 2004; Saha 2009). Parenteral
nutrition is associated with a high incidence of complications including infection, thrombosis, and mechanical failure, and therefore is recommended only in the failure of medical management
and enteral nutrition (ACOG 2004; Holmgren 2008).
Pharmacological interventions
A number of different classes of pharmaceutical agents have been
evaluated for the treatment of hyperemesis gravidarum.
Vitamin B6

Vitamin B6 or pyridoxine is commonly used as a first line treatment for nausea and vomiting in pregnancy. It is a water soluble
vitamin used as a cofactor in a wide array of metabolic processes
and in the synthesis of nucleic acids and some neurotransmitters.
Used on its own, it is associated with a decrease in nausea but
not in vomiting (Mella 2011). Vitamin B6 has not been shown to
cause increased risk in major or minor congenital malformations
(Arsenault 2002; Mazzotta 2000).
Antihistamines

Antihistamines may act through different mechanisms. Doxylamine is a H-1 receptor antagonist that had been used frequently
in combination with B6. When the combination B6 and doxylamine was available in the United States, there was an association with decreased admissions for hyperemesis, however it was
removed from the market secondary to safety concerns that were
later unfounded (ACOG 2004; Ismail 2007). The combination of
doxylamine/B6 has been found to be both safe, with no evidence
of teratogenicity, and effective in the treatment of nausea and vomiting in pregnancy (Arsenault 2002; Mazzotta 2000; Mella 2011).
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H1-receptor antagonists such as doxylamine, hydroxyzine, and
diphenhydramine are thought centrally to reduce vestibular symptoms. There is one randomized controlled trial showing that
diphenhydrinate is as effective as ginger in the treatment of nausea
and vomiting of pregnancy (Pongrojpaw 2007).
H2-receptor antagonists such as famotidine and ranitidine act peripherally in reducing reflux, which may help with reducing symptoms of nausea and vomiting, although this has not been well
studied either.
A meta-analysis of antihistamines showed no increased risk of
congenital malformations, risk of miscarriage, or preterm delivery
(Gill 2009; Mella 2011).

resort intervention (ACOG 2004; Arsenault 2002; Ismail 2007;
Mazzotta 2000).

Why it is important to do this review
Although a recent Cochrane review examined the efficacy and safety of many of these interventions for nausea/vomiting of early
pregnancy (Matthews 2015), there has not yet been a review assessing interventions for the more severe condition of hyperemesis
gravidarum.

Dopamine antagonists

Dopamine-2 antagonists such as metoclopramide stimulate GI
motility and have been shown to be effective in decreasing vomiting. Limited studies have demonstrated its safety in pregnancy
(Arsenault 2002; Mella 2011). Phenothiazines, such as promethazine, are dopamine 2-receptor antagonists that act centrally to
suppress the chemoreceptor trigger zone (CTZ) that is responsible
for stimulating vomiting. These have been shown to be safe in
pregnancy with regards to teratogenicity (Arsenault 2002).

OBJECTIVES
To assess the effectiveness as well as maternal and fetal safety of all
published interventions for hyperemesis gravidarum.

METHODS

Benzodiazepines

Benzodiazepines such as diazepam are thought to be helpful in
the condition of hyperemesis gravidarum, presumably through
alleviating psychosomatic symptoms such as anxiety. However,
the safety of these medications in pregnancy is still controversial
with some studies demonstrating a positive association between
neonatal exposure to diazepam and prematurity and low birth
weight (Mella 2011; Tasci 2009).
Serotonin antagonists

Serotonin antagonists such as ondansetron also act centrally to
suppress the CTZ. Safety data are limited, animal studies and
small case studies have not demonstrated any teratogenic effect
(Mazzotta 2000). Recently, a large retrospective cohort study in
Denmark found no association between ondansetron and adverse
fetal outcomes (Pasternak 2013). Despite the limited safety and
efficacy data, its efficacy in treating chemotherapy-associated nausea/vomiting has led to increased use of this medication (ACOG
2004).

Criteria for considering studies for this review

Types of studies
We included all randomized controlled trials of any intervention
for hyperemesis gravidarum. We included randomized controlled
trials reported in abstract, provided that there was sufficient information in the abstract or available from the author to allow us to
assess eligibility and risk of bias. We excluded quasi-randomized
trials and trials using a cross-over design. Multi-armed trials were
included and pair-wise comparison were conducted separately.

Types of participants
Pregnant women with a normal intrauterine pregnancy up to 20
weeks’ gestation diagnosed with hyperemesis gravidarum according to the definition of the trials.

Corticosteroids

Types of interventions

Corticosteroids are often used as a last resort for treatment of
refractory hyperemesis. They have been used for the treatment of
chemotherapy-associated nausea and are postulated to modify the
CTZ. However, their use in early pregnancy has been associated
with oral cleft malformations, so it is generally reserved as a last

We included all published interventions for hyperemesis gravidarum. Each intervention (i.e. acupressure or ondansetron) was
analyzed separately versus placebo or no treatment, and versus
other interventions. Compound interventions (i.e. ondansetron
and metoclopramide) were treated as single unique interventions.
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Types of outcome measures
For the sake of comparison, some outcome measures for this review
align with the outcome measures used in the previous Cochrane
review on interventions for nausea and vomiting in early pregnancy (Matthews 2015). The time frame for follow-up of outcome measures, including maternal and neonatal safety data, was
defined by individual trials. The outcomes below are slightly different from what was initially published in the protocol for this
review. Severity of nausea/vomiting was added as a primary outcome because it was found that this was often what was reported in
the included studies. Similarly, rather than reporting the number
of women requiring additional antiemetics, the outcome “number
of antiemetics required” was used instead as this was more often
reported.
Primary outcomes

Intervention efficacy
1. Severity, reduction, or cessation in nausea/vomiting
2. Number of episodes of emesis
3. Days of hospital admission
Secondary outcomes

Intervention efficacy
1. Hospital readmission
2. Number of women requiring additional antiemetics
3. Need for enteral or parenteral nutrition
Adverse maternal outcomes
1. Pregnancy complications (i.e. antepartum hemorrhage, preeclampsia, gestational hypertension)
2. Weight loss
Adverse fetal/neonatal outcomes
1.
2.
3.
4.
5.

Spontaneous abortion
Stillbirth and neonatal death
Congenital abnormalities
Low birthweight
Preterm birth

Quality of life
1. Quality of life outcomes including emotional,
psychological, and physical well-being
2. Intervention side effects
3. Decision to terminate the pregnancy

Economic costs
1. Direct financial costs to women
2. Productivity costs
3. Healthcare system costs

Search methods for identification of studies
The following methods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.

Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s
(PCG) Trials Register by contacting the Trials Search Co-ordinator (20 December 2015).
The Register is a database containing over 20,000 reports of controlled trials in the field of pregnancy and childbirth. For full search
methods used to populate the PCG Trials Register including the
detailed search strategies for CENTRAL, MEDLINE, Embase and
CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness
service, please follow this link to the editorial information about
the Cochrane Pregnancy and Childbirth Group in The Cochrane
Library and select the ‘Specialized Register ’ section from the options on the left side of the screen.
Briefly, the Cochrane PCG Trials Register is maintained by the
Trials Search Co-ordinator and contains trials identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a specific
PCG review topic (or topics), and is then added to the Register.
The Trials Search Co-ordinator searches the Register for each review using this topic number rather than keywords. This results
in a more specific search set which has been fully accounted for in
the relevant review sections (Included, Excluded, Awaiting Classification or Ongoing).
In addition, we contacted the Cochrane Complementary
Medicine Field to search their Trials Register (20 September 2014)
and checked again via The Cochrane Register of Studies (CRSO)
(20 December 2015) (see: Appendix 1).
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Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.

Data collection and analysis
Selection of studies
Two review authors (RB and SB) independently assessed for inclusion all the potential studies we identify as a result of the search
strategy. We resolved any disagreement through discussion or, if
required, we consulted a third review author (AK).
Data extraction and management
We designed a form to extract data. For eligible studies, three
review authors (RB, SB, GS) extracted the data using the agreed
form. We resolved discrepancies through discussion or, if required,
we consulted a fourth author (AK). We entered data into Review
Manager software (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors (RB and SB) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreement by discussion or by involving an
additional assessor (AK).
(1) Random sequence generation (checking for possible
selection bias)

We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)

We described for each included study the method used to conceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.

We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
• unclear risk of bias.

(3.1) Blinding of participants and personnel (checking for
possible performance bias

We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered studies to be
low risk of bias if they were blinded, or if we judged that the lack of
blinding would be unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.

(3.2) Blinding of outcome assessment (checking for possible
detection bias)

We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.

(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)

We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and exclusions were reported and the numbers included in the analysis at
each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or supplied by the trial
authors, we re-included missing data in the analyses.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomization);
• unclear risk of bias.
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(5) Selective reporting (checking for reporting bias)

We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.

(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)

We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.

(7) Overall risk of bias

We made explicit judgements about whether studies are at high risk
of bias, according to the criteria given in the Cochrane Handbook
(Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it likely to impact on the findings.

We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
’Summary of findings’ tables. A summary of the intervention effect
and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Where reported, the above seven outcomes have been set out in
’Summary of findings’ tables. Other important outcomes such
as hospital readmission, pregnancy termination and the use of
additional antiemetics have been described in full in the results
section.
A broad range of interventions for hyperemesis gravidarum were
examined in the included trials and so to summarize findings, we
selected those non-pharmacological and pharmacological comparisons that we considered to be most clinically relevant. Findings
for nine different comparisons have been set out in the ’Summary
of findings’ tables.
1. Acupuncture versus placebo
2. Acupuncture versus metoclopramide
3. Pyridoxine versus placebo
4. Metoclopramide versus ondansetron
5. Hydrocortisone versus metoclopramide
6. Metoclopramide versus promethazine
7. Ondansetron versus promethazine
8. Corticosteroids versus promethazine
9. Corticosteroids versus placebo
Measures of treatment effect

Assessment of the quality of the evidence using the
GRADE approach
For this update the quality of the evidence has been assessed using
the GRADE approach as outlined in the GRADE handbook in
order to assess the quality of the body of evidence relating to the
following outcomes.
1. Severity, reduction or cessation in nausea/vomiting
2. Number of episodes of emesis
3. Days of hospital admission
4. Intervention side effects
5. Quality of life outcomes including emotional,
psychological, and physical well-being
6. Pregnancy complications (i.e. antepartum hemorrhage, preeclampsia, gestational hypertension)
7. Adverse fetal/neonatal outcomes (i.e. spontaneous abortion,
stillbirth and neonatal death, congenital abnormalities, low
birthweight, preterm birth)

Dichotomous data

For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data

For continuous data, we planned to use the mean difference if
outcomes were measured in the same way between trials and the
standardized mean difference to combine trials that measured the
same outcome, but used different methods.
Unit of analysis issues

Cluster-randomized trials
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We planned to include cluster-randomized trials in the analyses
along with individually-randomized trials, however all included
studies were individually-randomized trials.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensitivity analysis, however because most trials had a unique comparison
and we were unable to group most included studies, therefore a
sensitivity analysis was not performed.
For all outcomes, we will carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all participants randomized to each group in the analyses, and all participants were analyzed in the group to which they were allocated, regardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomized minus any participants whose outcomes are known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as substantial if an I² was greater than 30% and either the T² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the metaanalysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager software (RevMan 2014). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged to be sufficiently similar. If there was
clinical heterogeneity sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity was detected, we used random-effects meta-analysis to
produce an overall summary, if an average treatment effect across
trials was considered clinically meaningful. The random-effects

summary was treated as the average range of possible treatment
effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was
not clinically meaningful, we did not combine trials.
Where we used random-effects analyses, we presented the results
as the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
The majority of our analyses are based on data from single studies with small numbers of participants. If we had identified substantial heterogeneity, we planned to investigate it using subgroup
analyses and sensitivity analyses. In future updates, if more trials are included, we will consider whether an overall summary is
meaningful, and if it is, use random-effects analysis to produce it.
We planned to carry out the following subgroup analyses:
1. women with weight loss of at least 5% of pre-pregnancy
weight versus women with weight loss of less than 5% of prepregnancy weight;
2. singleton gestation versus twin gestations;
3. primiparous versus multiparous.
We planned to use the primary outcomes in subgroup analysis.
1. Severity, reduction, or cessation in nausea/vomiting. We
will examine outcomes measured by all commonly used
instruments to assess nausea and vomiting.
2. Number of episodes of emesis.
3. Days of hospital admission.
We planned to assess subgroup differences by interaction tests
available within RevMan (RevMan 2014). However there were
insufficient data to conduct a subgroup analysis.
Sensitivity analysis
We planned to perform sensitivity analysis in trials found to have
a high or unclear risk of attrition bias, and high or unclear risk of
other biases. However, because most trials were unique comparisons we did not carry out a sensitivity analysis.

RESULTS

Description of studies
Results of the search
See: Figure 1).

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

Figure 1. Study flow diagram.
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The search strategy identified 78 total reports representing 67 distinct studies (some studies were resulted in more than one publication). Of these 67 studies, 25 met inclusion criteria for the review,
35 were excluded, two are awaiting translation (and are listed in
Characteristics of studies awaiting classification) and five studies
are ongoing (see Characteristics of ongoing studies).
Included studies
Twenty-five studies (involving 2052 women) met inclusion criteria. The included studies examined a range of interventions.
Non-pharmacological interventions

Acupuncture or acupressure at the P6 (or Neigun) point was examined in seven studies; in five studies it was compared with
placebo (Habek 2004; Heazell 2006; Mamo 1995; Miller 2001;
Shin 2007); in one study it was compared with metoclopramide
(Neri 2005); and in one study it was compared with Western
medicine (intravenous fluids, electrolyte repletion and phenobarbital) and Chinese medicine (Mao 2010). One study compared
the efficacy of progressive muscle relaxation with pharmacotherapy
versus pharmacotherapy alone (Gawande 2011). Pharmacotherapy in this case consisted of the progressive use of doxylamine
succinate, ondansetron, metoclopramide, and promethazine. One
study evaluated intravenous hydration with dextrose saline versus
normal saline (Tan 2013). One study compared midwife-led outpatient care versus routine care with inpatient admission (McParlin
2008). One study examined holistic assessment with individualized care plan and support and advice from nurses versus standard care (Fletcher 2015). There were no randomized controlled
trials on hyperemesis gravidarum that examined other dietary or
lifestyle modifications, or the use of ginger.
Pharmacological interventions

All studies recruited women with hyperemesis gravidarum or severe nausea and vomiting of pregnancy, as defined by the authors.
The spectrum of severe symptoms necessary for inclusion in these
studies varied but included failure of outpatient therapy, need for
inpatient admission, ketonuria, weight loss, electrolyte imbalance.
The gestational age of pregnancy at which women were recruited
was generally in the first and second trimester (less than 20 weeks),
although one study included women up to 30 weeks, however
none of the women recruited were beyond 12 weeks (Shin 2007).
Most studies collected data on the severity, reduction, or cessation
in nausea and vomiting. However, pooling data was complicated
by variations in reporting and the individual time frames used.
Most studies used a 10-point visual analogue scale (VAS) for the
severity of nausea and/or vomiting, where a higher number represented more severe symptoms (Abas 2014; Ditto 1999; Kashifard

2013; Nelson-Piercy 2001; Sullivan 1996; Tan 2009; Tan 2010;
Tan 2013; Ziaei 2004). Other studies used individualized measures such as a scale of zero to two for nausea/vomiting/food intake/functioning (Neri 2005), and a “severity” and “relief ” scoring
system developed by the authors of Ylikorkala 1979. Other scales
such as the “Hyperemesis Impact of Symptoms Questionnaire”
(Fletcher 2015), the “Pregnancy Unique Quantification of Emesis
and Vomiting” (McParlin 2008), and the “Rhodes Index of Nausea, Vomiting, and Retching” (Miller 2001; Shin 2007) were also
used. A number of studies reported on the number of episodes of
vomiting (Abas 2014; Bondok 2006; Kashifard 2013; Tan 2009;
Tan 2010; Tan 2013; Ziaei 2004). Other measures of nausea and
vomiting that we did not analyze included recurrence of vomiting
(Duggar 2001), number of antiemetics required and days required
to achieve no vomiting (Gawande 2011), lack of need for medication (Habek 2004), number of antiemetic doses and need for
additional antiemetics (Heazell 2006), need for antiemetic medication (Mamo 1995), and therapy failure defined by persistent
vomiting (more than five times/day), inability to tolerate liquids
by mouth, or the impression that the woman was not better (Safari
1998). In this review we chose to describe outcomes relating to
women’s nausea and vomiting at the time points reported by the
study. In addition to the severity of nausea/vomiting and number of episodes of emesis, our primary outcomes also included
the number of days of hospital admission, which was reported in
several studies (Abas 2014; Ditto 1999; Heazell 2006; McParlin
2008; Nelson-Piercy 2001; Sullivan 1996; Tan 2009; Tan 2010;
Tan 2013; Yost 2003).
Our secondary outcomes included intervention efficacy, which
included the number of women requiring additional antiemetics,
hospital readmission rate, and the need for enteral or parenteral
nutrition. The number of women requiring additional antiemetics
was reported in a few studies (Ditto 1999; Habek 2004; NelsonPiercy 2001; Safari 1998). Hospital readmission was reported by
several studies (Bondok 2006; Ditto 1999; Duggar 2001; NelsonPiercy 2001; Safari 1998; Tabatabaii 2008; Tan 2009; Ylikorkala
1979; Yost 2003). Only Bondok 2006 reported on the need for
enteral or parenteral nutrition.
Other secondary maternal and neonatal outcomes included adverse pregnancy outcomes, pregnancy complications, and maternal weight loss. A number of studies reported on adverse pregnancy outcomes and complications (Ditto 1999, Nelson-Piercy
2001, Heazell 2006, McParlin 2008, Safari 1998, Yost 2003).
A few studies reported change in weight (Nelson-Piercy 2001;
Sullivan 1996; Tan 2009; Ylikorkala 1979). Another secondary
outcome was quality of life, which included measures of quality of life, intervention side effects, and the decision to terminate the pregnancy. A few studies that evaluated quality of a
life with a variety of measures including a Clinical Global Im-
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provement score (Gawande 2011), Anxiodepressive Symptom Index (Habek 2004), pregnancy-unique quantification of emesis
and nausea (PUQE) score (McParlin 2008), well-being rating
(Nelson-Piercy 2001; Tan 2009; Tan 2010; Tan 2013), well-being verbal numeric rating scale (VNRS) (Abas 2014), and Short
Form (36) Health Survery (McParlin 2008). Several studies reported on the number of women who decided to terminate the
pregnancy (Ditto 1999; Gawande 2011; Heazell 2006; McParlin
2008; Nelson-Piercy 2001; Safari 1998). Several studies also reported on intervention side effects (Abas 2014; Duggar 2001;
Kashifard 2013; Sullivan 1996; Tan 2009; Tan 2010; Tan 2013;
Ziaei 2004). The final secondary outcome was economic costs,
which were only reported in one study (McParlin 2008).

Studies awaiting further assessment and ongoing
studies
There are two studies awaiting further classification. Translations
were not available for He 2009 or Eftekhari 2013.
There are five ongoing studies. Cyna 2008 is a randomized controlled trial examining the efficacy of hypnosis on hyperemesis and
is still recruiting. One randomized controlled trial (Mehrolhasani
2012) evaluated demitron versus promethazine in the treatment
of hyperemesis gravidarum; according to the trial registry, recruitment has been completed, but no results were found. We have
contacted the authors for information. Guttuso 2014 is a randomized trial comparing gabapentin and metoclopramide that is currently recruiting. Mitchell-Jones 2014 is a randomized controlled
trial comparing inpatient versus outpatient management of severe
nausea and vomiting of pregnancy that is also currently recruiting. Finally, Koren 2014 is an ongoing multicenter randomized
controlled trial evaluating the safety and efficacy of doxylamine
succinate and pyridoxine hydrochloride (trade name Diclegis) in
nausea and vomiting of pregnancy; the inclusion criteria does not
specify hyperemesis gravidarum but there is no exclusion of severe
nausea and vomiting so the final study results may include a subgroup of women with hyperemesis.

Excluded studies
After assessment of study eligibility, we excluded 35 studies. The
main reasons for exclusion were that the study was on nausea and
vomiting of pregnancy and not hyperemesis gravidarum (19 studies), or the study used a cross-over design (five studies). Two studies
were quasi-randomized, and in one study it was unclear whether
the study was randomized or quasi-randomized. Two studies were
not randomized controlled trials. Three studies were not reports
on trials. Finally, three studies were on prophylactic treatment for
prevention rather than treatment of the condition and as such were
excluded.

Risk of bias in included studies

Sequence generation (selection bias)
In 10 of the included studies, the methods used to randomize women were not described or were unclear (Duggar 2001;
Gawande 2011; Habek 2004; Mamo 1995; Mao 2010; McParlin
2008; Miller 2001; Sullivan 1996; Tabatabaii 2008; Ylikorkala
1979). The remainder of the studies were assessed to have adequate randomization methods. Eight studies used computer-generated randomization list (Bondok 2006; Fletcher 2015; Kashifard
2013; Nelson-Piercy 2001; Neri 2005; Safari 1998; Tan 2013;
Yost 2003). Two studies used a random number table (Ditto 1999;
Ziaei 2004). Only one study used coin toss (Shin 2007) as a
method of randomization. Three studies used block randomization (Abas 2014; Tan 2009; Tan 2010), and one study used external randomization services (Heazell 2006).

Allocation
Fourteen of the included studies were unclear on allocation concealment (Ditto 1999; Duggar 2001; Habek 2004; Kashifard
2013; Mamo 1995; Mao 2010; McParlin 2008; Miller 2001;Shin
2007; Sullivan 1996; Tabatabaii 2008; Ylikorkala 1979; Yost 2003;
Ziaei 2004). One study was deemed to have a high risk of bias
in allocation concealment - Gawande 2011 reported treating obstetricians were blinded to whether the women received a muscle relaxation session, however there was no report on concealment of allocation, and the control group received no placebo intervention. The remaining studies were judged to have adequate
allocation concealment. Four studies used a code that was held
by a third party: Bondok 2006 described using a withheld code
and identical appearing interventions. Nelson-Piercy 2001 used
sequentially numbered trial packs with the copy of the allocation
schedule held by the pharmacy, Neri 2005 used a code that was
held under the control of a midwife, Safari 1998 used envelopes
that were prepared in advance by a third party, although the envelopes were not specified to be opaque. Four studies described
using opaque, sealed envelopes (Abas 2014; Tan 2009; Tan 2010;
Tan 2013). One study described drawing ticket from an opaque
bag (Heazell 2006).One study reported random allocation done
remotely via telephone (Fletcher 2015).

Blinding
Blinding of participants was unclear or not described in 12 studies
(Ditto 1999; Duggar 2001; Kashifard 2013; Mamo 1995; Mao
2010; McParlin 2008; Miller 2001; Safari 1998; Tabatabaii 2008;
Tan 2009; Ylikorkala 1979; Ziaei 2004). There was a high risk of
bias in three studies. Gawande 2011, as mentioned previously, had
a control group of women called into the office but they received
no kind of placebo muscle relaxation intervention. Similarly, in
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Fletcher 2015 participants were not blinded. Neri 2005 had a
comparison group but no placebo intervention for acupuncture
or acupressure. The remainder of the studies were deemed to have
adequate participant blinding with masking of participants and
similar appearing interventions.
Blinding of outcome assessors was unclear or not described in
seventeen studies (Ditto 1999; Duggar 2001; Gawande 2011;
Heazell 2006; Mamo 1995; Mao 2010; McParlin 2008; Miller
2001; Neri 2005; Shin 2007; Sullivan 1996; Tabatabaii 2008; Tan
2010; Tan 2013; Ylikorkala 1979; Yost 2003; Ziaei 2004). Fletcher
2015 primary outcomes were self reported and the participants
were not blinded, thus was deemed to have a high risk of bias. The
remainder of the studies were deemed to have adequately described
blinding of investigators.

Incomplete outcome data
Attrition was either unclear or not reported in 13 studies (Bondok
2006; Ditto 1999; Duggar 2001; Habek 2004; Kashifard 2013;
Mamo 1995; McParlin 2008; Miller 2001; Neri 2005; Shin 2007;
Sullivan 1996; Tabatabaii 2008; Tan 2009). The remainder of the
studies were deemed to have a low risk of attrition bias, with a
low rate of attrition, accompanying reasons provided, and similar
numbers lost to follow-up in each comparison group.

Selective reporting
The risk of reporting bias was unclear or not described in six studies, five of which were abstracts in which there was not enough information to adequately judge the presence of bias (Duggar 2001;
Mamo 1995; McParlin 2008; Miller 2001; Tabatabaii 2008). Mao
2010 reported outcomes as described in the methods, however it
was unclear how the outcomes were measured, whether standard
tools were used or not, as such, we considered the risk of reporting
bias to be unclear. The remainder of the studies were deemed to
be low risk of reporting bias with expected outcomes reported, or
outcomes specified as being predetermined.
Other potential sources of bias
Most studies did not have enough information to adequately assess the presence other forms of bias and as such were deemed
to have an unclear risk of bias. There was a high risk of bias in
one study. Nelson-Piercy 2001 reported that their trial was prematurely ended due to a combination of factors including departure
of key staff members and “the erroneous belief that steroids had
such a dramatic beneficial effect that continued randomization
was not justified”.
Figure 2 and Figure 3 provides a summary of our ’Risk of bias’
assessment.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.

Effects of interventions
See: Summary of findings for the main comparison
Acupuncture versus placebo; Summary of findings 2
Acupuncture versus metoclopramide; Summary of findings
3 Pyridoxine versus placebo; Summary of findings 4
Metoclopramide versus ondansetron; Summary of findings 5
Metoclopramide versus promethazine; Summary of findings
6 Ondansetron versus promethazine; Summary of findings 7
Corticosteroids versus promethazine; Summary of findings 8
Corticosteroids versus placebo
We included 25 studies (involving 2052 women) in this review but
the majority of our analyses are based on data from single studies
with small numbers of participants.

band applied to each wrist versus control with no acupressure and
reported more women required additional antiemetics than in the
control group, again without specific data reported.

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting

Acupunture/Acupressure

With regards to this primary outcome, only one study (Shin 2007)
reported a decreased mean nausea score (using Rhodes index of
nausea vomiting or retching), however, no standard deviation was
reported so this could not be entered into our data and analysis
tables.

Acupuncture and acupressure versus placebo

Number of episodes of emesis

Three studies (involving 182 women) compared P6 acupressure
or acupuncture versus placebo and were included in the analysis.
Two additional studies were in abstract form only and did not have
data that could be entered into the analysis. Miller 2001 compared
nerve stimulation with a watch-like device at P6 versus placebo
and reported lower symptoms in the intervention group, without
specific data reported. Mamo 1995 compared acupressure Sea-

None of the studies reported on the number of episodes of emesis.

Days of hospital admission
None of the studies reported on the number days of hospital admission.
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Secondary outcomes

Secondary outcomes

Regarding the secondary outcomes. The number of women requiring additional antiemetics was lower in the acupuncture/
acupressure group compared to placebo (risk ratio (RR) 0.20, 95%
confidence interval (CI) 0.08 to 0.50, one study (Habek 2004),
36 women (Analysis 1.1)). However, there was no difference between the treatment group and placebo control with regard to
spontaneous abortion (RR 0.48, 95% CI 0.05 to 5.03, one study
(Heazell 2006), 57 women (Analysis 1.2), low-quality evidence),
preterm birth less than 37 weeks (RR 0.12, 95% CI 0.01 to
2.26, one study (Heazell 2006), 36 women (Analysis 1.3), lowquality evidence), stillbirth or neonatal death (RR 0.57, 95% CI
0.04 to 8.30, one study (Heazell 2006), 36 women (Analysis 1.4),
low-quality evidence), decision to terminate the pregnancy (RR
0.72, 95% CI 0.18 to 2.95 (Heazell 2006), 57 women (Analysis
1.5)), or anxiodepressive symptomology (RR 1.01, 95% CI 0.73
to 1.40, one study (Habek 2004), 36 women (Analysis 1.6), very
low-quality evidence). (Findings for this comparison are set out in
Summary of findings for the main comparison.)

There were no data available on any of this review’s secondary
outcomes.

Acupuncture versus Western medicine (phenobarbital)

There was one study (Mao 2010), involving 90 women that evaluated acupuncture versus Western medicine. Both groups received
fluid hydration and electrolyte repletion, Acupuncture was performed at BL11, ST37, PC6, SP4, RN12, and ST36, as determined by symptoms. The Western medicine group received 30
mg phenobarbital three times a day.

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Acupuncture versus metoclopramide

One study (Neri 2005, involving 81 women), evaluated the efficacy of acupuncture twice weekly versus metoclopramide infusion in the treatment of hyperemesis gravidarum. Findings for this
comparison are set out in Summary of findings 2.

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Regarding the primary outcome, after the cessation of the last treatment, the rate of women who experienced a reduction of nausea in
the acupuncture group was no different from the metoclopramide
group (RR 1.40, 95% CI 0.79 to 2.49 (Analysis 2.1), very lowquality evidence) neither was the rate of women who experienced
a reduction in vomiting (RR 1.51, 95% CI 0.92 to 2.48 (Analysis
2.2), very low-quality evidence).

Results were reported as Complete Recovery: cessation of nausea
and vomiting, normal appetite; Obvious Effects: reduction by at
least 50% in frequency of nausea and vomiting, appetite improved;
Effects Showed: reduction by 25% to 50% in nausea and vomiting, somewhat improved appetite; and Ineffective: reduction less
than 25% in nausea/vomiting, no improvement in appetite. Total
effectiveness rate was defined as the number of women with either Complete Recovery, Obvious Effects, or Effects Showed. At
the end of one week of treatment, there were significantly more
women with complete recovery and less women with ineffective
therapy in the acupuncture versus the phenobarbital group (RR
6.75, 95% CI 2.69 to 16.94 (Analysis 3.1) and (RR 0.06, 95% CI
0.01 to 0.44 (Analysis 3.4)). Acupuncture was more likely to have
any effectiveness (total effective rate) compared to phenobarbital
(RR 2.07, 95% CI 1.40 to 3.05, (Analysis 3.5)).

Number of episodes of emesis
There were no data available on number of episodes of emesis.

Number of episodes of emesis

Days of hospital admission

There were no data available on number of episodes of emesis.

There were no data available on the number of days of hospital
admission.

Days of hospital admission

Secondary outcomes

There were no data available on the number of days of hospital
admission.

There were no data available on any of this review’s secondary
outcomes.
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Acupuncture versus Chinese medicine

There was one study (Mao 2010, involving 90 women) that evaluated acupuncture versus Chinese medicine. Both groups received
fluid hydration and electrolyte repletion, Acupuncture was performed at BL11, ST37, PC6, SP4, RN12, and ST36, as determined by symptoms. Women in the Chinese medicine group received a selection of traditional Chinese medication according to
the dialectical classification.

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Results were reported as Complete Recovery: cessation of nausea
and vomiting, normal appetite; Obvious Effects: reduction by at
least 50% in frequency of nausea and vomiting, appetite improved;
Effects Showed: reduction by 25% to 50% in nausea and vomiting, somewhat improved appetite; and ’Ineffective’: reduction less
than 25% in nausea/vomiting, no improvement in appetite. Total
effectiveness rate was defined as the number of women with either Complete Recovery, Obvious Effects, or Effects Showed. At
the end of one week of treatment, there were significantly more
women with complete recovery and less women with ineffective
therapy in the acupuncture versus Chinese medicine group (RR
9.00, 95% CI 3.06 to 26.51(Analysis 4.1) and (RR 0.08, 95% CI
0.01 to 0.60 (Analysis 4.4)). Acupuncture was more likely to have
any effectiveness (total effective rate) than Chinese medicine (RR
1.61, 95% CI 1.19 to 2.17, (Analysis 4.5))

medicine group received a selection of traditional Chinese medication according to the dialectical classification and the “Western
Medicine” group received phenobarbital 30 mg orally three times
daily.

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Results were reported as Complete Recovery: cessation of nausea
and vomiting, normal appetite; Obvious Effects: reduction by at
least 50% in frequency of nausea and vomiting, appetite improved;
Effects Showed: reduction by 25% to 50% in nausea and vomiting, somewhat improved appetite; and Ineffective: reduction less
than 25% in nausea/vomiting, no improvement in appetite. Total
effectiveness rate was defined as the number of women with either
Complete Recovery, Obvious Effects, or Effects Showed. At the
end of one week of treatment, there was no significant difference
between the two groups in number of women with either complete recovery (RR 0.75, 95% CI 0.18 to 3.07 (Analysis 5.1)) or
any effectiveness (total effective rate) (RR 1.29, 95% CI 0.79 to
2.08, (Analysis 5.5)).

Number of episodes of emesis
There were no data available on number of episodes of emesis.

Number of episodes of emesis
There were no data available on number of episodes of emesis.

Days of hospital admission
There were no data available on the number of days of hospital
admission.

Days of hospital admission
There were no data available on the number of days of hospital
admission.

Secondary outcomes
There were no data available on any of this review’s secondary
outcomes.

Secondary outcomes
There were no data available on any of this review’s secondary
outcomes.

Chinese medicine versus Western medicine
(phenobarbital)
There was one study (Mao 2010, involving 90 women) that evaluated Chinese medicine versus Western medicine. The Chinese

Progressive muscle relaxation and pharmacotherapy
versus pharmacotherapy
One study (Gawande 2011, involving 30 women) compared progressive muscle relaxation with pharmacotherapy versus pharmacotherapy alone. Pharmacotherapy included the progressive
use of doxylamine succinate, ondansetron, metoclopramide, and
promethazine.
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Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Regarding the primary outcome, Gawande 2011 reported a Clinical Global Improvement Score, a significant improvement in
muscle relaxation with pharmacotherapy compared to pharmacotherapy alone (mean difference (MD) -0.54 points, 95% CI 1.04 to -0.04 (Analysis 6.1)).

Number of episodes of emesis
None of the studies reported on the number of episodes of emesis.

Days of hospital admission
Women who received midwife-led care remained in the hospital
for fewer hours (MD -33.20 hours, 95% CI -46.91 to -19.49
(Analysis 7.2).
Secondary outcomes
Regarding secondary outcomes, there was no clear difference in
the rate of women who decided to terminate the pregnancy (RR
2.89, 95% CI 0.12 to 67.96 (Analysis 7.3)). There was also no clear
difference in spontaneous miscarriage (RR 0.96, 95% CI 0.15
to 6.34 (Analysis 7.4)), or in the rate ofsmall-for-gestational-age
infants (RR 1.44, 95% CI 0.26 to 7.96) (Analysis 7.5)).In terms of
economic costs there was also no evidence of a difference between
groups in relation to the rate of women who lost time from paid
employment (RR 1.04, 95% CI 0.28 to 3.87 (Analysis 7.6)).
Data were not available for any other secondary outcomes in this
review.

Days of hospital admission
None of the studies reported on the number of days of hospital
admission.

Secondary outcomes
Regarding secondary outcomes, there were no women in either
group who decided to terminate the pregnancy.
No data were reported for any of this review’s other secondary
outcomes.

Midwife-led outpatient care versus routine care
We found one study (involving 53 women) that examined
midwife-led outpatient care versus routine care with admission
(McParlin 2008). Data were obtained from communication with
the authors.

Primary outcomes

Holistic assessment with standard care versus
standard care
One study (Fletcher 2015, involving 273 women) compared holistic assessment with an individualized care plan in addition to standard medical care versus standard medical care alone. The holistic assessment involved a Hyperemeis impact of symptoms (HIS)
questionnaire (Power 2009) that was used to tailor a care package
comprising practical and supportive care. Standard care was intravenous rehydration and antiemetic therapy.
Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
There was no significant difference in the severity of nausea and
vomiting as measured by PUQE (MD -0.20, 95% CI -1.10 to
0.70, (Analysis 8.1)).

Severity, reduction, or cessation in nausea/vomiting

Number of episodes of emesis

There was no clear differences in the mean PUQE (pregnancyunique quantification of emesis and nausea) score between the
group of women who received midwife-led outpatient care and
women who received routine care with admission (MD -0.70
points, 95% CI -3.17 to 1.77 (Analysis 7.1)).

None of the studies reported on the number of episodes of emesis.

Number of episodes of emesis
No data were reported for this outcome.

Days of hospital admission
Fletcher 2015 reported days of hospital admission for the two
groups but did not include a standard deviation so this data could
not be entered for analysis. Per the authors’ report, there was a
significantly shorter length of stay in the holistic assessment group
(4.97 days versus 6.14 days, P = 0.05).
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Secondary outcomes
Fletcher 2015 reported on quality of life by assessing both social
functioning and client satisfaction and found no clear difference
between holistic assessment with standard care versus standard care
alone (MD 2.00, 95% CI -6.70 to 10.70 (Analysis 8.2)); (MD 0.50, 95% CI -1.90 to 0.90 (Analysis 8.3)).
Fletcher 2015 reported on economic costs by looking at both
productivity costs from days lost at work and health system costs
but did not report standard deviations so this data could not be
entered for analysis. Per the authors report the total healthcare costs
were higher in the standard care arm (£1360.50 versus 1185.90),
however the holistic assessment group was associated with more
days lost from work (£1930.50 versus £1468.80), thus the holistic
assessment group had a higher societal cost than the standard care
alone group (£3174.90 versus £2977.50).
Dextrose saline versus normal saline

There were no data available on any other secondary outcomes.

Vitamin B6

Pyridoxine versus placebo

One study (Tan 2009, involving 94 women) randomized women
to receive pyridoxine 20 mg orally three times a day versus placebo,
in addition to all women receiving standard care with intravenous
rehydration, metoclopramide, and oral thiamine. Interventions
were continued for two weeks, outcomes examined a the one- and
two-week mark, results reported here are at the one-week mark due
to significant attrition by two weeks. Findings for this comparison
are set out in Summary of findings 3.

Primary outcomes

One study (Tan 2013, involving 203 women) randomized women
to either rehydration with dextrose saline versus normal saline.
Severity, reduction, or cessation in nausea/vomiting
Primary outcomes

Tan 2009, reported nausea score as a median rather than a mean
score - so the data could not be used for the RevMan tables, however the trialist reported no significant difference in nausea scores.

Severity, reduction, or cessation in nausea/vomiting
Regarding the primary outcome, improvement in nausea/vomiting and number of episodes of emesis was reported in median (interquartile range), so that data could not be used for analysis in
the RevMan tables. Tan 2013 reported a reduction in the median
nausea visual numerical rating scale score at eight and 16 hours
favoring dextrose saline, however this difference dissipated at 24
hours.

Number of episodes of emesis
There was no strong evidence of a difference in the daily mean
vomiting episodes (MD 0.50 vomiting episodes, 95% CI -0.40 to
1.40, 66 women (Analysis 10.1), low-quality evidence)

Days of hospital admission
Number of episodes of emesis
No data were reported for this outcome.

There was a slightly longer hospital stay associated with B6 compared with placebo (MD 0.80 day, 95% CI 0.08 to 1.52, 92
women (Analysis 10.2, moderate-quality evidence).

Secondary outcomes
Days of hospital admission
There was no difference identified in the length of hospital stay
between the two groups (MD -5.00 hours, 95% CI -10.78 to 0.78
(Analysis 9.1)).
Secondary outcomes
Regarding secondary outcomes, quality of life was reported, but as
a median so the data could not be used for analysis in our RevMan
tables, however the authors reported no significant difference in
median well-being score at 24 hours.

Regarding the secondary outcomes, there was no clear difference
in hospital readmission (RR 1.78, 95% CI 0.85 to 3.71, 78
women (Analysis 10.3) or in weight loss after one week (MD
0.00 kg, 95% CI -0.93 to 0.93) (Analysis 10.4). Quality of life
was reported as a median and therefore could not be included
in the analysis, however Tan 2009 reports no difference between
groups in well-being score. Tan 2009 did report on intervention
side effects, and there was no differences in the rate of dizziness
(RR 1.67, 95% CI 0.85 to 3.26, 66 women, low-quality evidence
(Analysis 10.5)), headaches, (RR 1.33, 95% CI 0.52 to 3.42, 66
women, low-quality evidence (Analysis 10.6)), diarrhea (RR 3.00,
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95% CI 0.13 to 71.07, 66 women (Analysis 10.7)), palpitations
(RR 1.00, 95% CI 0.22 to 4.60, 66 women, low-quality evidence
(Analysis 10.8)) and dry mouth (RR 0.82, 95% CI 0.49 to 1.38,
66 women, low-quality evidence (Analysis 10.9)) in the pyridoxine
group compared to placebo after one week of treatment. There
were also no cases of rash or photosensitivity in either group.
There were no data available on any other secondary outcomes.

Number of episodes of emesis
No data were reported for this outcome.

Days of hospital admission
No data were reported for this outcome.

Antihistamines
No studies that examined antihistamines were identified.

Dopamine antagonists

Metoclopramide versus acupuncture

One study (Neri 2005) evaluated the efficacy of acupuncture twice
weekly versus metoclopramide infusion in the treatment of hyperemesis gravidarum - the results have already been reported under
the comparison of acupuncture versus metoclopramide (see above
and Comparison 2 in Data and analyses).

Metoclopramide versus ondansetron

There were two studies (involving 243 women) that compared
metoclopramide with ondansetron (Abas 2014; Kashifard 2013).
Abas 2014 used 10 mg intravenous metoclopramide every eight
hours for four doses versus 4 mg ondansetron intravenous every
eight hours for four doses, while Kashifard 2013 used oral medications in the same doses for two weeks and assessed severity of
nausea and vomiting during the treatment period and two days
one week after completion of therapy. Results for this comparison
have been set out in Summary of findings 4.

Secondary outcomes
Regarding secondary outcomes, Abas 2014 provided data (from
160 women) in relation to intervention side effects. The number of women who felt drowsy (RR 2.40, 95% CI 1.23 to 4.69
(Analysis 11.3) moderate-quality evidence), and who had a dry
mouth (RR 2.38, 95% CI 1.10 to 5.11 (Analysis 11.4), moderatequality evidence) was higher in the metoclopramide group compared to the group of women who received ondansetron. There
were no clear differences in the rate of women unable to sleep (RR
1.29, 95% CI 0.50 to 3.28 (Analysis 11.5), felt dizzy (RR 2.33,
95% CI 0.94 to 5.77, low-quality evidence (Analysis 11.6)), had
diarrhea (RR 9.00, 95% CI 0.49 to 164.46 (Analysis 11.7)), had
headache (RR 1.22, 95% CI 0.54 to 2.79 (Analysis 11.8)), experienced palpitations (RR 2.50, 95% CI 0.50 to 12.51 (Analysis
11.9)), or noticed skin rash (RR 1.00, 95% CI 0.06 to 15.71
(Analysis 11.10)); no cases of dystonia in both groups were reported (Analysis 11.11). Kashifard 2013 reported no side effects in
either the metoclopramide or the ondansetron group, although the
side effects examined were not specified. In addition, Abas 2014
reported no difference in the well-being VNRS score about quality of life outcome (MD -0.40 points, 95% CI -0.83 to 0.03, one
study 160 women, moderate-quality evidence (Analysis 11.12)).
There were no data available on any other secondary outcomes.

Hydrocortisone versus metoclopramide

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Regarding this primary outcome, Abas 2014 reported nausea score
as a median so it could not be analyzed in combination with the
other study (Kashifard 2013), but Abas 2014 reports no significant
difference between groups. Kashifard 2013 reported no significant
difference between the metoclopramide and ondansetron groups
in terms of the severity of nausea (MD 1.70 point, 95% CI -0.15
to 3.55, one study, 83 women (Analysis 11.1), very low-quality
evidence), or in the severity of vomiting according to a 10-point
VAS rating score on the second day one week after completion of
therapy (MD -0.10 points, 95% CI -1.63 to 1.43, one study, 83
women (Analysis 11.2), very low-quality evidence).

There was one study (Bondok 2006, involving 40 women) that
compared women receiving 300 mg intravenous hydrocortisone
daily for three days, tapered over the week, versus 10 mg of metoclopramide intravenously three times daily for one week. We had
intended to produce a ’Summary of findings’ table for this comparison but none of the pre-specified outcomes were reported.

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
There were no data on the subjective severity, reduction, or cessation of nausea.
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Number of episodes of emesis

Secondary outcomes

Mean number of daily episodes of emesis were reported by Bondok
2006 as significantly decreased in the hydrocortisone group, although the actual numbers were not available to be included into
the analysis.

In relation to quality of life, the mean well-being VNRS score was
similar in the metoclopramide group and the promethazine groups
(MD 0.50 points, 95% CI -0.22 to 1.22, low-quality evidence,
(Analysis 13.1)). Tan 2010, provided data on the intervention
side effects - there was no strong evidence showing any differences
in the number of women unable to sleep (RR 0.78, 95% CI 0.40
to 1.53, (Analysis 13.2)), had a dry mouth (RR 0.91, 95% CI 0.62
to 1.34 (Analysis 13.3)), had diarrhea (RR 1.39, 95% CI 0.32 to
5.99 (Analysis 13.4)), had headache (RR 0.81, 95% CI 0.47 to
1.38 (Analysis 13.5)) (low-quality evidence for the aforementioned
side effects), experienced palpitations (RR 0.61, 95% CI 0.25 to
1.46 (Analysis 13.6)), and noticed skin rash (RR 1.39, 95% CI
0.32 to 5.99 (Analysis 13.7) . However, the number of women
who felt drowsy (RR 0.70, 95% CI 0.56 to 0.87, moderate-quality
evidence (Analysis 13.8), the number of women who felt dizzy (RR
0.48, 95% CI 0.34 to 0.69, moderate-quality evidence (Analysis
13.9)) and the number of women who experienced dystonia (RR
0.31, 95% CI 0.11 to 0.90 (Analysis 13.10)) was lower in the
metoclopramide group compared to the group of women who
received promethazine.
No other secondary outcomes were reported.

Days of hospital admission
No data were reported for this outcome.

Secondary outcomes
Regarding secondary outcomes, there was no difference in the rate
of hospital readmission between the metoclopramide and hydrocortisone groups (RR 0.08, 95% CI 0.00 to 1.28 (Analysis 12.1)
moderate-quality evidence). Similarly, there was no clear difference
in the number of women requiring enteral or parenteral nutrition between the two groups (RR 0.33, 95% CI 0.01 to 7.72
(Analysis 12.2)).
No other secondary outcomes were reported.

Metoclopramide versus promethazine

One study (Tan 2010) compared 10 mg intravenous metoclopramide versus 25 mg intravenous promethazine given eight
hourly for 24 hours. (See Summary of findings 5.)

Benzodiazepines

Parenteral fluid with diazepam versus without diazepam

Primary outcomes

There was one study (Ditto 1999, involving 50 women) that evaluated the treatment of hyperemesis gravidarum with or without
10 mg intravenous diazepam twice daily while admitted, and with
5 mg oral diazepam twice daily versus placebo on discharge.

Severity, reduction, or cessation in nausea/vomiting
Nausea score was reported by Tan 2010 as a median so data could
not be included in our analysis, but the trialist reported no significant difference in nausea score between groups.

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Number of episodes of emesis
The number of vomiting episodes were reported by Tan 2010
as a median so these data could not be included in our analysis,
but the trialist reported no significant difference in the number of
vomiting episodes between groups.

The trial authors did not report a MD in nausea score, but did
report a significantly decreased number of women with severe
nausea in the diazepam group.

Number of episodes of emesis
Days of hospital admission
No data were reported for this outcome.

Ditto 1999 did not report the specific number of episodes of emesis
but reported a similar number of women with decreased emesis in
both groups.
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Days of hospital admission

Days of hospital admission

The mean hospital stay was shorter in the diazepam group compared to placebo (MD -1.10, 95% CI -2.07 to -0.13 (Analysis
14.1)).

There was no difference between the ondansetron and promethazine groups in terms of the number of days of hospital admission (MD 0.00 days, 95% CI -1.39 to 1.39 (Analysis 15.1), very
low-quality evidence).

Secondary outcomes
Regarding secondary outcomes, there were no clear differences
in hospital readmission (RR 0.17, 95% CI 0.02 to 1.29
(Analysis 14.2)), or the number of women requiring additional
antiemetic drugs (RR 0.50, 95% CI 0.05 to 5.17 (Analysis 14.3))
between the group of women who received parenteral fluid with
diazepam group and those who received parenteral fluid without
diazepam. Similarly, there was no differences identified between
the two groups in terms of the number of women who had congenital abnormalities (the trialist authors reported no congenital abnormalities in either group, Analysis 14.4), the incidence of
preterm delivery (RR 0.50, 95% CI 0.05 to 5.17 (Analysis 14.5)),
or in the rate of women who decided to terminate the pregnancy
due to the hyperemesis (RR 3.00, 95% CI 0.13 to 70.30) (Analysis
14.6).
No other secondary outcome data were available for analysis.

Secondary outcomes
Regarding secondary outcomes, the rate of sedation (adverse effect) was decreased with ondansetron (RR 0.06, 95% CI 0.00 to
0.94 (Analysis 15.2), low-quality evidence), no other side effects
were observed.
No other secondary outcomes were reported.

Ondansetron versus metoclopramide (two studies with 243
women)

Two studies (involving 243 women) compared ondansetron with
metoclopramide - the results have already been reported under
the comparison of metoclopramide versus ondansetron (see above
and Comparison 11 in Data and analyses).

Phenothiazines
Serotonin antagonist
Promethazine versus metoclopramide
Ondansetron versus promethazine

One study (Sullivan 1996, involving 30 women) randomized
women to receive either 10 mg intravenous ondansetron or 50 mg
intravenous promethazine for one dose then every eight hours as
needed. (See Summary of findings 6.)

One study (Tan 2010, involving 149 women) compared 10 mg
intravenous metoclopramide to 25 mg intravenous promethazine
given every 8 hours for 24 hours - the results have already been
reported under the comparison of metoclopramide versus promethazine (see above and Comparison 13 in Data and analyses).

Ondansetron versus promethazine

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Specific subjective nausea scores were not reported by Sullivan
1996 and could not be entered into our RevMan tables. However,
the trialist reported no significant difference in the severity of
nausea between the two groups.

Number of episodes of emesis
There were no data available on number of episodes of emesis.

One study (Sullivan 1996, involving 30 women) randomized
women to receive either 10 mg intravenous ondansetron or 50 mg
intravenous promethazine for one dose then every eight hours as
needed. The results have already been reported under the comparison of promethazine versus ondansetron (see above and Comparison 15 in Data and analyses).

Corticosteroids versus promethazine (two studies with 120
women)

Two studies (involving a total of 120 women) were involved in
this comparison. One study (Safari 1998) evaluated oral methylprednisolone 16 mg three times daily versus oral promethazine 25
mg three times daily, while another one (Ziaei 2004) compared 5
mg oral prednisolone with 75 mg oral promethazine daily for 10
days. (See Summary of findings 7.)
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Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
In one study (Ziaei 2004), the number of women with severe nausea at 48 hours was higher in the prednisolone group compared to
the promethazine group (RR 2.00, 95% CI 1.08 to 3.72 (Analysis
16.1), low-quality evidence) and at day 17 was not significantly different between groups (RR 0.81, 95% CI 0.58 to 1.15 (Analysis
16.2), very low-quality evidence). We did not find any difference in
the number of episodes of vomiting at 48 hours (RR 3.00, 95%
CI 0.33 to 27.63 (Analysis 16.3)) and at 17 days (RR 1.00, 95%
CI 0.21 to 4.65 (Analysis 16.4), very low-quality evidence).
In another study, Safari 1998 reported on therapy failure as defined
by persistence of vomiting more than five times/day, inability to
tolerate liquids, and the women’s impression that they were not
better, and there was no difference between groups (RR 1.50, 95%
CI 0.28 to 8.04 (Analysis 16.5)).

Number of episodes of emesis
Ziaei (Ziaei 2004) reported increased number of episodes of emesis
in the prednisolone group at 48 hours, but no difference at day
17; however data were reported as a median so were not able to be
analyzed.

(RR 0.08, 95% CI 0.00 to 1.32 (Ziaei 2004, 80 women), lowquality evidence (Analysis 16.13)). Regarding quality of life, the
number of women who reported becoming well or partially well
by 48 hours was lower in the prednisolone group compared to
promethazine (RR 0.67, 95% CI 0.47 to 0.95 (Analysis 16.14)),
while no difference was identified in the number of women who
reported becoming well or partially well by 17 days (RR 1.67,
95% CI 0.95 to 2.92 (Analysis 16.15)) (Ziaei 2004).
No other secondary outcomes were reported.

Steroid hormones

Corticosteroids versus placebo

There were four studies (involving 271 women) that evaluated
the efficacy of steroids versus placebo in hyperemesis gravidarum
(Duggar 2001; Nelson-Piercy 2001; Tabatabaii 2008; Yost 2003).
The women in Duggar 2001 received oral methylprednisone 12
tablets of 4 mg methylprednisone daily for three days followed
by a 10-day taper. The women in Nelson-Piercy 2001 received
20 mg of oral prednisolone every 12 hours for one week; they
also received additional antiemetics as deemed necessary by the
providers. The women in Tabatabaii 2008 and Yost 2003 received
125 mg of intravenous methylprednisolone followed by an oral
prednisone taper; in the former study the women also received B6,
in the latter study the women also received metoclopramide and
promethazine as standard of care. Results for this comparison are
set out in Summary of findings 8.

Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes
Regarding secondary outcomes, there was no strong evidence of
differences in the rate of hospital readmission (RR 0.09, 95%
CI 0.01 to 1.53 (Safari 1998, 34 women) (Analysis 16.6)), in the
number of women requiring additional antiemetics (RR 1.50,
95% CI 0.28 to 8.04 (Safari 1998, 40 women) (Analysis 16.7)), or
in the rate of stillbirth/neonatal death (RR 3.00, 95% CI 0.13
to 69.52 (Safari 1998, 40 women, low-quality evidence) (Analysis
16.8), in the rate of preterm birth (RR 3.00, 95% CI 0.13 to
69.52 (Safari 1998, 40 women, low-quality evidence) (Analysis
16.9)), or in the rate of women who decided to terminate the
pregnancy (RR 3.00, 95% CI 0.13 to 69.52 (Safari 1998, 40
women) (Analysis 16.10)). In terms of side effects, there was no
difference in the rate of women who felt abdominal pain during
the first 48 hours (RR 0.33, 95% CI 0.07 to 1.55 (Ziaei 2004, 80
women) (Analysis 16.11)), and between the third and 10th day
(RR 0.11, 95% CI 0.10 to 2.00 (Ziaei 2004, 80 women) (Analysis
16.12)). The rate of drowsiness was also not substantially different

Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
Nelson-Piercy 2001 reported a non-significant reduction in severity of nausea in the steroid versus placebo group, however this was
reported as a median and could not be included into the analysis.

Number of episodes of emesis
There were no data available on number of episodes of emesis.

Days of hospital admission
Days of hospital admission were available from Yost 2003, there
was no clear difference (MD -0.30 day, 95% CI -0.70 to 0.10, very
low-quality evidence) in the number of days of hospital admission
between groups (Analysis 17.1).
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Secondary outcomes
Regarding secondary outcomes, the rate of hospital readmission
was lower in the steroid hormone group compared to the placebo
group of women (RR 0.69, 95% CI 0.50 to 0.94, four studies,
269 women (Analysis 17.2)) (Duggar 2001; Nelson-Piercy 2001;
Tabatabaii 2008; Yost 2003). There was no difference in the rate
of pregnancy complications (pregnancy hypertension or gestational diabetes (RR 0.61, 95% CI 0.26 to 1.47, very low-quality
evidence (Analysis 17.3)) based on data reported in Yost 2003 (110
women). There was no significant difference in the rate of spontaneous abortion (RR 0.64, 95% CI 0.11 to 3.70 (Yost 2003, 110
women, very low-quality evidence) (Analysis 17.4)). There was no
difference in the rate of stillbirth or neonatal death (RR 0.70,
95% CI 0.09 to 5.29, two studies, 134 women, very low-quality
evidence) (Analysis 17.5)). Only one study (Yost 2003) reported on
congenital abnormalities, and there was no difference between
groups (RR 0.32, 95% CI 0.01 to 7.73, one study 110 women,
very low-quality evidence (Analysis 17.6)). One study (Yost 2003)
reported on low birthweight (RR 1.35, 95% CI 0.46 to 4.00,
110 women (Analysis 17.7), very low-quality evidence) and another
study (Nelson-Piercy 2001) reported on small-for-gestationalage infants (RR 1.00, 95% CI 0.07 to 14.21, 24 women (Analysis
17.8)) and there was no significant difference between groups for
either outcome. One study (Yost 2003) reported on preterm birth
less than 36 weeks and Nelson-Piercy 2001 reported on preterm
birth less than 37 weeks, when we combined these data using a
random-effects analysis (due to substantial statistical heterogeneity) there was no difference between groups (average RR 1.01, 95%
CI 0.31 to 3.28; two studies, 134 women, Tau² = 0.27, I² = 37%
(Analysis 17.9), very low-quality evidence). Duggar 2001 reported
intervention side effects (specifics side effects not reported) and
found no difference in the rate of side effects (RR 0.79, 95%
CI 0.06 to 11.20, 25 women, very low-quality evidence (Analysis
17.10)). One study (Nelson-Piercy 2001) reported on the number
of women requiring additional antiemetics and there was no
clear difference between groups for this outcome (RR 0.56, 95%
CI 0.26 to 1.17, 24 women (Analysis 17.11)) and there was also
no difference in the number of women who decided to terminate
the pregnancy (RR 0.33, 95% CI 0.01 to 7.45, (Nelson-Piercy
2001) 24 women (Analysis 17.12)).
There were no data available on any other secondary outcome.

son of corticosteroids versus promethazine above (see above and
Comparison 14 in Data and analyses).
Hydrocortisone versus metoclopramide (one study with 40
women)

One study (Bondok 2006, involving 40 women) compared
women receiving 300 mg intravenous hydrocortisone daily for
three days, tapered over the week, versus 10 mg of intravenous
metoclopramide three times daily for one week. The results have
already been reported under the comparison of hydrocortisone
versus metoclopramide (see above and Comparison 12 in Data
and analyses).
Adrenocorticotropic hormone (ACTH) versus placebo

One study (Ylikorkala 1979, involving 32 women) randomized
women to 0.5 mg intramuscular ACTH versus placebo for four
days. There were no data available on number of episodes of emesis
or days of hospital admission.
Primary outcomes

Severity, reduction, or cessation in nausea/vomiting
In terms of mean relief score, there was no difference between
the group of women who received intramuscular ACTH and the
group of women who received a placebo (MD 0.60 points, 95%
CI -1.65 to 2.85 (Analysis 18.1)).

Number of episodes of emesis
There were no data available on number of episodes of emesis.

Days of hospital admission
There were no data available on the number of days of hospital
admission.
Secondary outcomes

Corticosteroids versus promethazine (two studies with 120
women)

Two studies (involving a total of 120 women) were involved in
this comparison. One study (Safari 1998) evaluated oral methylprednisolone 16 mg three times daily versus oral promethazine 25
mg three times daily, while another one (Ziaei 2004) compared 5
mg oral prednisolone with 75 mg oral promethazine daily for 10
days. The results have already been reported under the compari-

Regarding secondary outcomes, the group of women who received
intramuscular ACTH had a higher mean weight gain than the
women in the placebo group (MD 1.0 kg, 95% CI 0.34 to 1.66
(Analysis 18.2)). There was no difference between groups in terms
of the rate of hospital readmission (RR 1.00, 95% CI 0.16 to
6.25 (Analysis 18.3)), rate of spontaneous abortion (RR 1.00,
95% CI 0.07 to 14.64 (Analysis 18.4), or rate of preterm birth
(RR 3.00, 95% CI 0.13 to 68.57 (Analysis 18.5)).
Data on other secondary outcomes were not available.
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Subgroup analysis
Subgroup analysis on primary outcomes was planned to be performed on the following subgroups: singleton versus multiple gestation, prime versus multiparous, and women with over 5% weight
loss versus women without less than 5% weight loss. Unfortunately, there were insufficient data to carry out these subgroup
analyses. No studies that included multiple gestations or multiparous women reported data separately for those groups. Eight
studies included only singleton gestations, but they were all also
the only study in their comparison group (Bondok 2006; Ditto
1999; Gawande 2011; Neri 2005; Sullivan 1996; Tan 2009; Tan

2010; Tan 2013). Both Kashifard 2013, which included only singletons, and Abas 2014, which included multiple gestations, compared metoclopramide and ondansetron, however Kashifard 2013
did not have data available on primary outcomes for analysis.
Three studies included weight loss over 5% as an inclusion criteria (Bondok 2006; Ditto 1999; Neri 2005), one study required
women to have more than 2.25 kg weight loss (Sullivan 1996),
and one study required women to have had weight loss of at least
3 kg (Kashifard 2013), but again they were the only studies in
their comparison group or did not have data on primary outcomes
available for analysis.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]

Acupuncture versus m etoclopram ide
Patient or population: pregnant wom en with hyperem esis gravidarum
Setting: Study in Italy
Intervention: Acupuncture
Comparison: M etoclopram ide
Outcomes

Anticipated absolute effects∗ (95% CI)

Risk with
pramide

of participants
(studies)

Quality of the evidence Comments
(GRADE)

RR 1.40
(0.79 to 2.49)

81
(1 RCT)

⊕
VERY LOW 12

Absolute ef f ects calculated f rom results of
single study.

RR 1.51
(0.92 to 2.48)

81
(1 RCT)

⊕
VERY LOW 12

Absolute ef f ects calculated f rom results of
single study.

metoclo- Risk with Acupuncture

Reduction or cessation Study population
in nausea
316 per 1000

Reduction or cessation Study population
in vom iting
368 per 1000

1. Num ber of episodes Not reported
of em esis
2. Days of hospital adm ission
3. Intervention side ef f ects
4. Quality of lif e outcom es
5. Pregnancy com plications
6. Adverse f etal/ neonatal outcom es

Relative effect
(95% CI)

442 per 1000
(249 to 786)

556 per 1000
(339 to 914)
Not estim able

The study included in
this com parison did not
report these review outcom es
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1
2

Single study with design lim itations contributing data
Sm all sam ple size and wide 95% CIs crossing the line of no ef f ect
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Pyridoxine versus placebo
Patient or population: pregnant wom en with hyperem esis gravidarum
Setting: Study in M alaysia
Intervention: Pyridoxine
Comparison: Placebo
Outcomes

Anticipated absolute effects∗ (95% CI)

Risk with placebo
Num ber of episodes of M ean episodes 1.4
em esis

Relative effect
(95% CI)

of participants
(studies)

Quality of the evidence Comments
(GRADE)

Risk with Pyridoxine
⊕⊕
LOW 1

The absolute ef f ects
were f rom a single
study

Days of hospital adm is- The m ean days of hos- The m ean days of hos- The m ean days of hos- 92
sion
pital adm ission was 3. pital adm ission was 3. pital adm ission in the (1 RCT)
1
9.
intervention group was
0.8 days m ore (0.08
m ore to 1.52 m ore)

⊕⊕⊕
M ODERATE 2

The absolute ef f ects
were f rom a single
study

Interventions side ef - Study population
f ects: dizziness
273 per 1000

Interventions side ef - Study population
f ects: headaches
182 per 1000

M ean episodes 1.9

The m ean num ber of 66
episodes of em esis in (1 RCT)
the intervention group
was 0.5 m ore (0.4 f ewer
to 1.4 m ore)

RR 1.67
(0.85 to 3.26)

66
(1 RCT)

⊕⊕
LOW 1

The absolute ef f ects
were calculated f rom a
single study

RR 1.33
(0.52 to 3.42)

66
(1 RCT)

⊕⊕
LOW 1

The absolute ef f ects
were calculated f rom a
single study

455 per 1000
(232 to 889)

242 per 1000
(95 to 622)
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Interventions side ef - Study population
f ects: diarrhoea
0 per 1000

Interventions side ef - Study population
f ects: palpitations
91 per 1000

Interventions side ef - Study population
f ects: dry m outh
515 per 1000

RR 3.00
(0.13 to 71.07)

66
(1 RCT)

3

The absolute ef f ects
were calculated f rom a
single study

RR 1.00
(0.22 to 4.60)

66
(1 RCT)

⊕⊕
LOW 3

The absolute ef f ects
were calculated f rom a
single study

RR 0.82
(0.49 to 1.38)

66
(1 RCT)

⊕⊕
LOW 1

The absolute ef f ects
were calculated f rom a
single study

0 per 1000
(0 to 0)

91 per 1000
(20 to 418)

422 per 1000
(252 to 711)

1. Severity, reduction Not reported
or cessation in nausea/
vom iting
2. Quality of lif e outcom es
3. Pregnancy com plications
4. Adverse f etal/ neonatal outcom es

Not estim able

The studies included
in this com parison did
not include these review outcom es

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1
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Sm all sam ple size and wide 95% CIs crossing the line of no ef f ect
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M etoclopram ide versus ondansetron
Patient or population: pregnant wom en with hyperem esis gravidarum
Setting: Studies in Iran (1) and M alaysia (1)
Intervention: M etoclopram ide
Comparison: Ondansetron
Outcomes

Anticipated absolute effects∗ (95% CI)

Risk with ondansetron Risk with
pramide

Relative effect
(95% CI)

of participants
(studies)

Quality of the evidence Comments
(GRADE)

M etoclo-

Severity of nausea

The m ean severity The m ean severity The m ean severity of 83
score with ondansetron score with m etoclo- nausea in the interven- (1 RCT)
was 3.4
pram ide was 5.1
tion group was 1.7 m ore
(0.15 less to 3.55 m ore)

⊕
VERY LOW 12

Absolute ef f ects f rom
single study

Severity of vom iting

The m ean severity of The m ean severity The m ean severity of 83
vom iting score with on- score with m etoclo- vom iting in the interven- (1 RCT)
dansetron was 4.8
pram ide was 4.7.
tion group was 0.1 less
(1.63 less to 1.43 m ore)

⊕
VERY LOW 12

Absolute ef f ects f rom
single study

Quality of lif e

The m ean quality of lif e The m ean quality of The m ean quality of 160
score with ondansetron lif e score with m etoclo- lif e in the intervention (1 RCT)
was 8.7.
pram ide was 8.3.
group was 0.4 less (0.
83 less to 0.03 m ore)

⊕⊕⊕
M ODERATE 3

Absolute ef f ects f rom
single study

Intervention side ef - Study population
f ects: f elt drowsy
125 per 1000

Intervention side ef - Study population
f ects: unable to sleep

RR 2.40
(1.23 to 4.69)

160
(1 RCT)

⊕⊕⊕
M ODERATE 3

Absolute ef f ects calculated f rom single study

RR 1.29
(0.50 to 3.28)

160
(1 RCT)

⊕⊕
LOW 2

Absolute ef f ects calculated f rom single study

300 per 1000
(154 to 586)
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88 per 1000

Intervention side ef - Study population
f ects: dry m outh
100 per 1000

Intervention side ef - Study population
f ects: f elt dizzy
75 per 1000

113 per 1000
(44 to 287)
RR 2.38
(1.10 to 5.11)

160
(1 RCT)

⊕⊕⊕
M ODERATE 3

Absolute ef f ects calculated f rom single study

RR 2.33
(0.94 to 5.77)

160
(1 RCT)

⊕⊕
LOW 2

Absolute ef f ects calculated f rom single study

238 per 1000
(110 to 511)

175 per 1000
(71 to 433)

1. Severity, reduction Not reported
or cessation in nausea/
vom iting
2.Days of hospital adm ission
3. Pregnancy com plications
4. Adverse f etal/ neonatal outcom es

Not estim able

The studies included in
this com parison did not
report these review outcom es

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1

Single study with design lim itations contributing data
Sm all sam ple size and wide 95% CIs crossing the line of no ef f ect
3 Estim ate based on single study with sm all sam ple size

2
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M etoclopram ide versus prom ethazine
Patient or population: Pregnant wom en with hyperem esis gravidarum
Setting: Study in M alaysia
Intervention: M etoclopram ide
Comparison: Prom ethazine
Outcomes

Anticipated absolute effects∗ (95% CI)

Risk with
hazine
Quality of lif e

promet- Risk with
pramide

Relative effect
(95% CI)

of participants
(studies)

M etoclo-

The m ean quality of lif e The m ean quality of lif e The m ean quality of lif e 149
score was 7.1
score was 7.6
score in the interven- (1 RCT)
tion group was 0.5 m ore
(0.22 less to 1.22 m ore)

Intervention side ef - Study population
f ects: drowsy
836 per 1000

Intervention side ef - Study population
f ects: unable to sleep
219 per 1000

Intervention side ef - Study population
f ects: dry m outh
438 per 1000

Intervention side ef - Study population
f ects: f elt dizzy

Quality of the evidence Comments
(GRADE)

⊕⊕
LOW 1

Absolute ef f ects f rom
single study.

RR 0.70
(0.56 to 0.87)

143
(1 RCT)

⊕⊕⊕
M ODERATE 2

Absolute ef f ects calculated f rom single study.

RR 0.78
(0.40 to 1.53)

143
(1 RCT)

⊕⊕
LOW 1

Absolute ef f ects calculated f rom single study.

RR 0.91
(0.62 to 1.34)

143
(1 RCT)

⊕⊕
LOW 1

Absolute ef f ects calculated f rom single study.

RR 0.48
(0.34 to 0.69)

143
(1 RCT)

⊕⊕⊕
M ODERATE 2

Absolute ef f ects calculated f rom single study.

585 per 1000
(468 to 727)

171 per 1000
(88 to 335)

399 per 1000
(272 to 587)
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712 per 1000

Intervention side ef - Study population
f ects: diarrhea
41 per 1000

Intervention side ef - Study population
f ects: headache
301 per 1000

342 per 1000
(242 to 492)
RR 1.39
(0.32 to 5.99)

143
(1 RCT)

⊕⊕
LOW 3

Absolute ef f ects calculated f rom single study.

RR 0.81
(0.47 to 1.38)

143
(1 RCT)

⊕⊕
LOW 1

Absolute ef f ects calculated f rom single study.

57 per 1000
(13 to 246)

244 per 1000
(142 to 416)

1. Severity, reduction Not reported
or cessation in nausea/
vom iting
2. Num ber of episodes
of em esis
3. Days of hospital adm ission
4. Pregnancy com plications
5. Adverse f etal/ neonatal outcom es

Not estim able

The study included in
this com parison did not
report these review outcom es

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
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Estim ate based on single study with sm all sam ple size
Sm all sam ple size, low event rate and wide 95% CIs crossing the line of no ef f ect
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Ondansetron versus prom ethazine
Patient or population: Pregnant wom en with hyperem esis gravidarum
Setting: Study in the USA
Intervention: Ondansetron
Comparison: Prom ethazine
Outcomes

Anticipated absolute effects∗ (95% CI)

Risk with
hazine

Relative effect
(95% CI)

of participants
(studies)

Quality of the evidence Comments
(GRADE)

promet- Risk with Ondansetron

Days of hospital adm is- The m ean days of hos- The m ean days of hos- The m ean dif f erence in 30
sion
pital adm ission was 4. pital adm ission was days of hospital adm is- (1 RCT)
47 with prom ethazine 4.47 days with on- sion in the intervention
dansetron
group was 0 (1.39 f ewer
to 1.39 m ore)

⊕
VERY LOW 12

Absolute ef f ect f rom
one study

Intervention side ef f ect: Study population
sedation
533 per 1000

⊕⊕
LOW 13

Absolute ef f ects calculated f rom one study

1. Severity, reduction Not reported
or cessation in nausea/
vom iting
2. Num ber of episodes
of em esis
3. Quality of lif e outcom es
4. Pregnancy com plications
5. Adverse f etal/ neonatal outcom es

RR 0.06
(0.00 to 0.94)

30
(1 RCT)

32 per 1000
(0 to 501)
Not estim able

The study included in
this com parison did not
report these review outcom es
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1

Single study with design lim itations contributing data
Sm all sam ple size and wide 95% CIs crossing the line of no ef f ect
3 Estim ated based on single study with sm all sam ple size

2
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Corticosteroids versus prom ethazine
Patient or population: Pregnant wom en with hyperem esis gravidarum
Setting: Studies in the USA (1) and Iran (1)
Intervention: Corticosteroids
Comparison: Prom ethazine
Outcomes

Anticipated absolute effects∗ (95% CI)

Risk with
hazine

promet- Risk with
teroids

Severe nausea 48 hours Study population
250 per 1000

Episodes of vom iting Study population
48 hours
25 per 1000

Episodes of vom iting Study population
17th day
77 per 1000

41

InStudy population
tervention side ef f ects:
drowsiness 48hrs and
3-10 days

of participants
(studies)

Quality of the evidence Comments
(GRADE)

RR 2.00
(1.08 to 3.72)

80
(1 RCT)

⊕⊕
LOW 12

Absolute estim ates calculated f rom single
study

RR 0.81
(0.58 to 1.15)

78
(1 RCT)

⊕
VERY LOW 13

Absolute estim ates calculated f rom single
study

RR 3.00
(0.33 to 27.63)

80
(1 RCT)

⊕
VERY LOW 14

Absolute estim ates calculated f rom single
study

RR 1.00
(0.21 to 4.65)

78
(1 RCT)

⊕
VERY LOW 14

Absolute estim ates calculated f rom single
study

RR 0.08
(0.00 to 1.32)

80
(1 RCT)

⊕⊕
LOW 15

Absolute estim ates calculated f rom single
stud

Corticos-

500 per 1000
(270 to 930)

Severe nausea 17th day Study population
692 per 1000

Relative effect
(95% CI)

561 per 1000
(402 to 796)

75 per 1000
(8 to 691)

77 per 1000
(16 to 358)
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150 per 1000

12 per 1000
(0 to 198)

Stillbirth and neonatal
death

RR 3.00
(0.13 to 69.52)

40
(1 RCT)

⊕⊕
LOW 12

Low event rate. Absolute estim ate not calculated

Preterm birth

RR 3.00
(0.13 to 69.52)

40
(1 RCT)

⊕⊕
LOW 4

Low event rate. Absolute estim ate not calculated

1. Days of hospital ad- Not reported
m ission
2. Quality of lif e outcom es
3. Pregnancy com plications

Not estim able

The studies included in
this com parison did not
report these review outcom es

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1

Single study with design lim itations contributing data
Estim ate based on single study with sm all sam ple size
3 Sm all sam ple size and wide 95% CIs crossing the line of no ef f ect
4
Sm all sam ple size, low event rate and wide 95% CIs crossing the line of no ef f ect
5 Estim ate based on single study with sm all sam ple size and low event rate
2
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Corticosteroids versus placebo
Patient or population: Pregnant wom en with hyperem esis gravidarum
Setting: Studies in the USA (2) and UK (1)
Intervention: Corticosteroids
Comparison: Placebo
Anticipated absolute effects∗ (95% CI)

Outcomes

Risk with placebo

Risk with
teroids

Relative effect
(95% CI)

of participants
(studies)

Quality of the evidence Comments
(GRADE)

Corticos-

Days of hospital adm is- The m ean days of hos- The m ean days of hos- The m ean days of hos- 110
sion
pital adm ission was 2. pital adm ission was 1. pital adm ission in the (1 RCT)
2 days
9 days
intervention group was
0.3 days f ewer (0.7
f ewer to 0.1 m ore)

⊕
VERY LOW 12

Absolute ef f ects f rom a
single study

Pregnancy
tions

com plica- Study population
204 per 1000

Spontaneous abortion

Stillbirth and neonatal Study population
death
45 per 1000

Congenital abnorm ali- Study population
ties
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110
(1 RCT)

⊕
VERY LOW 12

Absolute ef f ects calculated f rom a single
study

RR 0.64
(0.11 to 3.70)

110
(1 RCT)

⊕
VERY LOW 13

Absolute ef f ects calculated f rom a single
study

RR 0.70
(0.15 to 3.34)

134
(2 RCTs)

⊕
VERY LOW 13

Absolute ef f ects calculated f rom a single
study

RR 0.32
(0.01 to 7.73)

110
(1 RCT)

⊕
VERY LOW 13

Absolute ef f ects calculated f rom a single
study

124 per 1000
(53 to 299)

Study population
56 per 1000

RR 0.61
(0.26 to 1.47)

36 per 1000
(6 to 206)

32 per 1000
(7 to 152)
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19 per 1000

Intervention side ef - Study population
f ects
91 per 1000

Preterm birth

6 per 1000
(0 to 143)

1. Severity, reduction Not reported
or cessation in nausea/
vom iting
2. Num ber of episodes
of em esis
3. Quality of lif e outcom es

25
(1 RCT)

⊕
VERY LOW 13

Absolute ef f ects calculated f rom a single
study

RR 1.01
(0.31 to 3.28)

134
(2 RCTs)

⊕
VERY LOW 245

Absolute ef f ects based
on inconsistent f indings in 2 studies

72 per 1000
(5 to 1000)

Study population
121 per 1000

RR 0.79
(0.06 to 11.20)

122 per 1000
(38 to 398)
Not estim able

The studies included in
this com parison did not
report these review outcom es

* The risk in the intervention group (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its
95% CI).
CI: Conf idence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect
M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is
substantially dif f erent
Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect
Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect
1

Single study with design lim itations contributing data
Sm all sam ple size and wide 95% CIs crossing the line of no ef f ect
3 Sm all sam ple size, low event rate and wide 95% CIs crossing the line of no ef f ect
4
Data f rom studies with design lim itations
5 Inconsistent ef f ect in the two studies contributing data

2
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DISCUSSION

Summary of main results
This review included 25 studies (involving 2052 women), but
the majority of our analyses are based on data from single studies
with small numbers of participants. The included studies covered
a range of interventions (both pharmacological and non-pharmacological, such as acupressure/acupuncture, outpatient care, intravenous fluids, and various pharmaceutical interventions) for treating hyperemesis gravidarum. There were no studies of dietary or
other lifestyle interventions. However, the majority of interventions were evaluated in small, often unique, trials, making strong
clinical recommendations impossible.
1. Acupuncture/acupressure was associated with fewer women
requiring additional antiemetics compared to placebo. There was
no clear difference in miscarriage, preterm birth, stillbirth or
neonatal death, decision to terminate the pregnancy, or
anxiodepressive symptoms compared to placebo. There was no
difference in the rate of women who experienced a reduction in
nausea or vomiting compared to metoclopramide. Acupuncture
was associated with greater improvement in nausea/vomiting
compared to phenobarbital and Chinese medicine.
2. Chinese medicine compared to phenobarbital had no
difference in improvement in nausea and vomiting.
3. There were no studies solely on dietary or lifestyle
modification, although, midwife-led outpatient care was
associated with fewer hours of hospital admission than routine
inpatient admission with no difference in pregnancy-unique
quantification of emesis and nausea (PUQE) score, decision to
terminate the pregnancy, miscarriage, small-for-gestational age
infants, or time off work when compared with routine care.
4. Tailored care based on a holistic assessment in addition to
standard care compared to standard care alone did not
demonstrate any difference in improvement of nausea and
vomiting or quality of life.
5. There was greater degree of subjective improvement found
with muscle relaxation therapy and pharmacotherapy compared
to pharmacotherapy alone with no clear difference in decision to
terminate the pregnancy.
6. There was no difference in duration of hospital stay with
dextrose saline fluids versus normal saline for rehydration.
7. Vitamin B6 showed a slightly longer hospital admission
compared with placebo, but no difference in the number of
episodes of emesis. There was also no difference found in the rate
of hospital readmission, weight loss, or medication side effects
compared to placebo.
8. Parenteral fluid with diazepam compared to parenteral fluid
alone had a decreased mean duration of hospital admission, but
there was no difference in the hospital readmission rate, number
of women requiring additional antiemetics, number of women

choosing to terminate the pregnancy, or in the rate of preterm
delivery. Neither group had any cases of congenital anomalies.
9. Metoclopramide compared to ondansetron had similar
nausea and vomiting severity, but increased rate of drowsiness
and dry mouth. Compared to hydrocortisone, metoclopramide
had similar rates of hospital readmission and need for enteral/
parenteral nutrition. Compared to promethazine, there was no
difference in quality of life measures, but there were decreased
rates of drowsiness, dizziness and dystonia with metoclopramide.
10. Ondansetron compared to promethazine had no clear
difference in days of hospital admission but decreased rate of
sedation, and compared to metoclopramide, had a lower rate of
drowsiness and dry mouth with no difference in nausea/
vomiting severity.
11. Promethazine compared to metoclopramide had similar
mean well-being outcomes with increased rate of drowsiness,
dizziness and dystonia. Promethazine compared with
ondansetron showed no difference in days of hospital admission
but had an increased rate of sedation. Promethazine compared
with corticosteroids had improved well-being scores and
improved nausea at 48 hours, but not by day 17. Compared with
corticosteroids, there was no difference episodes of emesis, in the
number of women who had persistent vomiting, inability to
tolerate oral intake, or participant perceived improvement. There
was also no significant difference in readmission rate, women
requiring additional antiemetics, rate of stillbirth, neonatal
death, preterm delivery, decision to terminate the pregnancy, or
medication side effects.
12. Corticosteroids compared to placebo had a lower rate of
hospital readmission, but otherwise demonstrated no difference
in days of hospital admission, medication side effects, number of
women requiring additional antiemetics, decision to terminate
the pregnancy or adverse pregnancy outcomes including
hypertension, diabetes, stillbirth or neonatal death, congenital
anomalies, and low birthweight. Compared to promethazine,
steroids were associated with lower well-being, and had more
severe nausea at 48 hours, although this did not persist by day
17. There was also no significant difference in readmission rate,
women requiring additional antiemetics, rate of stillbirth,
neonatal death, preterm delivery, decision to terminate the
pregnancy, or medication side effects. Compared to
metoclopramide, treatment with corticosteroids demonstrated
no difference in hospital readmission.
13. Treatment with ACTH compared to placebo had no strong
evidence of difference in mean relief score, but did demonstrate
increased mean weight gain. There was also no clear difference
found in rate of readmission, miscarriage, or preterm delivery.

Overall completeness and applicability of
evidence
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We attempted to be as inclusive as possible in the search strategy and have included studies in languages other than English.
Nonetheless, the studies reported are predominantly from European and North American journals, which may limit the external
validity of these result.
Interpreting and comparing the findings of the studies included
was difficult because of the variation in the reporting of the subjective outcome of severity of nausea and vomiting, thus the metaanalysis component of this review is limited. In addition, even
within a comparison, often dosages or route of administration varied between studies, we treated them as equivalent which is not
necessarily clinically true.
Limited data were available regarding adverse maternal and neonatal outcomes, thus the lack of report on adverse events or the lack
of statistical significance does not necessarily mean no harm is
present. Larger studies on individual interventions need to be examined to determine the safety of these many interventions.
There was also very limited reporting on the economic impact of
hyperemesis gravidarum and the impact on this economic burden
that interventions may have. Although studies often reported an
overall well-being score, this does not necessarily equate with ability to return to work.

validation in nausea and vomiting of pregnancy. Other studies
used the Rhodes Index of Nausea, Vomiting, and Retching, which
was originally developed to measure symptoms of chemotherapy,
but has been validated in pregnancy (Rhodes 1984; Zhou 2001).
Other studies used pregnancy specific questionnaires, either of the
author’s creation, without support of validation, or the more commonly used PUQE, which has been validated (Koren 2005).
For important outcomes and comparisons we graded the quality of
the evidence using the GRADE approach. When outcomes were
reported, at best the evidence was graded as being of moderate
quality, while for most outcomes the evidence was assessed as being
of low or very low quality. The main reasons for downgrading
the evidence were design limitations in the studies contributing
data, but most importantly the imprecision of effect estimates. For
most outcomes, single studies with relatively small sample sizes
contributed data. Studies were mainly under-powered to identify
differences between comparison groups and most effect estimates
had wide 95% CIs crossing the line of no effect.
See Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Summary of
findings 7; Summary of findings 8.

Quality of the evidence

Potential biases in the review process

We were unable to pool findings for most interventions reviewed
here because of heterogeneity in intervention and comparison
groups and in outcomes measured, thus most results presented
are from individual studies. Additionally, inclusion and exclusion
criteria varied between studies. Studies were included on the basis
of their own definition of hyperemesis gravidarum, which may
or may not have included objective criteria like weight loss. The
methodological quality of the included studies varied. A number
of studies were published in abstract form only, and not enough
methodological detail was provided to appropriately assess any
type of risk of bias. For studies published in full, the quality was
generally good with adequate quality in randomization, outcome
reporting, and limited attrition. However, for a number of studies were there was not enough information to appropriately assess
blinding of either participants or investigators. Additionally, no
study reported on the quality of their blinding, thus it is possible that, for example, sham acupuncture was not believable. Appropriate blinding is especially important in this condition because the primary outcomes are often subjective and self-reported.
There was one study on outpatient versus inpatient management
where blinding was inherently impossible. Another limitation is
that studies with a placebo comparison often included standard
care for both groups which involved one or a combination of other
antiemetic medications, which varied by study, and the details
of which were not reported. Finally, there was heterogeneity in
the way in which outcomes were measured. Most studies used a
10-point visual analogue scale, without providing support of its

There is potential for bias in every step of the review process. We
attempted to limit the bias by having at least two review authors
independently carry out the evaluation of studies for inclusion,
data extraction, and quality assessment, with any discrepancies being resolved by a third review author. However, such an assessment
is still by nature subjective and a different team of review authors
may have had a different assessment.

Agreements and disagreements with other
studies or reviews
There are several other reviews and overviews on hyperemesis
gravidarum, with varying degrees of support from the literature
(Eliakim 2000; Goodwin 1998; Ismail 2007; Jarvis 2011; Maltepe
2013; McCarthy 2014a; Philip 2003; Sonkusare 2008). Goodwin
1998 mentions randomized trials on both nausea and vomiting of
pregnancy as well as hyperemesis gravidarum and acknowledges
the limited support from trials of various interventions. The authors do mention studies reviewed here (Sullivan 1996; Ylikorkala
1979), as well as a study we excluded based on cross-over design,
on the effect of ginger (Fischer-Rasmussen 1991). Their review
also supports the use of steroids in reducing the need for hospitalization, although does not include the more recent studies reviewed here.
Eliakim and colleagues (Eliakim 2000) mention a few interventions in their review, but with limited data supporting their con-
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clusion. In contrast to our review, they mention benefit of vitamin
B6, although the study they cite is for the treatment of nausea and
vomiting in pregnancy, rather than hyperemesis gravidarum. They
mention beneficial results for a number of antiemetics including
Bendectin, meclizine, metoclopramide, promethazine, hydroxyzine, trimethobenzamine, thielpyrazin, mepryramine, dimenhydrinate, droperidol, diphenhydramine, ondansetron, methylprednisolone, and ginger, but cites other reviews on nausea and vomiting of pregnancy as their sources rather than specific studies.
Philip 2003 provides a review that includes randomized trials, most
of which we have also included, as well as retrospective studies. The
authors have similarly found no benefit with ACTH (Ylikorkala
1979), no benefit of ondansetron over promethazine (Sullivan
1996), and possible benefit of corticosteroids (Duggar 2001; Safari
1998). They also conclude no benefit with vitamin B6. In contrast
to our review, they found no benefit from P6 acupressure where we
have found that there may be some benefit compared to placebo.
A review by Ismail and colleagues (Ismail 2007) similarly concludes limited benefit acupuncture/acupressure; they recommend
use of antiemetics, but do not provide data to support their efficacy
in hyperemesis gravidarum, and, in contrast to our review, found
no benefit with corticosteroids, while we did find a decreased rate
of hospitalization compared to placebo. Sonkusare 2008 examines
a number of different interventions, however includes trials on
nausea and vomiting of pregnancy along with hyperemesis gravidarum, and is not limited to randomized controlled trials. In contrast to our review, they found benefit with vitamin B6 and ginger.
They found no benefit with corticosteroids, based on only one
study, also included in this review (Yost 2003), and finally, they
concluded there was benefit with diazepam, nerve stimulation,
erythromycin, and cannabis (Sonkusare 2008).
The review by Jarvis in 2011 (Jarvis 2011) mentions trials for both
nausea and vomiting and pregnancy as well as hyperemesis, and
is not limited to randomized controlled trials. The authors similarly found little benefit of one antiemetic over another, describe
similar side-effect profiles to our review, although they conclude
drowsiness is most common with phenothiazines, which is not
something supported by evidence in our review. They also recommend normal saline over dextrose saline, for the risk of Wernicke’s
encephalopathy, although our review found no difference between
the two. They also found that corticosteroids may reduce hospital admissions. Maltepe 2013 provides a review primarily on nausea and vomiting of pregnancy with some mention of antiemetics
for hyperemesis gravidarum, without specific recommendations
or conclusions on their benefit. McCarthy 2014a provides a brief
overview on treatment for hyperemesis gravidarum, citing, however, the previously published Cochrane review on nausea and
vomiting of pregnancy, which specifically excludes hyperemesis
gravidarum (Matthews 2015). They similarly conclude limited evidence regarding the benefit of one antiemetic over another.

AUTHORS’ CONCLUSIONS
Implications for practice
Although there have been a number of reviews on the management of hyperemesis gravidarum, as described above, they often
have limited evidence to support their conclusions, and combine
interventions for nausea and vomiting of pregnancy with the more
severe condition of hyperemesis gravidarum.
On the basis of this review, there is little high-quality and consistent evidence supporting any one intervention, which should
be taken into account when making management decisions. Additionally, in evaluating various interventions, we have combined
various forms of a specific therapy for the purpose of the metaanalysis, such as intravenous and oral forms and different dosages,
so we cannot provide guidelines on specific doses or routes of the
antiemetics examined here.

Implications for research
The difficulty in interpreting the results of this review highlights
the importance of having a specific definition of hyperemesis gravidarum for use in trials, conducting randomized controlled trials in
comparing interventions, and using validated instruments for the
measurement of severity of nausea and vomiting. There should be
an agreed-upon set of clearly-defined and measurable outcomes
in trials of interventions for hyperemesis gravidarum, so that outcomes of trials can be combined in future meta-analyses.
The vast majority of the trials evaluating interventions for hyperemesis gravidarum were evaluated in only small, often unique, trials, so almost all interventions deserve to be evaluated further in
much larger, well-designed trials. We found little data on the use of
ginger, antihistamines, and dietary and lifestyle modifications in
the treatment of hyperemesis gravidarum, which is an area of further research. There was only one study on outpatient-led care that
found reduced hospital stay compared with routine care, which
certainly warrants further study. There were a number of studies comparing the commonly used antiemetics metoclopramide,
ondansetron, and promethazine, although data on primary outcomes were limited and the main differences found were in sideeffect profiles. There were also a number of studies on corticosteroids, but the heterogeneity in inclusion criteria, specific medications, and comparison groups in these studies makes it difficult
to draw conclusions from our results. Placebo-controlled trials on
steroids included other antiemetics in both groups as standard of
care, which varied by study, but the finding of decreased hospital
readmission rate warrants further study.
Finally, given that there was little evidence to support the superiority of one intervention over another in the treatment of hyperemesis, more research should be done comparing the side-effect
profiles and safety, as well as the economic costs and benefits of
these interventions to aid in the selection of the optimal regimen.
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]
Abas 2014
Methods

Randomized controlled trial.

Participants

Pregnant women with singleton gestations of 16 weeks or less with clinical diagnosis
of HG with clinical dehydration and ketonuria (2+ or greater) hospitalized for the first
time with this diagnosis. 80 women randomized to interventions and 80 to controls

Interventions

4 mg ondansetron IV infused over 10 minutes every 8 hours for 4 doses versus 10 mg
metoclopramide IV infused over 10 minutes every 8 hours for 4 doses

Outcomes

Vomiting episodes, well-being (10-point visual numeric rating scale), nausea intensity
(10-point visual numeric rating scale), ketonuria all at 24 hours, treatment curtailment,
open-label use of IV metoclopramide after the study, length of hospital stay

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that randomization was carried out in blocks
of 4 or 8 with sequence generated by computer

Allocation concealment (selection bias)

Low risk

Numbered, sealed, opaque envelopes were used to allocate treatment

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

1 author prepared and labeled the solutions. Study drug
packs were identical. Labeling of drugs was swapped periodically to prevent inadvertent elucidation of allocation from adverse effects

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Person self-reported number of emesis episodes and
recorded nausea in a diary. Maintenance of masking was
high and person unlikely to be aware of treatment allocation

Incomplete outcome data (attrition bias)
All outcomes

Low risk

The number of women lost to follow-up was low, and
accompanying reasons are reported. 4/80 and 3/80 from
each group did not complete the trial drug

Selective reporting (reporting bias)

Low risk

Methods state that predetermined outcomes were used
and reported, all expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias
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Bondok 2006
Methods

Randomized controlled trial.

Participants

Pregnant women at less than 16 weeks’ gestation with diagnosis of intractable HG
(severe persistent vomiting, ketonuria, and weight loss > 5% of prepregnancy weight)
necessitation ICU admission. 20 women randomized to interventions and 20 to controls

Interventions

300 mg IV hydrocortisone daily with taper versus 10 mg metoclopramide IV every 8
hours

Outcomes

Number of vomiting episodes, readmission to ICU.

Notes

1 participant required TPN.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Randomization conducted with a computer-generated
randomized list

Allocation concealment (selection bias)

Low risk

The code was held and syringes used for both groups
were identical in appearance

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

The study is described as a double-blind study. It is
stated that the personnel administering the drugs was
masked to treatment. The description of the administration schedule is a little ambiguous but it seems that
people in each group received a 10 mL injection every
8 hours. The syringes were identical in appearance

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Nurses recording the number of episodes of emesis were
blinded to the treatment, main investigators were also
blinded to which participants were in which group

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias
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Ditto 1999
Methods

Randomized controlled trial.

Participants

Women with HG at less than 16 weeks’ gestation, defined by persistent nausea and
vomiting for 1 week with at least 1 of the following: weight loss > 5% since beginning of
symptoms, ketonuria (3% increase), serum potassium less than 3.4 mEq/L. 25 women
randomized to interventions and 25 to controls

Interventions

IV saline, glucose, multivitamins with 10 mg IV twice daily and PO 5 mg bid diazepam
on discharge versus IV saline, glucose, multivitamins without diazepam

Outcomes

Severity of nausea (VAS 0-10), number of episodes of vomiting, hospital admission
length, number of readmissions, pregnancy outcome, neonatal outcome. lack of improvement defined by persistent (> 5 x/day) vomiting

Notes

Lack of improvement defined as persistent (> 5 x/day) vomiting. Primary outcome
reported as number of participants with improvement in figure form, specific numbers
not reported. No response from authors in request for additional data

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Random number table used to allocate participants.

Allocation concealment (selection bias)

Unclear risk

Details on methods used to conceal allocation not available.

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Insufficient reporting to determine presence of other
forms of bias

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias
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Duggar 2001
Methods

Randomized controlled trial.

Participants

Pregnant women with admission diagnosis of HG. 14 women randomized to interventions and 11 to controls

Interventions

Methylprednisone PO versus placebo.

Outcomes

Recurrence of vomiting after randomization, readmission, medication tolerance

Notes

Abstract only.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

Study is described as randomized, but details on method
of randomization not available

Allocation concealment (selection bias)

Unclear risk

Details on methods of allocation concealment not available.

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

The study is described as double-blind and it is stated
that treatment in the placebo group “looked like” that in
the methylprednisolone group. However, it is not stated
who was masked to treatment

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Number of people randomized to each group not reported. It is unclear whether anyone withdrew from
treatment or was lost to follow-up

Selective reporting (reporting bias)

Unclear risk

As a conference abstract, insufficient information reported to determine presence of selective reporting

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Fletcher 2015
Methods

Randomized controlled trial.

Participants

Pregnant women at least 16 years old diagnosed with HG defined as need for admission
with nausea and vomiting early in pregnancy, admitted within the previous 24 hours,
excluded women if nausea/vomiting commenced after 14 weeks
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Fletcher 2015

(Continued)

Interventions

Intervention comprised creation of a bespoke treatment plan for each patient based on
their response to the Hyperemesis Impact of Symptoms questionnaire. Scale based on 10
questions, scoring 0-3. A score of 2 or more indicates woman needs support in that area.
Treatment plan included practical and supportive care (dietary advice, practical advice
on symptom management and advice on psychological impact of symptoms). These
Women also received standard care (IV hydration plus antiemetic therapy). Comparison
group received standard care alone

Outcomes

Womens’ health status assessed using SF-36 and EQ-5D.
PUQE score recorded.
Client Satisfaction Questionnaire used to evaluate satisfaction with health care. Hospital
readmission rate. Cost-effectiveness. Primary outcome is social functioning, as assessed
using the SF-36

Notes

Data for analysis taken from the 2-week time point because this point had the highest
response rate

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that randomization was carried out remotely
by the York Trials Unit, using computer-generated simple allocation

Allocation concealment (selection bias)

Allocation randomized remotely via telephone.

Low risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Participants were not blinded. Unclear whether research
personnel were blinded

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Participants were not blinded. Unclear whether research
personnel were blinded. Outcomes were reported by participants, thus the fact that they were not blinded may
influence outcomes

Incomplete outcome data (attrition bias)
All outcomes

Low risk

The number of women lost to follow-up was low, and
accompanying reasons are reported. The proportion of
women lost to follow-up from each group was similar

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes, given the objective of the trial,
are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

Gawande 2011
Methods

Randomized controlled trial.

Participants

Pregnant women at less than 12 weeks’ gestation with HG defined by severe vomiting,
dehydration, acidosis and hypokalemia. 15 women randomized to interventions and 15
to controls

Interventions

Progressive muscle relaxation daily for 2 weeks and pharmacotherapy versus pharmacotherapy alone

Outcomes

Number of antiemetics required, number of days to achieve complete response (no
vomiting 24 hours), number of participants with recurrence after complete response,
clinical global improvement at the end of 2 weeks (CGI score)

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on the
method of randomization are not reported

Allocation concealment (selection bias)

High risk

Treatment group received progressive muscle relaxation
sessions, placebo group were called to psychiatric OPD
but received no intervention. Treating obstetricians were
reported to be blinded, details not specified, risk of compromise given that participants were not blinded. Methods used to conceal allocation not available

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Treating obstetricians were reportedly blinded but participants were not, participants were called to psychiatric
OPD sessions but did not receive a placebo intervention, so there is a high risk treating providers would still
be able to determine group allocation by speaking with
participants

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is stated that the “observer” was masked to treatment.
It is unclear whether the observer is the person assessing
outcomes

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Data analyzed on all people randomized.

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

Habek 2004
Methods

Randomized controlled trial.

Participants

Pregnant women with HG. 22 women randomized to interventions and 15 to controls

Interventions

2 active interventions:
1: bilateral manual acupuncture of Pc6 acupoints (30 mins a day for 7 days);
2: bilateral acupressure of Pc6 acupoints (self-applied for 30 mins when feeling nausea
throughout the day)
2 placebo groups:
1: superficial acupuncture;
2: superficial acupressure.

Outcomes

Resolution of symptoms of nausea and vomiting, and lack or need for medication for
treatment of symptoms

Notes

Outcome criteria were defined as disappearance of symptoms and no requirement for
additional medication. However, efficacy was based on participant report and independent evaluation of the participant’s clinical condition. No further details reported

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on the
method of randomization are not reported

Allocation concealment (selection bias)

Details on methods used to conceal allocation not available.

Unclear risk

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Described as a double-blind study. It is stated that the
women and the clinician assessing therapeutic efficacy
were masked to treatment. Sham treatment used to mask
key personnel to treatment

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

The clinician assessing therapeutic efficacy was masked
to treatment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias
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Heazell 2006
Methods

Randomized controlled trial.

Participants

Women with nausea and vomiting on their first inpatient admission and between 5 and
14 weeks’ gestation. Women also had to have at least 2+ of ketonuria on urinalysis, an
inability to tolerate oral fluids and a requirement for antiemetic medication. 40 women
randomized to interventions and 40 to controls

Interventions

Acupressure at the P6 meridian point (wristbands worn for 8 hours a day) versus placebo
acupressure at a point on the dorsal aspect of the forearm (wristbands worn for 8 hours
a day)

Outcomes

Days of hospital admission, number of participants requiring 4 or more days, requirement of additional antiemetic treatment, amount of IV fluids required within 24 hours,
and number of additional antiemetics required. Pregnancy outcome (SAB, TAB, PTD,
IUFD, term delivery, congenital anomalies)

Notes

No response from authors for request for additional data.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that women were randomly allocated to either the treatment or placebo group by an independent
remote researcher with no prior knowledge of the participant

Allocation concealment (selection bias)

Low risk

It is stated that a ticket that indicated either placebo or
treatment group was drawn from an opaque bag

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Participants were blinded to their assignment, identical
bead was placed at an acupressure versus alternate forearm site

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment. However, the outcomes assessed are predominantly objective outcomes (e.g., number of days of hospital stay) and at a low risk of bias

Incomplete outcome data (attrition bias)
All outcomes

Low risk

The number of women lost to follow-up was low, and
accompanying reasons are reported. The proportion of
women lost to follow-up from each group was similar

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias
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Kashifard 2013
Methods

Randomized controlled trial.

Participants

18-35 years, gestational age less than 16 weeks, vomiting 3 times a day with weight
loss more than 3 kg and ketonuria. 34 women randomized to interventions and 49 to
controls

Interventions

10 mg metoclopramide PO 3 times daily versus ondansetron 4 mg PO 3 times daily

Outcomes

Severity of nausea (VAS 1-10), number of vomiting episodes within 2 weeks

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that the randomized list was computer-generated

Allocation concealment (selection bias)

Unclear risk

Details on methods used to conceal allocation not available.

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

The study is described as a double-blind study, with investigators and participants masked to treatment. It is
unclear whether the treatments were of similar appearance and, thus, whether masking could have been compromised

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Investigators reported to be blinded.

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Mamo 1995
Methods

Randomized controlled trial.

Participants

Pregnant women in first trimester with severe pregnancy vomiting. 19 women randomized to interventions and 19 to controls

Interventions

Sea-band acupressure versus placebo.
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Mamo 1995

(Continued)

Outcomes

Need for antiemetic medication, need for hospitalization.

Notes

Abstract only.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on the
method of randomization are not reported

Allocation concealment (selection bias)

Details on methods used to conceal allocation not available.

Unclear risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

No details reported on level of masking.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Unclear risk

As a conference abstract, insufficient information reported to determine presence of selective reporting

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Mao 2010
Methods

Randomized controlled trial.

Participants

Pregnant women age 20-36 years with frequent vomiting, inability to tolerate food, dehydration, electrolyte abnormalities, diagnosed with HG by the Obstetrics and Gynaecology department; based on definition in a medical textbook. Study included women
with gestation up to 12 weeks, although this was not a specified inclusion criterion

Interventions

Acupuncuncture - standard care (hydration, electrolytes) plus acupuncture at BL11,
ST37, PC6, SP4, RN12, ST36; OR Western medicine - 30 mg luminal (phenobarbital)
orally 3 times daily in addition to standard care; OR Chinese medicine based according
to dialectical classification

Outcomes

Ketone bodies, CO2-CP decline, electrolyte imbalance and severity of nausea and vomiting
Severity of nausea and vomiting defined as:

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

Mao 2010

(Continued)

Complete Recovery: Nausea and vomiting ceased and normal appetite returned.
Obvious Effects: The frequency of nausea and vomiting reduced by over 50% and the
appetite has increased.
Effects Showed: The frequency of nausea and vomiting was reduced by 25%-50% and
the appetite has some slight increase.
Ineffectiveness: Frequent vomiting continued, the reduction of vomiting frequency was
below 25% and there was no change in appetite
Notes

Data for analysis taken from day 7 time point as that was the completion of therapy

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on the
method of randomization are not reported

Allocation concealment (selection bias)

Unclear risk

Details on methods used to conceal allocation not available.

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Details on level of masking unclear.
Possibly an open-label trial as it is likely to be difficult to mask the intervention (acupuncture versus oral
medicine)

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Details on level of masking unclear.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

It is not stated whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up. However, results are reported based on all women analyzed
(total 30 women in each group at the 2 time points assessed)

Selective reporting (reporting bias)

Unclear risk

Although outcomes captured were described and absolute event rates for some clinical outcomes are reported,
methods to measure said outcomes were not specified,
so it is unclear whether key or expected outcomes were
measured appropriately and reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias
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McParlin 2008
Methods

Randomized controlled trial.

Participants

Pregnant women with severe nausea and vomiting in pregnancy. 27 women randomized
to interventions and 26 to controls

Interventions

Outpatient care: rapid IV rehydration (3 liters over 6 hours), and IV cyclizine, followed
by discharge home with oral cyclizine, and an advice leaflet. Participants also received
ongoing midwifery support through 2 follow-up telephone calls versus inpatient admission and routine care

Outcomes

Physical symptoms evaluated by the pregnancy unique quantification of emesis and
vomiting score on admission and at 7 days. Quality of life measured on days 1 and 7
using the SF36.v2 score. Readmission rate and admission time

Notes

Abstract only. Outcomes were not pre-specified.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on the
method of randomization are not reported

Allocation concealment (selection bias)

Unclear risk

Details on method used to conceal allocation not available, given nature of intervention not possible to blind
those who participated

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Details on method used to conceal allocation not available, given nature of intervention not possible to blind
those who participated

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Itis unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up. There
was only 69% protocol adherence in the intervention
group; effect on outcome unclear

Selective reporting (reporting bias)

Unclear risk

As a conference abstract, insufficient information reported to determine presence of selective reporting

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias
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Miller 2001
Methods

Randomized controlled trial.

Participants

Pregnant women at 6-12 weeks’ gestation with severe nausea and vomiting. 45 women
randomized to interventions and 28 to controls

Interventions

Nerve stimulation therapy (with a watch-like device) over the volar aspect of the wrist
at the P6 point (Reliefband) versus placebo

Outcomes

Rhodes index of nausea, vomiting, and retching and 1, 2, and 3 weeks. Medication use,
weight gain, urinary ketones

Notes

Abstract only, specific data not reported, unable to contact author for additional data

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

Study described as randomized, but details on method
of randomization not reported

Allocation concealment (selection bias)

Details on methods used to conceal allocation not reported.

Unclear risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Details on level of masking unclear.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Details on level of masking unclear.

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Conference abstract only, unclear whether any person
was lost to follow-up or withdrew from treatment

Selective reporting (reporting bias)

Unclear risk

Abstract only, unclear whether all outcomes reported.

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Nelson-Piercy 2001
Methods

Randomized controlled trial.

Participants

Pregnant women with severe or prolonged HG, with onset of symptoms before 12 weeks’
gestation. Women were also dependent on IV fluids for at least 1 week (first admission
for HG) or for 24 hours (second or subsequent admission for HG), were receiving
regular treatment with at least 1 antiemetic, had ketonuria on admission, no infection
(as evidence by mid-stream urine sample), normal random blood glucose (unless known
diabetic), vomiting at least twice a day, or nausea so severe they were unable to eat or
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(Continued)

drink, and were receiving thiamine. 12 women randomized to interventions and 13 to
controls
Interventions

Prednisolone 20 mg orally every 12 hours for 1 week. If after 72 hours, a woman was still
vomiting and was dependent on IV fluid, the regimen was changed to an IV equivalent
versus placebo at same dosing regimen as prednisolone (either oral tablet or saline)

Outcomes

Frequency of vomiting (vomiting score measured on a scale from 0 to 4), dependence on
IV fluids after 1 week of treatment, length of hospital stay, duration of IV fluid therapy
after randomization, severity of nausea (measured on a scale from 0 to 10), need for
antiemetics, presence of ptyalism, well-being rating (measured on a scale from 0 to 10),
intake of oral fluids and food, change in thyroid function tests, change in liver function
tests, weight gain. Pregnancy outcomes: birthweight, preterm delivery, gestational age of
delivery, birthweight < 5th percentile, stillbirth, multiple gestation

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that women were randomly allocated individually using a computer-generated allocation schedule

Allocation concealment (selection bias)

Low risk

It is stated that each center was allocated sequentially
numbered trial packs held in the pharmacy, and each
pharmacy held a copy of the allocation schedule

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

It is stated that the clinicians (assessors), nurses, midwives and participants were blinded to the study medication. The prednisolone tablets were identical in appearance to the placebo tablets. The local pharmacists
were blinded until the need for IV therapy

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

The clinician assessing outcomes was masked to treatment.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Only 1 woman withdrew from the study due to pregnancy termination on day 1

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

High risk

Per the authors’ report, this study was prematurely halted
due to “a combination of different factors in different
centers, including the departure of key members of staff,
and the erroneous belief that steroids had had such a
dramatic beneficial effect that continued randomization
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of women was not justified”

Neri 2005
Methods

Randomized controlled trial.

Participants

Women with HG and who had a singleton pregnancy, were at less than 12 weeks’
gestation, and had a diagnosis of HG based on the commonly accepted criteria of nausea
and vomiting leading to clinical symptoms of dehydration and weight loss > 5%. 43
women randomized to interventions and 38 to controls

Interventions

Acupuncture (includes stimulation at 5 acupoints) twice a week for 2 weeks. Women
were also advised to wear a device giving acupressure at the Pc6 point (worn for 6-8
hours per day) versus metoclopramide infusion (20 mg/500 mL saline infused over 60
mins) twice a week for 2 weeks. Oral treatment was supplemented with vitamin B12 (30
mg/day)

Outcomes

Number of participants with improved intensity of nausea, improved episodes of vomiting, improved rate of food intake, daily functioning. Pregnancy outcome (gestational
age at delivery, birthweight, rate of cesarean section)

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that a computer-generated random list was
used to allocate women to treatment group: odd and
even numbers formed the basis of allocation to treatment

Allocation concealment (selection bias)

Allocation code held under the control of a midwife.

Low risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

No placebo used, participants not blinded.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Results are based on 81 out of 88 women randomized.
The number of women lost from the metoclopramide
group was considerably higher than that from the acupressure group (6 women versus 1 woman, respectively)
. 1 woman withdrew from acupuncture group due to
perceived inefficacy. 4 women refused to take metoclopramide, and 2 had spontaneous abortions at 10 weeks.
The influence of this imbalance on estimate of effect is

Unclear risk
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unclear
Selective reporting (reporting bias)

Low risk

Although the protocol of the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Safari 1998
Methods

Randomized controlled trial.

Participants

Women with an intrauterine pregnancy of gestation of 16 weeks or less and diagnosis of
HG (persistent vomiting, large ketonuria, and weight loss). If nausea and vomiting did
not resolve after IV hydration, or if a woman had been previously admitted to hospital
for hyperemesis, they were offered participation in the study. 20 women randomized to
interventions and 20 to controls

Interventions

Methylprednisolone 16 mg orally 3 times a day for 3 days, followed by a tapering regimen
(halving of dose every 3 days) to none during the course of 2 weeks versus promethazine
25 mg tablets 3 times a day for 2 weeks

Outcomes

Improvement of symptoms within 2 weeks of starting therapy. Lack of improvement was
defined as persistent vomiting (> 5 times a day), inability to tolerate liquids by mouth,
or participant’s impression that she was not better, readmission to hospital

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that a computer-generated random list was
used to allocate women to treatment group

Allocation concealment (selection bias)

It is stated that “Envelopes containing the study assignment were prepared in advance and sequentially labeled
by a third party not involved in the study”

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

The primary investigators, attending physicians, and the
participants were masked to treatment. However, Nurses
dispensing the medication were able to observe the difference in the shape of the pills but were not informed
which pills corresponded to which medication

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Attending physician was masked to treatment.
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Incomplete outcome data (attrition bias)
All outcomes

Low risk

The number of women lost to follow-up was low, with
the same number of women lost from each group (3
women, 6 women in total)

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine the presence of other
forms of bias

Shin 2007
Methods

Randomized controlled trial.

Participants

Women diagnosed with HG, defined as consistent nausea and vomiting, electrolyte
imbalance, more than 5% loss of weight, dehydration, positive ketonuria, and increased
urine specific gravity. Women were also aged 20 to 40 years and at gestation of 5 to 30
weeks. Women were receiving only conventional IV fluid therapy. Women had no other
complications of pregnancy. 23 women randomized to interventions and 22 to controls

Interventions

Acupressure at the P6 meridian point. Pressure was applied for 7 seconds with 2-second
pauses, 3 times daily before breakfast, lunch and dinner. Each session lasted 10 minutes
versus placebo acupressure (as for acupressure but pressure applied at a bony part around
the radial pulse) versus control (no treatment other than conventional IV therapy)

Outcomes

Degree of nausea and vomiting (measured using a modified version of the Rhodes Index;
score between 6 and 30), ketonuria

Notes

Insufficient reporting to determine the presence of other forms of bias

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Allocation by coin toss.

Allocation concealment (selection bias)

Details on methods used to conceal allocation not available.

Unclear risk

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

The study is described as double-blind. The nurses administering treatment were not aware of treatment allocation

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Reported to be double-blind, however unclear whether
or how the person assessing outcomes was blinded
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Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine the presence of other
forms of bias

Sullivan 1996
Methods

Randomized controlled trial.

Participants

Women with severe HG during the first and second trimesters of pregnancy that had not
been previously treated by IV medication or hospitalization. Women also had to have
2 of: at least a 5-pound weight loss compared with the initial prenatal visit or previous
record; ketonuria > 80 mg/dL in a random urine specimen; hypokalemia (potasium < 3.
0 mEq/dL) or hyponatremia (sodium < 134 mEq/dL requiring IV replacement; positive
test result for serum acetone; or more than 2 visits to the obstetric emergency department requiring IV hydration or promethazine suppositories. 15 women randomized to
interventions and 15 to controls

Interventions

Ondansetron 10 mg IV every 8 hours (infused over 30 minutes) versus promethazine
50 mg IV every 8 hours (infused over 30 minutes)

Outcomes

Severity of nausea (assessed on a VAS; 10 cm scale), duration of hospital stay, treatment
failure, daily weight gain, antiemetic usage, and adverse effects

Notes

Unclear how many women were randomized. Seems to be 30, but states that 30 were
evaluable, which suggests more women were randomized than analyzed

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on
method of randomization are not reported

Allocation concealment (selection bias)

Details on method used to conceal allocation not available.

Unclear risk

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

The study is described as double-blind, but it is unclear
who was masked to treatment. Although it is unclear
who was masked to treatment, maintenance of masking
seems adequate: the infusion solution was marked as
“hyperemesis study drug” and the infusion bag covered
with a plain brown bag
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Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Tabatabaii 2008
Methods

Randomized controlled trial.

Participants

Pregnant women with HG in first half of pregnancy. 48 women randomized to interventions and 48 to controls

Interventions

Methylprednisolone (125 mg) IV infusion followed by an oral prednisone taper (40 mg
for 1 day, 20 mg for 3 days, 10 mg for 3 days, 5 mg for 7 days) versus placebo. Both
groups also received 100 mg vitamin B6 daily

Outcomes

Number of women requiring rehospitalization for HG.

Notes

Abstract only

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on the
method of randomization are not reported

Allocation concealment (selection bias)

Unclear risk

Details on methods used to conceal allocation not available.

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Study is described as double-blind but details on who
was masked, or how masking was maintained (other than
that the placebo infusion was identical in appearance to
the methylprednisolone infusion), are not reported

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether personnel assessing outcomes
were masked to treatment
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Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

It is unclear whether anyone randomized to treatment
withdrew from treatment or was lost to follow-up

Selective reporting (reporting bias)

Unclear risk

As a conference abstract, insufficient information reported to determine the presence of selective reporting

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Tan 2009
Methods

Randomized controlled trial.

Participants

Women with singleton gestation at less than 20 weeks and with presumed HG (severe
nausea and vomiting during pregnancy with clinical features warranting hospitalization)
. Women were experiencing their first hospital admission for HG and were enrolled
within 12 hours of admission. 47 women randomized to interventions and 45 to controls

Interventions

Oral pyridoxine (20 mg 3 times daily from admission to 2 weeks after hospital discharge)
versus placebo

Outcomes

Readmission rate for HG in the 2 weeks after hospital discharge, daily vomiting episodes
at home by diary, and nausea score at enrollment, hospital discharge and week 1 and 2
reviews, adverse effects
Other outcomes were admission to discharge interval, compliance, body weight, ketonuria, dry retching episodes by diary and an overall well-being score using a 10-point
VAS (higher score denotes greater well-being)
Nausea evaluated with a 10-point VAS (higher score denotes more severe nausea)

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The allocation sequence was randomly generated in
blocks of 10. Randomization was carried out by opening
the next available envelope

Allocation concealment (selection bias)

Envelopes were sealed and opaque. Treatment allocation
was not revealed to the participants or providers

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Treatment allocation was not revealed to the participants
or the providers. At hospital discharge, women were supplied their allocated medication in identical packaging.
Pyridoxine tablets were white. Placebo tablets were white
“tic tacs”, which have a mint flavor. It is unclear whether
tic tacs are sufficiently similar in appearance or taste to

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

Tan 2009

(Continued)

pyridoxine tablets to maintain the masking of treatment
Blinding of outcome assessment (detection Low risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

The number of women lost to follow-up was low with
similar rates of attrition between groups at week 1, <
20%, similar rate of attrition between groups at week 2,
> 20%

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine the presence of other
forms of bias

Tan 2010
Methods

Randomized controlled trial.

Participants

Women with singleton gestation at 16 weeks or less and with presumed HG (dehydration
and detectable ketonuria by urine dipstick test). Women were experiencing their first
hospital admission for HG. 73 women randomized to interventions and 76 to controls

Interventions

Metoclopramide 10 mg IV (infused over 1 to 2 mins)
Treatment given just after randomization and again at 8, 16 and 24 hours
versus
Promethazine 25 mg IV (infused over 1 to 2 mins)
Treatment given just after randomization and again at 8, 16 and 24 hours

Outcomes

Vomiting episodes, severity of nausea (as measured using a 10-point VAS), well-being
(as measured using a 10-point VAS), ketonuria, treatment curtailment, total doses of
IV antiemetic during admission, interval of admission, time needed for IV rehydration,
adverse effects

Notes

Contact authors regarding the numbers for each group for primary outcome

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The allocation sequence was computer-generated in random blocks of 4 or 8. Women were assigned randomly
by the sequential opening of numbered, sealed, opaque
envelopes stating “Drug A” or “Drug B”

Allocation concealment (selection bias)

Envelopes were sealed and opaque.

Low risk
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Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Participant allocation was concealed and study drugs
were in identical vials

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing the outcomes was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Only 6 out of 149 did not complete symptom profile
questionnaire, the proportion of women lost from each
group was similar

Selective reporting (reporting bias)

Low risk

Preset primary and secondary outcomes.

Other bias

Unclear risk

Insufficient reporting to determine the presence of other
forms of bias

Tan 2013
Methods

Randomized controlled trial.

Participants

Women aged 18 years or older, with singleton gestation at 16 weeks or less and with
presumed HG (intractable nausea and vomiting of pregnancy with dehydration and
starvation clinically judged to require hospitalization for IV rehydration and antiemetic
drug administration)
Women also had ketonuria by urine dipstick of at least 1+ on admission, plasma glucose
110 mg/dL or less, and sodium 125 mmol/L or greater
Women were experiencing their first hospital admission for HG and were enrolled within
2 hours of admission to the ward. 111 women randomized to interventions and 111 to
controls

Interventions

5% dextrose-0.9% saline (IV infusion at a rate 125 mL/h over 24 hours) versus 0.9%
saline (IV infusion at a rate 125 mL/h over 24 hours)
All women also received oral thiamine daily plus IV antiemetic

Outcomes

Severity of nausea (as measured using a 10-point VAS), well-being (as measured using a
10-point VAS), ketonuria, frequency of vomiting, hyponatremia (135 mmol/L or less),
hypokalemia (3.5 mmol/L or less), hypochloremia (99 mmol/L or less), hyperglycemia
(8 mmol/L or greater), duration of IV antiemetic and IV rehydration during admission,
interval of admission, time to oral intake

Notes

Women already under IV rehydration therapy were not eligible for enrollment
All women also received a multivitamin containing thiamine and IV antiemetic

Risk of bias
Bias

Authors’ judgement

Support for judgement
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Random sequence generation (selection Low risk
bias)

It is stated that the allocation sequence was computergenerated

Allocation concealment (selection bias)

Envelopes were sealed and opaque.

Low risk

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

The study was double-blind. Participants and healthcare
providers were masked to treatment. IV solutions were
prepared in 500 mL containers with the manufacturer’s
label removed and the container relabeled as solution
A or B. The solutions and containers were identical in
appearance, with the exception of labels (A or B)

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
were masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Low risk

The number of women lost to follow-up was low and
similar between groups. 2/111 and 1/111 in each group
withdrew, 7/111 and 9/111 in each group excluded for
pre-specified criteria

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine presence of other
forms of bias

Ylikorkala 1979
Methods

Randomized controlled trial.

Participants

Women admitted to hospital because of HG and whose vomiting did not stop or decrease
significantly during their first 2 days in hospital. 16 women randomized to interventions
and 16 to controls

Interventions

Synthetic ACTH (tetracosactid) 0.5 mg IM on 4 consecutive days versus placebo IM on
4 consecutive days

Outcomes

Symptom severity, daily number of vomiting attacks, weight gain/loss, serum cortisol
and urine steroids

Notes

Symptom severity was evaluated using a scoring system designed by the authors. Scoring
system differed across symptoms

Risk of bias
Bias

Authors’ judgement

Support for judgement
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Random sequence generation (selection Unclear risk
bias)

The study is described as randomized, but details on
method of randomization are not reported

Allocation concealment (selection bias)

Unclear risk

Details on methods used to conceal allocation not available.

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

The study is described as double-blind, however details
on who was masked to the treatment are not reported.
It is stated that treatments were numbered and similar
in appearance

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is stated that nurses counted the daily number of
episodes of emesis. It is unclear whether the nurses were
masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Low risk

No-one withdrew from the study.

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Insufficient reporting to determine the presence of other
forms of bias

Yost 2003
Methods

Randomized controlled trial.

Participants

Women at less than 20 weeks’ gestation with HG, and who had not responded to outpatient therapy and who had 3+ or 4+ dipstick urinary ketones (evidence of dehydration).
64 women randomized to interventions and 62 to controls

Interventions

Methylprednisolone 125 mg IV, followed by a tapering regimen of oral prednisone (40
mg for 1 day, 20 mg for 3 days, 10 mg for 3 days, and 5 mg for 7 days)
Standard of care also included IV fluids, metoclopramide, and promethazine versus
placebo IV followed by oral placebo tablets (tapering regimen)
Standard of care also included IV fluids, metoclopramide, and promethazine

Outcomes

Number of ER visits, hospital readmission, number of hospital admissions, hospital
length of stay, total hospital days for all admissions in pregnancy, pregnancy outcomes
(SAB, gestational diabetes, pregnancy hypertension, preterm delivery < 26 weeks, cesarean delivery), neonatal outcomes (gender, anomalies, birthweight, IUGR, stillbirth,
neonatal death)

Notes

Study was under powered to detect a difference between groups

Risk of bias
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Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

It is stated that randomization was performed by computer-generated blocks of 20

Allocation concealment (selection bias)

Details on methods used to conceal allocation are not
available

Unclear risk

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Women were reported to be blinded and the intervention and placebo were identical in appearance

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to the treatment

Incomplete outcome data (attrition bias)
All outcomes

Low risk

A similar number of women, < 15%, was lost to followup in each group, accompanying reasons are reported

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Based on the reported power calculations, the study may
have been underpowered to identify a statistically significant difference, unclear what effect this may have had.
Insufficient reporting to determine presence of other
forms of bias

Ziaei 2004
Methods

Randomized controlled trial.

Participants

Women at between 6 and 12 weeks’ gestation and vomiting more than 3 times per day
during the last 72 hours or ketonuria that did not respond to dietary manipulation and
caused weight loss. 39 women randomized to interventions and 39 to controls

Interventions

Prednisolone 5 mg/day orally in the morning for 10 days versus promethazine 25 mg 3
times daily (oral) for 10 days

Outcomes

Severity of nausea (VAS 10-point scale), number of vomiting episodes per day, response
to treatment, adverse effects (abdominal pain, drowsiness). Participants were also asked
to rate how ill they felt (became completely or partially well, no change or became worse)

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement
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Ziaei 2004

(Continued)

Random sequence generation (selection Low risk
bias)

It is stated that randomization was carried out using a
random number table

Allocation concealment (selection bias)

Unclear risk

Details on methods used to conceal allocation not available.

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

It is stated that the main investigators did not which participants were placed in each group. It is unclear whether
the participants were masked to treatment

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

It is not stated whether the personnel assessing outcomes
was masked to treatment

Incomplete outcome data (attrition bias)
All outcomes

Low risk

The number of women lost to follow-up was low, and
accompanying reasons are reported. The proportion of
women lost to follow-up was similar in each group, 1/
40 women in each group were lost to follow-up on the
17th day

Selective reporting (reporting bias)

Low risk

Although the protocol for the trial is not available, expected clinical outcomes are reported

Other bias

Unclear risk

Based on the reported power calculations, the study may
have been underpowered to identify a statistically significant difference, unclear what effect this may have had.
Insufficient reporting to determine presence of other
forms of bias

ACTH: adrenocorticotropic hormone
CGI: clinical global improvement
ER: emergency room
HG: hyperemesis gravidarum
ICU: intensive care unit
IM: intramuscular
IUFD: intrauterine fetal demise
IUGR: intrauterine growth restriction
IV: intravenous
OPD: outpatient department
PO: oral administration
PTD: preterm delivery
PUQE: pregnancy-unique quantification of emesis and nausea
SAB: spontaneous abortion
SF-36v2: Short form 36, version 2
TAB: therapeutic/elective abortion
TPN: total parenteral nutrition
VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Adamczak 2007

Not a study on hyperemesis gravidarum.

Carlsson 2000

Cross-over design.

Dehkordi 2013

Study excluded participants with severe nausea and vomiting, not a study on hyperemesis gravidarum

Erez 1971

Not a study on hyperemesis gravidarum.

Ferruti 1982

Not a study on hyperemesis gravidarum.

Fischer-Rasmussen 1991

Cross-over design.

Ghahiri 2011

Not randomized. Not a study on hyperemesis gravidarum.

Gordon 2013

Letter to editor, not a study.

Kadan 2009

Cross-over design. Not a study on hyperemesis gravidarum.

Koren 2006

Study on pre-emptive treatment or prophylaxis, not for treatment of diagnosed hyperemesis gravidarum

Koren 2010

Not a study on hyperemesis gravidarum.

Koren 2013

Study on pre-emptive treatment or prophylaxis, not for treatment of diagnosed hyperemesis gravidarum

Koren 2015

Not a study specifically on hyperemesis gravidarum.

Lask 1953

Not clearly a study on hyperemesis gravidarum.

Ling 1994

Quasi-randomized.

Liu 1994

Not clear whether study was randomized or quasi-randomized

Madegard-Linh 2004

Cross-over design.

Magee 1996

Case report, not randomized controlled trial

Maina 2012

Cross-over design.

Maina 2014

Cross-over design.

Maltepe 2012

Study on pre-emptive treatment or prophylaxis, not for treatment of diagnosed hyperemesis gravidarum
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(Continued)

Matok 2013

Not a randomized controlled trial

Matok 2014

Not a randomized controlled trial

McCarthy 2014b

Not a study on hyperemesis gravidarum.

Nguyen 2008

Not a study on hyperemesis gravidarum.

Oliveira 2014

Not a study on hyperemesis gravidarum.

Ozgoli 2009

Not a study on hyperemesis gravidarum.

Ozgoli 2011

Not a study on hyperemesis gravidarum.

Price 1964

Not a study on hyperemesis gravidarum.

Rad 2010

Not a study on hyperemesis gravidarum.

Rosen 2003

Not a study on hyperemesis gravidarum.

Shin 2005

Quasi-randomized.

Weiner 1990

Letter, not a trial.

Wibowo 2012

Not a study on hyperemesis gravidarum.

Willetts 2003

Not a study on hyperemesis gravidarum.

Characteristics of studies awaiting assessment [ordered by study ID]
Eftekhari 2013
Methods

Randomized controlled trial

Participants

Pregnant women under 20 weeks gestation diagnosed with hyperemesis gravidarum

Interventions

Ondansetron and promethazine.

Outcomes

Treatment response and side effects, further details of outcomes not able to be determined

Notes

Full translation not available.
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He 2009
Methods
Participants
Interventions
Outcomes
Notes

Translation not available.

Characteristics of ongoing studies [ordered by study ID]
Cyna 2008
Trial name or title

Hypnosis for nausea and vomiting in early pregnancy: a randomized controlled trial

Methods

Randomized controlled trial.

Participants

Pregnant women suffering from nausea and vomiting of pregnancy

Interventions

Usual care (supportive and pharmacological medication and/or intravenous fluids as required) plus audio CD
on hypnosis lasting 1/2 hour for 7 consecutive days versus usual care

Outcomes

Suffering associated with nausea and vomiting as measured by a 5-point Likert scale, incidence of nausea in
previous 24 hours, incidence of vomiting in previous 24 hours, anxiety as measured by Spielberger, number
of days off work

Starting date

February 2007.

Contact information

Dr. A. M. Cyna: allan.cyna@cywhs.sa.gov.au

Notes

Still recruiting, results not yet published, authors contacted for further information

Guttuso 2014
Trial name or title

Comparison of gabapentin and metoclopramide for treating hyperemesis gravidarum

Methods

Randomized controlled trial.

Participants

Women 18years or older at less than 16 weeks gestation who have required at least 2 administrations of IV
hydration 1 week apart, or daily emesis for the last 14 days and 1 administration of IV hydration, with at
least 1 of the following: 3-4+ ketonuria, serum potassium < 3.4 mmol, or > 5% weight loss from initial
antenatal weight, having failed therapy with at least 1 antiemetic, excluding other medical problems that
could contribute to symptoms, with a PUQE score of >=12 for the 24-hour baseline

Interventions

Gapabentin versus metoclopramide.
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Guttuso 2014

(Continued)

Outcomes

Mean per cent change from baseline to study endpoint in daily PUQE score. Mean per cent change from
baseline to study endpoint in individual PUQE score, daily oral nutrition scores, days of hospital admission,
NVPQOL questionnaire, and relief score; need for repeat IV hydration or hospital admission for hyperemesis;
per cent of participants choosing to continue with experimental therapy, per cent of participants downgrading
from an answer of 3-5 at Baseline to 1-2 at study endpoint, maternal side effects and pregnancy outcomes,
mean per cent change in laboratory values, mean per cent change from baseline to days 26-28 in daily PUQE
and NVPQOL scores, mean satisfaction questionnaire scores day 28, per cent of participants downgrading
from an answer of 3-5 at baseline to 1-2 at day 28 on the HGPTC questionnaire

Starting date

June 2014.

Contact information

Thomas Guttuso, Jr MD: tguttuso@buffalo.edu

Notes

Currently recruiting.

Koren 2014
Trial name or title

A multicenter trial of the efficacy and safety of Diclegis® for nausea and vomiting of pregnancy in pregnant
adolescents

Methods

Randomized controlled trial.

Participants

Pregnant women ages 12-17 between 7-14 weeks’ gestation suffering from nausea and vomiting of pregnancy
with a PUQE score >= 6

Interventions

Diclegis 2 tablets at bedtime, increasing to 4 tablets as needed, for 14 days, versus placebo

Outcomes

Nausea and vomiting of pregnancy severity from baseline to day 15 using PUQE score and Global Assessment
of Well-being scores, severity and occurrences of maternal adverse events

Starting date

February 2014.

Contact information

Gideon Koren,MD- Hospital for Sick Children, 555 University Avenue, Toronto ON Canada, M5G-1X8

Notes

Currently recruiting.

Mehrolhasani 2012
Trial name or title

Comparison of Demitron and promethazine in treatment of hyperemesis gravidarum

Methods

Randomized controlled trial.

Participants

Pregnant women with gestation of 20 weeks or less, suffering from dehydration due to nausea and vomiting

Interventions

Demitron 8 mg intramuscular every eight hours for 48 hours versus promethazine 25 mg intramuscular every
eight hours for 48 hours
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Mehrolhasani 2012

(Continued)

Outcomes

Nausea and vomiting at 48 hours determined by a questionnaire, adverse drug reactions

Starting date

April 2011.

Contact information

Yasamin Mehrolhasani(MD)- yasamin m@yahoo.com

Notes

Recruitment completed, authors contacted for results.

Mitchell-Jones 2014
Trial name or title

Hyperemesis in Pregnancy (HIP) Trial: Inpatient versus outpatient management of severe nausea and vomiting
in pregnancy

Methods

Randomized controlled trial.

Participants

Pregnant women < 20 weeks gestation with symptoms of hyperemesis gravidarum and at least 1+ ketonuria,
excluding women with another medical condition that may induce nausea and vomiting, diabetes. Potassium
< 3.2, sodium < 130, or abnormal liver or thyroid function tests

Interventions

Rapid outpatient rehydration versus inpatient standard care.

Outcomes

Daily PUQE score, eating and drinking score, well-being score, weight, and blood test results, repeat attendance and admissions, weight change at 7 days, number of days of IV fluids needed, number of women still
taking antiemetics 1 week after discharge, costs of treatment

Starting date

1/3/2014

Contact information

Nicola Mitchell-Jones
Chelsea and Westminster Hospital
369 Fulham Road
London
SW10 9NH
United Kingdom
nicola.mitchell-jones@chelwest.nhs.uk

Notes

Currently recruiting.

HG: hyperemesis gravidarum
HGPTC: Hyperemesis Gravidarum Pregnancy Termination Consideration
IV: intravenous
NVPQOL: Health-Related Quality of Life for Nausea and Vomiting during Pregnancy
PUQE: pregnancy-unique quantification of emesis and nausea
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DATA AND ANALYSES

Comparison 1. Acupuncture and acupressure vs placebo

Outcome or subgroup title
1 Number of women requiring
additional antiemetics
2 Spontaneous abortion
3 Preterm birth less than 37 weeks
4 Stillbirth and neonatal death
5 Decision to terminate the
pregnancy
6 Quality of life: anxiodepressive
symptomatology

No. of
studies

No. of
participants

1

36

Risk Ratio (M-H, Fixed, 95% CI)

0.20 [0.08, 0.50]

1
1
1
1

57
36
36
57

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

0.48 [0.05, 5.03]
0.12 [0.01, 2.26]
0.57 [0.04, 8.30]
0.72 [0.18, 2.95]

1

36

Risk Ratio (M-H, Fixed, 95% CI)

1.01 [0.73, 1.40]

Statistical method

Effect size

Comparison 2. Acupuncture vs metoclopramide

Outcome or subgroup title
1 Reduction or cessation in nausea
2 Reduction or cessation in
vomiting

No. of
studies

No. of
participants

1
1

81
81

Statistical method
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

Effect size
1.40 [0.79, 2.49]
1.51 [0.92, 2.48]

Comparison 3. Acupunture vs Western medicine (Phenobarbital)

Outcome or subgroup title
1 Complete recovery
2 Obvious effects
3 Effects showed
4 Ineffective
5 Total effective rate

No. of
studies

No. of
participants

1
1
1
1
1

60
60
60
60
60

Statistical method
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
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Effect size
6.75 [2.69, 16.94]
0.33 [0.07, 1.52]
0.11 [0.01, 1.98]
0.06 [0.01, 0.44]
2.07 [1.40, 3.05]
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Comparison 4. Acupunture vs Chinese medicine

Outcome or subgroup title
1 Complete recovery
2 Obvious effects
3 Effects showed
4 Ineffective
5 Total effective rate

No. of
studies

No. of
participants

1
1
1
1
1

60
60
60
60
60

Statistical method
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

Effect size
9.0 [3.06, 26.51]
0.2 [0.05, 0.84]
0.09 [0.01, 1.57]
0.08 [0.01, 0.60]
1.61 [1.19, 2.17]

Comparison 5. Chinese medicine vs Western medicine (Phenobarbital)

Outcome or subgroup title
1 Complete recovery
2 Obvious effects
3 Effects showed
4 Ineffective
5 Total effective rate

No. of
studies

No. of
participants

1
1
1
1
1

60
60
60
60
60

Statistical method
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

Effect size
0.75 [0.18, 3.07]
1.67 [0.69, 4.00]
1.25 [0.37, 4.21]
0.75 [0.43, 1.30]
1.29 [0.79, 2.08]

Comparison 6. Muscle relaxation and pharmacotherapy vs only pharmacotherapy alone

Outcome or subgroup title
1 Clinical Global Improvement
score

No. of
studies

No. of
participants

1

30

Statistical method
Mean Difference (IV, Fixed, 95% CI)

Effect size
-0.54 [-1.04, -0.04]

Comparison 7. Midwife-led outpatient care vs routine care

No. of
studies

No. of
participants

1 PUQE
2 Hours of hospital admission

1
1

31
53

Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)

3 Decision to terminate the
pregnancy
4 Spontaneous miscarriage
5 Small for gestational age
6 Economic cost

1

53

Risk Ratio (M-H, Fixed, 95% CI)

-0.70 [-3.17, 1.77]
-33.2 [-46.91, -19.
49]
2.89 [0.12, 67.96]

1
1
1

53
53
31

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

0.96 [0.15, 6.34]
1.44 [0.26, 7.96]
1.04 [0.28, 3.87]

Outcome or subgroup title

Statistical method
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Comparison 8. Holistic assessment with standard care vs standard care

Outcome or subgroup title
1 PUQE
2 Quality of life: social functioning
3 Quality of life: client satisfaction

No. of
studies

No. of
participants

1
1
1

200
198
189

Statistical method
Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)

Effect size
-0.20 [-1.10, 0.70]
2.0 [-6.70, 10.70]
-0.5 [-1.90, 0.90]

Comparison 9. Dextrose saline vs normal saline rehydration

Outcome or subgroup title
1 Hours of hospital admission

No. of
studies

No. of
participants

1

203

Statistical method
Mean Difference (IV, Fixed, 95% CI)

Effect size
-5.0 [-10.78, 0.78]

Comparison 10. Pyridoxine vs placebo

Outcome or subgroup title
1 Number of episodes of emesis
2 Days of hospital admission
3 Hospital readmission
4 Weight change (kg)
5 Interventions side effects:
dizziness
6 Interventions side effects:
headaches
7 Interventions side effects:
diarrhea
8 Interventions side effects:
palpitations
9 Interventions side effects: dry
mouth

No. of
studies

No. of
participants

1
1
1
1
1

66
92
78
52
66

Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

0.5 [-0.40, 1.40]
0.80 [0.08, 1.52]
1.78 [0.85, 3.71]
0.0 [-0.93, 0.93]
1.67 [0.85, 3.26]

1

66

Risk Ratio (M-H, Fixed, 95% CI)

1.33 [0.52, 3.42]

1

66

Risk Ratio (M-H, Fixed, 95% CI)

3.0 [0.13, 71.07]

1

66

Risk Ratio (M-H, Fixed, 95% CI)

1.0 [0.22, 4.60]

1

66

Risk Ratio (M-H, Fixed, 95% CI)

0.82 [0.49, 1.38]

Statistical method
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Comparison 11. Metoclopramide vs ondansetron

Outcome or subgroup title
1 Severity of nausea
2 Severity of vomiting
3 Intervention side effects: felt
drowsy
4 Intervention side effects: dry
mouth
5 Intervention side effects: unable
to sleep
6 Intervention side effects: felt
dizzy
7 Intervention side effects: diarrhea
8 Intervention side effects:
headache
9 Intervention side effects:
palpitations
10 Intervention side effects: skin
rash
11 Intervention side effects:
dystonia
12 Quality of life

No. of
studies

No. of
participants

1
1
1

83
83
160

Mean Difference (IV, Fixed, 95% CI)
Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

1.70 [-0.15, 3.55]
-0.10 [-1.63, 1.43]
2.4 [1.23, 4.69]

1

160

Risk Ratio (M-H, Fixed, 95% CI)

2.38 [1.10, 5.11]

1

160

Risk Ratio (M-H, Fixed, 95% CI)

1.29 [0.50, 3.28]

1

160

Risk Ratio (M-H, Fixed, 95% CI)

2.33 [0.94, 5.77]

1
1

160
160

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

9.0 [0.49, 164.46]
1.22 [0.54, 2.79]

1

160

Risk Ratio (M-H, Fixed, 95% CI)

2.5 [0.50, 12.51]

1

160

Risk Ratio (M-H, Fixed, 95% CI)

1.0 [0.06, 15.71]

1

160

Risk Ratio (M-H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1

160

Mean Difference (IV, Fixed, 95% CI)

-0.40 [-0.83, 0.03]

Statistical method

Effect size

Comparison 12. Hydrocortisone vs metoclopramide

Outcome or subgroup title
1 Hospital readmission
2 Need for enteral or parenteral
nutrition

No. of
studies

No. of
participants

1
1

40
40

Statistical method
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

Effect size
0.08 [0.00, 1.28]
0.33 [0.01, 7.72]

Comparison 13. Metoclopramide vs promethazine

Outcome or subgroup title
1 Quality of life
2 Intervention side effects: unable
to sleep
3 Intervention side effects: dry
mouth
4 Intervention side effects: diarrhea

No. of
studies

No. of
participants

1
1

149
143

Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

0.5 [-0.22, 1.22]
0.78 [0.40, 1.53]

1

143

Risk Ratio (M-H, Fixed, 95% CI)

0.91 [0.62, 1.34]

1

143

Risk Ratio (M-H, Fixed, 95% CI)

1.39 [0.32, 5.99]

Statistical method
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5 Intervention side effects:
headache
6 Intervention side effects:
palpitations
7 Intervention side effects: skin
rash
8 Intervention side effects: drowsy
9 Intervention side effects: felt
dizzy
10 Intervention side effects:
dystonia

1

143

Risk Ratio (M-H, Fixed, 95% CI)

0.81 [0.47, 1.38]

1

143

Risk Ratio (M-H, Fixed, 95% CI)

0.61 [0.25, 1.46]

1

143

Risk Ratio (M-H, Fixed, 95% CI)

1.39 [0.32, 5.99]

1
1

143
143

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

0.70 [0.56, 0.87]
0.48 [0.34, 0.69]

1

146

Risk Ratio (M-H, Fixed, 95% CI)

0.31 [0.11, 0.90]

Comparison 14. Parenteral fluid with diazepam vs parenteral fluid without diazepam

Outcome or subgroup title
1 Days of hospital admission
2 Hospital readmission
3 Women requiring additional
antiemetics
4 Congenital anomalies
5 Preterm birth
6 Decision to terminate the
pregnancy

No. of
studies

No. of
participants

1
1
1

50
50
50

Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

-1.10 [-2.07, -0.13]
0.17 [0.02, 1.29]
0.5 [0.05, 5.17]

1
1
1

50
50
50

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

0.0 [0.0, 0.0]
0.5 [0.05, 5.17]
3.0 [0.13, 70.30]

Statistical method

Effect size

Comparison 15. Ondansetron vs promethazine

Outcome or subgroup title
1 Days of hospital admission
2 Intervention side effect: sedation

No. of
studies

No. of
participants

1
1

30
30

Statistical method
Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

Effect size
0.0 [-1.39, 1.39]
0.06 [0.00, 0.94]

Comparison 16. Corticosteroids vs promethazine

Outcome or subgroup title
1 Severe nausea 48 hours
2 Severe nausea 17th day
3 Episodes of vomiting 48 hours
4 Episodes of vomiting 17th day
5 Therapy failure in 2 days

No. of
studies

No. of
participants

1
1
1
1
1

80
78
80
78
40

Statistical method
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
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2.0 [1.08, 3.72]
0.81 [0.58, 1.15]
3.0 [0.33, 27.63]
1.0 [0.21, 4.65]
1.5 [0.28, 8.04]
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6 Hospital readmission
7 Number of women requiring
additional antiemetics
8 Stillbirth and neonatal death
9 Preterm birth
10 Decision to terminate the
pregnancy
11 Intevention side effects:
abdominal pain 48 hours
12 Intervention side effects:
abdominal pain 3-10 days
13 Intervention side effects:
drowsiness 48 hours and 3-10
days
14 Became completely or partially
well 48 hours
15 Became completely or partially
well 17th day

1
1

34
40

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

0.09 [0.01, 1.53]
1.5 [0.28, 8.04]

1
1
1

40
40
40

Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

3.0 [0.13, 69.52]
3.0 [0.13, 69.52]
3.0 [0.13, 69.52]

1

80

Risk Ratio (M-H, Fixed, 95% CI)

0.33 [0.07, 1.55]

1

80

Risk Ratio (M-H, Fixed, 95% CI)

0.11 [0.01, 2.00]

1

80

Risk Ratio (M-H, Fixed, 95% CI)

0.08 [0.00, 1.32]

1

80

Risk Ratio (M-H, Fixed, 95% CI)

0.67 [0.47, 0.95]

1

78

Risk Ratio (M-H, Fixed, 95% CI)

1.67 [0.95, 2.92]

Comparison 17. Corticosteroids vs placebo

Outcome or subgroup title
1 Days of hospital admission
2 Hospital readmission
3 Pregnancy complications
4 Spontaneous abortion
5 Stillbirth and neonatal death
6 Congenital abnormalities
7 Low birthweight
8 Small-for-gestational age
9 Preterm birth
10 Intervention side effects
11 Women requiring additional
antiemetic drugs
12 Decision to terminate the
pregnancy

No. of
studies

No. of
participants

1
4
1
1
2
1
1
1
2
1
1

110
269
110
110
134
110
110
24
134
25
24

Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Random, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

-0.30 [-0.70, 0.10]
0.69 [0.50, 0.94]
0.61 [0.26, 1.47]
0.64 [0.11, 3.70]
0.70 [0.15, 3.34]
0.32 [0.01, 7.73]
1.35 [0.46, 4.00]
1.0 [0.07, 14.21]
1.01 [0.31, 3.28]
0.79 [0.06, 11.20]
0.56 [0.26, 1.17]

1

24

Risk Ratio (M-H, Fixed, 95% CI)

0.33 [0.01, 7.45]

Statistical method
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Comparison 18. ACTH vs placebo

Outcome or subgroup title

No. of
studies

No. of
participants

1

32

Mean Difference (IV, Fixed, 95% CI)

0.60 [-1.65, 2.85]

1
1
1
1

32
32
32
32

Mean Difference (IV, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)
Risk Ratio (M-H, Fixed, 95% CI)

1.0 [0.34, 1.66]
1.0 [0.16, 6.25]
1.0 [0.07, 14.64]
3.0 [0.13, 68.57]

1 Reduction or cessation in
nausea/vomiting
2 Weight gain (kg)
3 Hospital readmission
4 Spontaneous abortion
5 Preterm birth

Statistical method

Effect size

Analysis 1.1. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 1 Number of women
requiring additional antiemetics.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 1 Number of women requiring additional antiemetics

Study or subgroup

Habek 2004

Total (95% CI)

AP or APr
stimulation

Placebo

n/N

n/N

4/21

14/15

100.0 %

0.20 [ 0.08, 0.50 ]

21

15

100.0 %

0.20 [ 0.08, 0.50 ]

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 4 (AP or APr stimulation), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.49 (P = 0.00048)
Test for subgroup differences: Not applicable

0.005

0.1

Favours AP or APr stim

1

10

200

Favours placebo
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Analysis 1.2. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 2 Spontaneous abortion.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 2 Spontaneous abortion

AP or APr
stimulation

Placebo

n/N

n/N

Heazell 2006

1/29

2/28

100.0 %

0.48 [ 0.05, 5.03 ]

Total (95% CI)

29

28

100.0 %

0.48 [ 0.05, 5.03 ]

Study or subgroup

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (AP or APr stimulation), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable

0.002

0.1

1

Favours AP or APr stim

10

500

Favours placebo

Analysis 1.3. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 3 Preterm birth less than
37 weeks.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 3 Preterm birth less than 37 weeks

AP or APr
stimulation

Placebo

n/N

n/N

Heazell 2006

0/23

2/13

100.0 %

0.12 [ 0.01, 2.26 ]

Total (95% CI)

23

13

100.0 %

0.12 [ 0.01, 2.26 ]

Study or subgroup

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (AP or APr stimulation), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable

0.002

0.1

Favours AP or APr stim

1

10

500

Favours placebo
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Analysis 1.4. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 4 Stillbirth and neonatal
death.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 4 Stillbirth and neonatal death

AP or APr
stimulation

Placebo

n/N

n/N

Heazell 2006

1/23

1/13

100.0 %

0.57 [ 0.04, 8.30 ]

Total (95% CI)

23

13

100.0 %

0.57 [ 0.04, 8.30 ]

Study or subgroup

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (AP or APr stimulation), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable

0.1 0.2

0.5

1

Favours AP or APr stim

2

5

10

Favours placebo

Analysis 1.5. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 5 Decision to terminate the
pregnancy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 5 Decision to terminate the pregnancy

AP or APr
stimulation

Placebo

n/N

n/N

Heazell 2006

3/29

4/28

100.0 %

0.72 [ 0.18, 2.95 ]

Total (95% CI)

29

28

100.0 %

0.72 [ 0.18, 2.95 ]

Study or subgroup

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (AP or APr stimulation), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable

0.002

0.1

Favours AP or APr stim

1

10

500

Favours placebo
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Analysis 1.6. Comparison 1 Acupuncture and acupressure vs placebo, Outcome 6 Quality of life:
anxiodepressive symptomatology.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 1 Acupuncture and acupressure vs placebo
Outcome: 6 Quality of life: anxiodepressive symptomatology

Study or subgroup

Habek 2004

Total (95% CI)

AP or APr
stimulation

Placebo

n/N

n/N

17/21

12/15

100.0 %

1.01 [ 0.73, 1.40 ]

21

15

100.0 %

1.01 [ 0.73, 1.40 ]

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 17 (AP or APr stimulation), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable

0.1 0.2

0.5

1

Favours AP or APr stim

2

5

10

Favours placebo

Analysis 2.1. Comparison 2 Acupuncture vs metoclopramide, Outcome 1 Reduction or cessation in nausea.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 2 Acupuncture vs metoclopramide
Outcome: 1 Reduction or cessation in nausea

Study or subgroup

Neri 2005

Total (95% CI)

Acupuncture

Metoclopramide

n/N

n/N

Risk Ratio

Weight

19/43

12/38

100.0 %

1.40 [ 0.79, 2.49 ]

43

38

100.0 %

1.40 [ 0.79, 2.49 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 19 (Acupuncture), 12 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable

0.1 0.2

0.5

Favours Metoclopramide

1

2

5

10

Favours Acupuncture
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Analysis 2.2. Comparison 2 Acupuncture vs metoclopramide, Outcome 2 Reduction or cessation in
vomiting.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 2 Acupuncture vs metoclopramide
Outcome: 2 Reduction or cessation in vomiting

Study or subgroup

Acupuncture

Metoclopramide

n/N

n/N

24/43

14/38

100.0 %

1.51 [ 0.92, 2.48 ]

43

38

100.0 %

1.51 [ 0.92, 2.48 ]

Neri 2005

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 24 (Acupuncture), 14 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable

0.1 0.2

0.5

1

Favours Metoclopramide

2

5

10

Favours Acupuncture

Analysis 3.1. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 1 Complete
recovery.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 1 Complete recovery

Study or subgroup

Mao 2010

Total (95% CI)

Acupunture

Phenobarbital

n/N

n/N

Risk Ratio

Weight

27/30

4/30

100.0 %

6.75 [ 2.69, 16.94 ]

30

30

100.0 %

6.75 [ 2.69, 16.94 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 27 (Acupunture), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 4.07 (P = 0.000047)
Test for subgroup differences: Not applicable

0.002

0.1

Favors Phenobarbital

1

10

500

Favours Acupuncture
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Analysis 3.2. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 2 Obvious effects.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 2 Obvious effects

Study or subgroup

Mao 2010

Total (95% CI)

Acupunture

Phenobarbital

n/N

n/N

Risk Ratio

Weight

2/30

6/30

100.0 %

0.33 [ 0.07, 1.52 ]

30

30

100.0 %

0.33 [ 0.07, 1.52 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 2 (Acupunture), 6 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable

0.002

0.1

1

Favours Acupunture

10

500

Favours Phenobarbital

Analysis 3.3. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 3 Effects showed.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 3 Effects showed

Study or subgroup

Mao 2010

Total (95% CI)

Acupunture

Phenobarbital

n/N

n/N

Risk Ratio

Weight

0/30

4/30

100.0 %

0.11 [ 0.01, 1.98 ]

30

30

100.0 %

0.11 [ 0.01, 1.98 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Acupunture), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable

0.002

0.1

Favours Acupunture

1

10

500

Favours Phenobarbital
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Analysis 3.4. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 4 Ineffective.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 4 Ineffective

Study or subgroup

Acupunture

Phenobarbital

n/N

n/N

1/30

16/30

100.0 %

0.06 [ 0.01, 0.44 ]

30

30

100.0 %

0.06 [ 0.01, 0.44 ]

Mao 2010

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Acupunture), 16 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 2.78 (P = 0.0055)
Test for subgroup differences: Not applicable

0.002

0.1

1

Favours Acupunture

10

500

Favours Phenobarbital

Analysis 3.5. Comparison 3 Acupunture vs Western medicine (Phenobarbital), Outcome 5 Total effective
rate.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 3 Acupunture vs Western medicine (Phenobarbital)
Outcome: 5 Total effective rate

Study or subgroup

Mao 2010

Total (95% CI)

Acupunture

Phenobarbital

n/N

n/N

Risk Ratio

Weight

29/30

14/30

100.0 %

2.07 [ 1.40, 3.05 ]

30

30

100.0 %

2.07 [ 1.40, 3.05 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 29 (Acupunture), 14 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00024)
Test for subgroup differences: Not applicable

0.01

0.1

Favours Phenobarbital

1

10

100

Favours Acupuncture
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Analysis 4.1. Comparison 4 Acupunture vs Chinese medicine, Outcome 1 Complete recovery.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 4 Acupunture vs Chinese medicine
Outcome: 1 Complete recovery

Study or subgroup

Acupunture

Chinese Medicine

n/N

n/N

27/30

3/30

100.0 %

9.00 [ 3.06, 26.51 ]

30

30

100.0 %

9.00 [ 3.06, 26.51 ]

Mao 2010

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 27 (Acupunture), 3 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.99 (P = 0.000067)
Test for subgroup differences: Not applicable

0.002

0.1

1

Favours Chinese Medicine

10

500

Favours Acupuncture

Analysis 4.2. Comparison 4 Acupunture vs Chinese medicine, Outcome 2 Obvious effects.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 4 Acupunture vs Chinese medicine
Outcome: 2 Obvious effects

Study or subgroup

Mao 2010

Total (95% CI)

Acupunture

Chinese Medicine

n/N

n/N

Risk Ratio

Weight

2/30

10/30

100.0 %

0.20 [ 0.05, 0.84 ]

30

30

100.0 %

0.20 [ 0.05, 0.84 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 2 (Acupunture), 10 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable

0.002

0.1

Favours Acupunture

1

10

500

Favours Chinese Medicine
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Analysis 4.3. Comparison 4 Acupunture vs Chinese medicine, Outcome 3 Effects showed.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 4 Acupunture vs Chinese medicine
Outcome: 3 Effects showed

Study or subgroup

Mao 2010

Total (95% CI)

Acupunture

Chinese Medicine

n/N

n/N

Risk Ratio

Weight

0/30

5/30

100.0 %

0.09 [ 0.01, 1.57 ]

30

30

100.0 %

0.09 [ 0.01, 1.57 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Acupunture), 5 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Acupuncture

10

100

Favours Chinese Medicine

Analysis 4.4. Comparison 4 Acupunture vs Chinese medicine, Outcome 4 Ineffective.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 4 Acupunture vs Chinese medicine
Outcome: 4 Ineffective

Study or subgroup

Mao 2010

Total (95% CI)

Acupunture

Chinese Medicine

n/N

n/N

Risk Ratio

Weight

1/30

12/30

100.0 %

0.08 [ 0.01, 0.60 ]

30

30

100.0 %

0.08 [ 0.01, 0.60 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Acupunture), 12 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable

0.002

0.1

Favours Acupunture

1

10

500

Favours Chinese Medicine
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Analysis 4.5. Comparison 4 Acupunture vs Chinese medicine, Outcome 5 Total effective rate.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 4 Acupunture vs Chinese medicine
Outcome: 5 Total effective rate

Study or subgroup

Acupunture

Chinese Medicine

n/N

n/N

29/30

18/30

100.0 %

1.61 [ 1.19, 2.17 ]

30

30

100.0 %

1.61 [ 1.19, 2.17 ]

Mao 2010

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 29 (Acupunture), 18 (Chinese Medicine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Chinese Medicine

10

100

Favours Acupuncture

Analysis 5.1. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 1 Complete
recovery.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 1 Complete recovery

Study or subgroup

Chinese Medicine

Phenobarbital

n/N

n/N

3/30

4/30

100.0 %

0.75 [ 0.18, 3.07 ]

30

30

100.0 %

0.75 [ 0.18, 3.07 ]

Mao 2010

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Chinese Medicine), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Phenobarbital
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10

100

Favours Chinese Medicine

100

Analysis 5.2. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 2 Obvious
effects.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 2 Obvious effects

Study or subgroup

Chinese Medicine

Phenobarbital

n/N

n/N

10/30

6/30

100.0 %

1.67 [ 0.69, 4.00 ]

30

30

100.0 %

1.67 [ 0.69, 4.00 ]

Mao 2010

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 10 (Chinese Medicine), 6 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Chinese Medicine

10

100

Favours Phenobarbital

Analysis 5.3. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 3 Effects
showed.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 3 Effects showed

Study or subgroup

Chinese Medicine

Phenobarbital

n/N

n/N

5/30

4/30

100.0 %

1.25 [ 0.37, 4.21 ]

30

30

100.0 %

1.25 [ 0.37, 4.21 ]

Mao 2010

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 5 (Chinese Medicine), 4 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Chinese Medicine
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100

Favours Phenobarbital
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Analysis 5.4. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 4 Ineffective.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 4 Ineffective

Study or subgroup

Chinese Medicine

Phenobarbital

n/N

n/N

12/30

16/30

100.0 %

0.75 [ 0.43, 1.30 ]

30

30

100.0 %

0.75 [ 0.43, 1.30 ]

Mao 2010

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 12 (Chinese Medicine), 16 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Chinese Medicine

10

100

Favours Phenobarbital

Analysis 5.5. Comparison 5 Chinese medicine vs Western medicine (Phenobarbital), Outcome 5 Total
effective rate.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 5 Chinese medicine vs Western medicine (Phenobarbital)
Outcome: 5 Total effective rate

Study or subgroup

Mao 2010

Chinese Medicine

Phenobarbital

n/N

n/N

18/30

14/30

100.0 %

1.29 [ 0.79, 2.08 ]

30

30

100.0 %

1.29 [ 0.79, 2.08 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 18 (Chinese Medicine), 14 (Phenobarbital)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Phenobarbital
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100

Favours Chinese Medicine
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Analysis 6.1. Comparison 6 Muscle relaxation and pharmacotherapy vs only pharmacotherapy alone,
Outcome 1 Clinical Global Improvement score.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 6 Muscle relaxation and pharmacotherapy vs only pharmacotherapy alone
Outcome: 1 Clinical Global Improvement score

Study or subgroup

Muscle relaxation

Mean
Difference

Pharmacotherapy

N

Mean(SD)

N

Mean(SD)

Gawande 2011

15

1.46 (0.52)

15

2 (0.85)

Total (95% CI)

15

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

100.0 %

15

-0.54 [ -1.04, -0.04 ]

100.0 % -0.54 [ -1.04, -0.04 ]

Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable

-10

-5

0

Favours Muscle relaxation

5

10

Favours Pharmacotherapy

Analysis 7.1. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 1 PUQE.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 1 PUQE

Study or subgroup

Midwife-led care

Mean
Difference

Routine care

N

Mean(SD)

N

Mean(SD)

McParlin 2008

18

6.2 (2.3)

13

6.9 (4.1)

Total (95% CI)

18

Weight

Mean
Difference

100.0 %

-0.70 [ -3.17, 1.77 ]

IV,Fixed,95% CI

IV,Fixed,95% CI

100.0 % -0.70 [ -3.17, 1.77 ]

13

Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable

-10

-5

Favours midwife-led care
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10

Favours routine care

103

Analysis 7.2. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 2 Hours of hospital
admission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 2 Hours of hospital admission

Study or subgroup

Midwifeled
outpatient

Mean
Difference

Routine care

N

Mean(SD)

N

Mean(SD)

McParlin 2008

27

13.3 (26.8)

26

46.5 (24.1)

Total (95% CI)

27

Weight

Mean
Difference

100.0 %

-33.20 [ -46.91, -19.49 ]

IV,Fixed,95% CI

IV,Fixed,95% CI

100.0 % -33.20 [ -46.91, -19.49 ]

26

Heterogeneity: not applicable
Test for overall effect: Z = 4.75 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 3 Decision to terminate
the pregnancy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 3 Decision to terminate the pregnancy

Study or subgroup

Midwife-led care

Routine care

n/N

n/N

Risk Ratio

Weight

McParlin 2008

1/27

0/26

100.0 %

2.89 [ 0.12, 67.96 ]

Total (95% CI)

27

26

100.0 %

2.89 [ 0.12, 67.96 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Midwife-led care), 0 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 4 Spontaneous
miscarriage.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 4 Spontaneous miscarriage

Study or subgroup

Midwife-led care

Routine care

n/N

n/N

Risk Ratio

Weight

McParlin 2008

2/27

2/26

100.0 %

0.96 [ 0.15, 6.34 ]

Total (95% CI)

27

26

100.0 %

0.96 [ 0.15, 6.34 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 2 (Midwife-led care), 2 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 5 Small for gestational
age.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 5 Small for gestational age

Study or subgroup

Midwife-led care

Routine care

n/N

n/N

Risk Ratio

Weight

McParlin 2008

3/27

2/26

100.0 %

1.44 [ 0.26, 7.96 ]

Total (95% CI)

27

26

100.0 %

1.44 [ 0.26, 7.96 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Midwife-led care), 2 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Midwife-led outpatient care vs routine care, Outcome 6 Economic cost.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 7 Midwife-led outpatient care vs routine care
Outcome: 6 Economic cost

Study or subgroup

Midwife-led care

Routine care

n/N

n/N

Risk Ratio

Weight

McParlin 2008

3/13

4/18

100.0 %

1.04 [ 0.28, 3.87 ]

Total (95% CI)

13

18

100.0 %

1.04 [ 0.28, 3.87 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Midwife-led care), 4 (Routine care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Holistic assessment with standard care vs standard care, Outcome 1 PUQE.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 8 Holistic assessment with standard care vs standard care
Outcome: 1 PUQE

Study or subgroup

Holistic assessment

Mean
Difference

Standard care

N

Mean(SD)

N

Mean(SD)

Fletcher 2015

93

7.6 (3.2)

107

7.8 (3.3)

Total (95% CI)

93

Weight

Mean
Difference

100.0 %

-0.20 [ -1.10, 0.70 ]

IV,Fixed,95% CI

IV,Fixed,95% CI

107

100.0 % -0.20 [ -1.10, 0.70 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Holistic assessment with standard care vs standard care, Outcome 2 Quality of
life: social functioning.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 8 Holistic assessment with standard care vs standard care
Outcome: 2 Quality of life: social functioning

Study or subgroup

Holistic assessment

Mean
Difference

Standard care

N

Mean(SD)

N

Mean(SD)

Fletcher 2015

93

34.7 (30.8)

105

32.7 (31.6)

Total (95% CI)

93

Weight

Mean
Difference

100.0 %

2.00 [ -6.70, 10.70 ]

IV,Fixed,95% CI

IV,Fixed,95% CI

105

100.0 % 2.00 [ -6.70, 10.70 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Holistic assessment with standard care vs standard care, Outcome 3 Quality of
life: client satisfaction.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 8 Holistic assessment with standard care vs standard care
Outcome: 3 Quality of life: client satisfaction

Study or subgroup

Holistic Assessment

Mean
Difference

Standard care

N

Mean(SD)

N

Mean(SD)

Fletcher 2015

88

25.3 (4.9)

101

25.8 (4.9)

Total (95% CI)

88

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

100.0 %

-0.50 [ -1.90, 0.90 ]

100.0 % -0.50 [ -1.90, 0.90 ]

101

Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Dextrose saline vs normal saline rehydration, Outcome 1 Hours of hospital
admission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 9 Dextrose saline vs normal saline rehydration
Outcome: 1 Hours of hospital admission

Study or subgroup

Dextrose Saline

Tan 2013

Total (95% CI)

Mean
Difference

Normal Saline

N

Mean(SD)

N

Mean(SD)

102

43 (21)

101

48 (21)

102

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

100.0 %

101

-5.00 [ -10.78, 0.78 ]

100.0 % -5.00 [ -10.78, 0.78 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Pyridoxine vs placebo, Outcome 1 Number of episodes of emesis.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 1 Number of episodes of emesis

Study or subgroup

Pyridoxine

Tan 2009

Total (95% CI)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

33

1.9 (2.4)

33

1.4 (1.1)

33

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

33

100.0 %

0.50 [ -0.40, 1.40 ]

100.0 %

0.50 [ -0.40, 1.40 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Pyridoxine vs placebo, Outcome 2 Days of hospital admission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 2 Days of hospital admission

Study or subgroup

Pyridoxine

Tan 2009

Total (95% CI)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

47

3.9 (2.3)

45

3.1 (1)

47

Mean
Difference

Weight

IV,Fixed,95% CI

IV,Fixed,95% CI

45

100.0 %

0.80 [ 0.08, 1.52 ]

100.0 %

0.80 [ 0.08, 1.52 ]

Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Pyridoxine vs placebo, Outcome 3 Hospital readmission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 3 Hospital readmission

Study or subgroup

Tan 2009

Total (95% CI)

Pyridoxine

Placebo

n/N

n/N

Risk Ratio

Weight

15/40

8/38

100.0 %

1.78 [ 0.85, 3.71 ]

40

38

100.0 %

1.78 [ 0.85, 3.71 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 15 (Pyridoxine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Pyridoxine vs placebo, Outcome 4 Weight change (kg).
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 4 Weight change (kg)

Study or subgroup

Pyridoxine

Tan 2009

Total (95% CI)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

27

-0.8 (1.9)

25

-0.8 (1.5)

27

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

25

100.0 %

0.0 [ -0.93, 0.93 ]

100.0 %

0.0 [ -0.93, 0.93 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Pyridoxine vs placebo, Outcome 5 Interventions side effects: dizziness.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 5 Interventions side effects: dizziness

Study or subgroup

Tan 2009

Total (95% CI)

Pyridoxine

Placebo

n/N

n/N

Risk Ratio

Weight

15/33

9/33

100.0 %

1.67 [ 0.85, 3.26 ]

33

33

100.0 %

1.67 [ 0.85, 3.26 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 15 (Pyridoxine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 Pyridoxine vs placebo, Outcome 6 Interventions side effects: headaches.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 6 Interventions side effects: headaches

Study or subgroup

Tan 2009

Total (95% CI)

Pyridoxine

Placebo

n/N

n/N

Risk Ratio

Weight

8/33

6/33

100.0 %

1.33 [ 0.52, 3.42 ]

33

33

100.0 %

1.33 [ 0.52, 3.42 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 8 (Pyridoxine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 10.7. Comparison 10 Pyridoxine vs placebo, Outcome 7 Interventions side effects: diarrhea.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 7 Interventions side effects: diarrhea

Study or subgroup

Tan 2009

Total (95% CI)

Pyridoxine

Placebo

n/N

n/N

Risk Ratio

Weight

1/33

0/33

100.0 %

3.00 [ 0.13, 71.07 ]

33

33

100.0 %

3.00 [ 0.13, 71.07 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Pyridoxine), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable

0.002

0.1

Favours pyridoxine

1

10

500

Favours placebo

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

Analysis 10.8. Comparison 10 Pyridoxine vs placebo, Outcome 8 Interventions side effects: palpitations.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 8 Interventions side effects: palpitations

Study or subgroup

Tan 2009

Pyridoxine

Placebo

n/N

n/N

3/33

3/33

100.0 %

1.00 [ 0.22, 4.60 ]

33

33

100.0 %

1.00 [ 0.22, 4.60 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Pyridoxine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 10.9. Comparison 10 Pyridoxine vs placebo, Outcome 9 Interventions side effects: dry mouth.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 10 Pyridoxine vs placebo
Outcome: 9 Interventions side effects: dry mouth

Study or subgroup

Tan 2009

Total (95% CI)

Pyridoxine

Placebo

n/N

n/N

Risk Ratio

Weight

14/33

17/33

100.0 %

0.82 [ 0.49, 1.38 ]

33

33

100.0 %

0.82 [ 0.49, 1.38 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 14 (Pyridoxine), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 Metoclopramide vs ondansetron, Outcome 1 Severity of nausea.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 1 Severity of nausea

Study or subgroup

Metoclopramide

Mean
Difference

Ondansetron

N

Mean(SD)

N

Mean(SD)

Kashifard 2013

34

5.1 (3.4)

49

3.4 (5.2)

Total (95% CI)

34

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

100.0 %

49

1.70 [ -0.15, 3.55 ]

100.0 % 1.70 [ -0.15, 3.55 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Metoclopramide vs ondansetron, Outcome 2 Severity of vomiting.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 2 Severity of vomiting

Study or subgroup

Metoclopramide

Mean
Difference

Ondansetron

N

Mean(SD)

N

Mean(SD)

Kashifard 2013

34

4.7 (3.5)

49

4.8 (3.5)

Total (95% CI)

34

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

100.0 %

-0.10 [ -1.63, 1.43 ]

100.0 % -0.10 [ -1.63, 1.43 ]

49

Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Metoclopramide vs ondansetron, Outcome 3 Intervention side effects: felt
drowsy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 3 Intervention side effects: felt drowsy

Study or subgroup

Abas 2014

Total (95% CI)

Metoclopramide

Ondansetron

n/N

n/N

Risk Ratio

Weight

24/80

10/80

100.0 %

2.40 [ 1.23, 4.69 ]

80

80

100.0 %

2.40 [ 1.23, 4.69 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 24 (Metoclopramide), 10 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Metoclopramide vs ondansetron, Outcome 4 Intervention side effects: dry
mouth.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 4 Intervention side effects: dry mouth

Study or subgroup

Abas 2014

Total (95% CI)

Metoclopramide

Ondansetron

n/N

n/N

Risk Ratio

Weight

19/80

8/80

100.0 %

2.38 [ 1.10, 5.11 ]

80

80

100.0 %

2.38 [ 1.10, 5.11 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 19 (Metoclopramide), 8 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 11.5. Comparison 11 Metoclopramide vs ondansetron, Outcome 5 Intervention side effects:
unable to sleep.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 5 Intervention side effects: unable to sleep

Study or subgroup

Metoclopramide

Ondansetron

n/N

n/N

9/80

7/80

100.0 %

1.29 [ 0.50, 3.28 ]

80

80

100.0 %

1.29 [ 0.50, 3.28 ]

Abas 2014

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 9 (Metoclopramide), 7 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 Metoclopramide vs ondansetron, Outcome 6 Intervention side effects: felt
dizzy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 6 Intervention side effects: felt dizzy

Study or subgroup

Abas 2014

Total (95% CI)

Metoclopramide

Ondansetron

n/N

n/N

Risk Ratio

Weight

14/80

6/80

100.0 %

2.33 [ 0.94, 5.77 ]

80

80

100.0 %

2.33 [ 0.94, 5.77 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 14 (Metoclopramide), 6 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
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Analysis 11.7. Comparison 11 Metoclopramide vs ondansetron, Outcome 7 Intervention side effects:
diarrhea.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 7 Intervention side effects: diarrhea

Study or subgroup

Abas 2014

Metoclopramide

Ondansetron

n/N

n/N

4/80

0/80

100.0 %

9.00 [ 0.49, 164.46 ]

80

80

100.0 %

9.00 [ 0.49, 164.46 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 4 (Metoclopramide), 0 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 11.8. Comparison 11 Metoclopramide vs ondansetron, Outcome 8 Intervention side effects:
headache.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 8 Intervention side effects: headache

Study or subgroup

Abas 2014

Metoclopramide

Ondansetron

n/N

n/N

11/80

9/80

100.0 %

1.22 [ 0.54, 2.79 ]

80

80

100.0 %

1.22 [ 0.54, 2.79 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 11 (Metoclopramide), 9 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 11.9. Comparison 11 Metoclopramide vs ondansetron, Outcome 9 Intervention side effects:
palpitations.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 9 Intervention side effects: palpitations

Study or subgroup

Metoclopramide

Ondansetron

n/N

n/N

5/80

2/80

100.0 %

2.50 [ 0.50, 12.51 ]

80

80

100.0 %

2.50 [ 0.50, 12.51 ]

Abas 2014

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 5 (Metoclopramide), 2 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable

0.01
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Favours metoclopramide

10

100

Favours ondansetron

Analysis 11.10. Comparison 11 Metoclopramide vs ondansetron, Outcome 10 Intervention side effects: skin
rash.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 10 Intervention side effects: skin rash

Study or subgroup

Metoclopramide

Ondansetron

n/N

n/N

1/80

1/80

100.0 %

1.00 [ 0.06, 15.71 ]

80

80

100.0 %

1.00 [ 0.06, 15.71 ]

Abas 2014

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Metoclopramide), 1 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 11.11. Comparison 11 Metoclopramide vs ondansetron, Outcome 11 Intervention side effects:
dystonia.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 11 Intervention side effects: dystonia

Study or subgroup

Metoclopramide

Ondansetron

n/N

n/N

0/80

0/80

Not estimable

80

80

Not estimable

Abas 2014

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Metoclopramide), 0 (Ondansetron)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable

0.01
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1

10

Favours metoclopramide

100

Favours ondansetron

Analysis 11.12. Comparison 11 Metoclopramide vs ondansetron, Outcome 12 Quality of life.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 11 Metoclopramide vs ondansetron
Outcome: 12 Quality of life

Study or subgroup

Metoclopramide

Abas 2014

Total (95% CI)

Mean
Difference

Ondansetron

N

Mean(SD)

N

Mean(SD)

80

8.3 (1.6)

80

8.7 (1.1)

80

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

100.0 %

-0.40 [ -0.83, 0.03 ]

100.0 % -0.40 [ -0.83, 0.03 ]

80

Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
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Analysis 12.1. Comparison 12 Hydrocortisone vs metoclopramide, Outcome 1 Hospital readmission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 12 Hydrocortisone vs metoclopramide
Outcome: 1 Hospital readmission

Study or subgroup

Hydrocortisone

Metoclopramide

n/N

n/N

Risk Ratio

Weight

Bondok 2006

0/20

6/20

100.0 %

0.08 [ 0.00, 1.28 ]

Total (95% CI)

20

20

100.0 %

0.08 [ 0.00, 1.28 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Hydrocortisone), 6 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
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Favours hydrocortisone

10

500
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Analysis 12.2. Comparison 12 Hydrocortisone vs metoclopramide, Outcome 2 Need for enteral or
parenteral nutrition.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 12 Hydrocortisone vs metoclopramide
Outcome: 2 Need for enteral or parenteral nutrition

Study or subgroup

Hydrocortisone

Metoclopramide

n/N

n/N

Risk Ratio

Weight

Bondok 2006

0/20

1/20

100.0 %

0.33 [ 0.01, 7.72 ]

Total (95% CI)

20

20

100.0 %

0.33 [ 0.01, 7.72 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Hydrocortisone), 1 (Metoclopramide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 13.1. Comparison 13 Metoclopramide vs promethazine, Outcome 1 Quality of life.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 1 Quality of life

Study or subgroup

Metoclopramide

Tan 2010

Total (95% CI)

Mean
Difference

Promethazine

N

Mean(SD)

N

Mean(SD)

73

7.6 (2.2)

76

7.1 (2.3)

73

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

100.0 %

0.50 [ -0.22, 1.22 ]

100.0 % 0.50 [ -0.22, 1.22 ]

76

Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.18)
Test for subgroup differences: Not applicable
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Favours promethazine
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Analysis 13.2. Comparison 13 Metoclopramide vs promethazine, Outcome 2 Intervention side effects:
unable to sleep.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 2 Intervention side effects: unable to sleep

Study or subgroup

Tan 2010

Metoclopramide

Promethazine

n/N

n/N

12/70

16/73

100.0 %

0.78 [ 0.40, 1.53 ]

70

73

100.0 %

0.78 [ 0.40, 1.53 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 12 (Metoclopramide), 16 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Metoclopramide vs promethazine, Outcome 3 Intervention side effects: dry
mouth.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 3 Intervention side effects: dry mouth

Study or subgroup

Tan 2010

Metoclopramide

Promethazine

n/N

n/N

28/70

32/73

100.0 %

0.91 [ 0.62, 1.34 ]

70

73

100.0 %

0.91 [ 0.62, 1.34 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 28 (Metoclopramide), 32 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Metoclopramide vs promethazine, Outcome 4 Intervention side effects:
diarrhea.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 4 Intervention side effects: diarrhea

Study or subgroup

Tan 2010

Metoclopramide

Promethazine

n/N

n/N

4/70

3/73

100.0 %

1.39 [ 0.32, 5.99 ]

70

73

100.0 %

1.39 [ 0.32, 5.99 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 4 (Metoclopramide), 3 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 13.5. Comparison 13 Metoclopramide vs promethazine, Outcome 5 Intervention side effects:
headache.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 5 Intervention side effects: headache

Study or subgroup

Tan 2010

Metoclopramide

Promethazine

n/N

n/N

17/70

22/73

100.0 %

0.81 [ 0.47, 1.38 ]

70

73

100.0 %

0.81 [ 0.47, 1.38 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 17 (Metoclopramide), 22 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 13.6. Comparison 13 Metoclopramide vs promethazine, Outcome 6 Intervention side effects:
palpitations.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 6 Intervention side effects: palpitations

Study or subgroup

Tan 2010

Metoclopramide

Promethazine

n/N

n/N

7/70

12/73

100.0 %

0.61 [ 0.25, 1.46 ]

70

73

100.0 %

0.61 [ 0.25, 1.46 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 7 (Metoclopramide), 12 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 13.7. Comparison 13 Metoclopramide vs promethazine, Outcome 7 Intervention side effects: skin
rash.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 7 Intervention side effects: skin rash

Study or subgroup

Tan 2010

Metoclopramide

Promethazine

n/N

n/N

4/70

3/73

100.0 %

1.39 [ 0.32, 5.99 ]

70

73

100.0 %

1.39 [ 0.32, 5.99 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 4 (Metoclopramide), 3 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Favours metoclopramide

10

200
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Analysis 13.8. Comparison 13 Metoclopramide vs promethazine, Outcome 8 Intervention side effects:
drowsy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 8 Intervention side effects: drowsy

Study or subgroup

Tan 2010

Total (95% CI)

Metoclopramide

Promethazine

n/N

n/N

Risk Ratio

Weight

41/70

61/73

100.0 %

0.70 [ 0.56, 0.87 ]

70

73

100.0 %

0.70 [ 0.56, 0.87 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 41 (Metoclopramide), 61 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Not applicable
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Analysis 13.9. Comparison 13 Metoclopramide vs promethazine, Outcome 9 Intervention side effects: felt
dizzy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 9 Intervention side effects: felt dizzy

Study or subgroup

Tan 2010

Total (95% CI)

Metoclopramide

Promethazine

n/N

n/N

Risk Ratio

Weight

24/70

52/73

100.0 %

0.48 [ 0.34, 0.69 ]

70

73

100.0 %

0.48 [ 0.34, 0.69 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 24 (Metoclopramide), 52 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 4.03 (P = 0.000056)
Test for subgroup differences: Not applicable
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Analysis 13.10. Comparison 13 Metoclopramide vs promethazine, Outcome 10 Intervention side effects:
dystonia.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 13 Metoclopramide vs promethazine
Outcome: 10 Intervention side effects: dystonia

Study or subgroup

Tan 2010

Total (95% CI)

Metoclopramide

Promethazine

n/N

n/N

Risk Ratio

Weight

4/70

14/76

100.0 %

0.31 [ 0.11, 0.90 ]

70

76

100.0 %

0.31 [ 0.11, 0.90 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 4 (Metoclopramide), 14 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 1 Days of hospital admission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 1 Days of hospital admission

Study or subgroup

Parenteral
fluid+diazepam

Ditto 1999

Total (95% CI)

Parenteral
fluid alone

Mean
Difference

N

Mean(SD)

N

Mean(SD)

25

4.5 (1.9)

25

5.6 (1.6)

25

Weight

Mean
Difference

100.0 %

-1.10 [ -2.07, -0.13 ]

100.0 %

-1.10 [ -2.07, -0.13 ]

IV,Fixed,95% CI

IV,Fixed,95% CI

25

Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 14.2. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 2 Hospital readmission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 2 Hospital readmission

Study or subgroup

Ditto 1999

Total (95% CI)

Parenteral
fluid+diazepam

Parenteral
fluid alone

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio

n/N

n/N

M-H,Fixed,95% CI

1/25

6/25

100.0 %

0.17 [ 0.02, 1.29 ]

25

25

100.0 %

0.17 [ 0.02, 1.29 ]

Total events: 1 (Parenteral fluid+diazepam), 6 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 3 Women requiring additional antiemetics.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 3 Women requiring additional antiemetics

Study or subgroup

Parenteral
fluid+diazepam

Ditto 1999

Total (95% CI)

Parenteral
fluid alone

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio

n/N

n/N

M-H,Fixed,95% CI

1/25

2/25

100.0 %

0.50 [ 0.05, 5.17 ]

25

25

100.0 %

0.50 [ 0.05, 5.17 ]

Total events: 1 (Parenteral fluid+diazepam), 2 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable

0.005

0.1

1

Favours fluid+diazepam

10

200

Favours fluid alone

Analysis 14.4. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 4 Congenital anomalies.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 4 Congenital anomalies

Study or subgroup

Parenteral
fluid+diazepam

Ditto 1999

Total (95% CI)

Parenteral
fluid alone

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio

n/N

n/N

M-H,Fixed,95% CI

0/25

0/25

Not estimable

25

25

Not estimable

Total events: 0 (Parenteral fluid+diazepam), 0 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 14.5. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 5 Preterm birth.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 5 Preterm birth

Study or subgroup

Ditto 1999

Total (95% CI)

Parenteral
fluid+diazepam

Parenteral
fluid alone

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio

n/N

n/N

M-H,Fixed,95% CI

1/25

2/25

100.0 %

0.50 [ 0.05, 5.17 ]

25

25

100.0 %

0.50 [ 0.05, 5.17 ]

Total events: 1 (Parenteral fluid+diazepam), 2 (Parenteral fluid alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable

0.002
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Favours fluid+diazepam

10

500
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Analysis 14.6. Comparison 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam,
Outcome 6 Decision to terminate the pregnancy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 14 Parenteral fluid with diazepam vs parenteral fluid without diazepam
Outcome: 6 Decision to terminate the pregnancy

Study or subgroup

Ditto 1999

Total (95% CI)

Parenteral
fluid+diazepam

Parenteral fluid

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio

n/N

n/N

M-H,Fixed,95% CI

1/25

0/25

100.0 %

3.00 [ 0.13, 70.30 ]

25

25

100.0 %

3.00 [ 0.13, 70.30 ]

Total events: 1 (Parenteral fluid+diazepam), 0 (Parenteral fluid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 15.1. Comparison 15 Ondansetron vs promethazine, Outcome 1 Days of hospital admission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 15 Ondansetron vs promethazine
Outcome: 1 Days of hospital admission

Study or subgroup

Ondansetron

Mean
Difference

Promethazine

N

Mean(SD)

N

Mean(SD)

Sullivan 1996

15

4.47 (2.3)

15

4.47 (1.5)

Total (95% CI)

15

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

15

100.0 %

0.0 [ -1.39, 1.39 ]

100.0 %

0.0 [ -1.39, 1.39 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 15.2. Comparison 15 Ondansetron vs promethazine, Outcome 2 Intervention side effect: sedation.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 15 Ondansetron vs promethazine
Outcome: 2 Intervention side effect: sedation

Study or subgroup

Ondansetron

Promethazine

n/N

n/N

Risk Ratio

Weight

Sullivan 1996

0/15

8/15

100.0 %

0.06 [ 0.00, 0.94 ]

Total (95% CI)

15

15

100.0 %

0.06 [ 0.00, 0.94 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Ondansetron), 8 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.045)
Test for subgroup differences: Not applicable
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Analysis 16.1. Comparison 16 Corticosteroids vs promethazine, Outcome 1 Severe nausea 48 hours.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 1 Severe nausea 48 hours

Study or subgroup

Ziaei 2004

Prednisolone

Promethazine

n/N

n/N

20/40

10/40

100.0 %

2.00 [ 1.08, 3.72 ]

40

40

100.0 %

2.00 [ 1.08, 3.72 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 20 (Prednisolone), 10 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 16.2. Comparison 16 Corticosteroids vs promethazine, Outcome 2 Severe nausea 17th day.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 2 Severe nausea 17th day

Study or subgroup

Ziaei 2004

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

22/39

27/39

100.0 %

0.81 [ 0.58, 1.15 ]

39

39

100.0 %

0.81 [ 0.58, 1.15 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 22 (Prednisolone), 27 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 16.3. Comparison 16 Corticosteroids vs promethazine, Outcome 3 Episodes of vomiting 48 hours.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 3 Episodes of vomiting 48 hours

Study or subgroup

Ziaei 2004

Prednisolone

Promethazine

n/N

n/N

3/40

1/40

100.0 %

3.00 [ 0.33, 27.63 ]

40

40

100.0 %

3.00 [ 0.33, 27.63 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Prednisolone), 1 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Favours prednisolone

10
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Favours promethazine

Analysis 16.4. Comparison 16 Corticosteroids vs promethazine, Outcome 4 Episodes of vomiting 17th day.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 4 Episodes of vomiting 17th day

Study or subgroup

Ziaei 2004

Prednisolone

Promethazine

n/N

n/N

3/39

3/39

100.0 %

1.00 [ 0.21, 4.65 ]

39

39

100.0 %

1.00 [ 0.21, 4.65 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Prednisolone), 3 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 16.5. Comparison 16 Corticosteroids vs promethazine, Outcome 5 Therapy failure in 2 days.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 5 Therapy failure in 2 days

Study or subgroup

Prednisolone

Promethazine

n/N

n/N

3/20

2/20

100.0 %

1.50 [ 0.28, 8.04 ]

20

20

100.0 %

1.50 [ 0.28, 8.04 ]

Safari 1998

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Prednisolone), 2 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Favour prednisolone

10

500
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Analysis 16.6. Comparison 16 Corticosteroids vs promethazine, Outcome 6 Hospital readmission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 6 Hospital readmission

Study or subgroup

Safari 1998

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

0/17

5/17

100.0 %

0.09 [ 0.01, 1.53 ]

17

17

100.0 %

0.09 [ 0.01, 1.53 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Prednisolone), 5 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
Test for subgroup differences: Not applicable
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Analysis 16.7. Comparison 16 Corticosteroids vs promethazine, Outcome 7 Number of women requiring
additional antiemetics.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 7 Number of women requiring additional antiemetics

Study or subgroup

Safari 1998

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

3/20

2/20

100.0 %

1.50 [ 0.28, 8.04 ]

20

20

100.0 %

1.50 [ 0.28, 8.04 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 3 (Prednisolone), 2 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable

0.002

0.1

1

Favour prednisolone

10

500

Favours promethazine

Analysis 16.8. Comparison 16 Corticosteroids vs promethazine, Outcome 8 Stillbirth and neonatal death.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 8 Stillbirth and neonatal death

Study or subgroup

Safari 1998

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

1/20

0/20

100.0 %

3.00 [ 0.13, 69.52 ]

20

20

100.0 %

3.00 [ 0.13, 69.52 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Prednisolone), 0 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 16.9. Comparison 16 Corticosteroids vs promethazine, Outcome 9 Preterm birth.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 9 Preterm birth

Study or subgroup

Safari 1998

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

1/20

0/20

100.0 %

3.00 [ 0.13, 69.52 ]

20

20

100.0 %

3.00 [ 0.13, 69.52 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Prednisolone), 0 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable

0.002
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1

Favour prednisolone

10

500

Favour promethazine

Analysis 16.10. Comparison 16 Corticosteroids vs promethazine, Outcome 10 Decision to terminate the
pregnancy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 10 Decision to terminate the pregnancy

Study or subgroup

Safari 1998

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

1/20

0/20

100.0 %

3.00 [ 0.13, 69.52 ]

20

20

100.0 %

3.00 [ 0.13, 69.52 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Prednisolone), 0 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 16.11. Comparison 16 Corticosteroids vs promethazine, Outcome 11 Intevention side effects:
abdominal pain 48 hours.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 11 Intevention side effects: abdominal pain 48 hours

Study or subgroup

Ziaei 2004

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

2/40

6/40

100.0 %

0.33 [ 0.07, 1.55 ]

40

40

100.0 %

0.33 [ 0.07, 1.55 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 2 (Prednisolone), 6 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable

0.002

0.1

1

Favours prednisolone

10

500

Favours promethazine

Analysis 16.12. Comparison 16 Corticosteroids vs promethazine, Outcome 12 Intervention side effects:
abdominal pain 3-10 days.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 12 Intervention side effects: abdominal pain 3-10 days

Study or subgroup

Ziaei 2004

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

0/40

4/40

100.0 %

0.11 [ 0.01, 2.00 ]

40

40

100.0 %

0.11 [ 0.01, 2.00 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Prednisolone), 4 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 16.13. Comparison 16 Corticosteroids vs promethazine, Outcome 13 Intervention side effects:
drowsiness 48 hours and 3-10 days.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 13 Intervention side effects: drowsiness 48 hours and 3-10 days

Study or subgroup

Ziaei 2004

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

0/40

6/40

100.0 %

0.08 [ 0.00, 1.32 ]

40

40

100.0 %

0.08 [ 0.00, 1.32 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Prednisolone), 6 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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1

Favours prednisolone

10

500

Favours promethazine

Analysis 16.14. Comparison 16 Corticosteroids vs promethazine, Outcome 14 Became completely or
partially well 48 hours.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 14 Became completely or partially well 48 hours

Study or subgroup

Ziaei 2004

Total (95% CI)

Prednisolone

Promethazine

n/N

n/N

Risk Ratio

Weight

20/40

30/40

100.0 %

0.67 [ 0.47, 0.95 ]

40

40

100.0 %

0.67 [ 0.47, 0.95 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 20 (Prednisolone), 30 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 16.15. Comparison 16 Corticosteroids vs promethazine, Outcome 15 Became completely or
partially well 17th day.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 16 Corticosteroids vs promethazine
Outcome: 15 Became completely or partially well 17th day

Study or subgroup

Ziaei 2004

Prednisolone

Promethazine

n/N

n/N

20/39

12/39

100.0 %

1.67 [ 0.95, 2.92 ]

39

39

100.0 %

1.67 [ 0.95, 2.92 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 20 (Prednisolone), 12 (Promethazine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable

0.002

0.1

Favours promethazine
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10

500

Favours prednisolone

Analysis 17.1. Comparison 17 Corticosteroids vs placebo, Outcome 1 Days of hospital admission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 1 Days of hospital admission

Study or subgroup

Corticosteroids

Yost 2003

Total (95% CI)

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

56

1.9 (0.9)

54

2.2 (1.2)

56

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

54

100.0 %

-0.30 [ -0.70, 0.10 ]

100.0 %

-0.30 [ -0.70, 0.10 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 17.2. Comparison 17 Corticosteroids vs placebo, Outcome 2 Hospital readmission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 2 Hospital readmission

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

Risk Ratio

Weight

Duggar 2001

1/14

4/25

4.9 %

0.45 [ 0.06, 3.61 ]

Nelson-Piercy 2001

5/12

8/12

13.7 %

0.63 [ 0.29, 1.36 ]

Yost 2003

19/56

19/54

33.2 %

0.96 [ 0.58, 1.61 ]

Tabatabaii 2008

15/48

28/48

48.1 %

0.54 [ 0.33, 0.87 ]

Total (95% CI)

130

139

100.0 %

0.69 [ 0.50, 0.94 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 40 (Corticosteroids), 59 (Placebo)
Heterogeneity: Chi2 = 2.91, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
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Favours corticosteroids

10

500
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Analysis 17.3. Comparison 17 Corticosteroids vs placebo, Outcome 3 Pregnancy complications.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 3 Pregnancy complications

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

7/56

11/54

100.0 %

0.61 [ 0.26, 1.47 ]

56

54

100.0 %

0.61 [ 0.26, 1.47 ]

Yost 2003

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 7 (Corticosteroids), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 17.4. Comparison 17 Corticosteroids vs placebo, Outcome 4 Spontaneous abortion.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 4 Spontaneous abortion

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

2/56

3/54

100.0 %

0.64 [ 0.11, 3.70 ]

56

54

100.0 %

0.64 [ 0.11, 3.70 ]

Yost 2003

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 2 (Corticosteroids), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 17.5. Comparison 17 Corticosteroids vs placebo, Outcome 5 Stillbirth and neonatal death.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 5 Stillbirth and neonatal death

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

Nelson-Piercy 2001

1/12

3/12

85.5 %

0.33 [ 0.04, 2.77 ]

Yost 2003

1/56

0/54

14.5 %

2.89 [ 0.12, 69.55 ]

68

66

100.0 %

0.70 [ 0.15, 3.34 ]

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 2 (Corticosteroids), 3 (Placebo)
Heterogeneity: Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 17.6. Comparison 17 Corticosteroids vs placebo, Outcome 6 Congenital abnormalities.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 6 Congenital abnormalities

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

0/56

1/54

100.0 %

0.32 [ 0.01, 7.73 ]

56

54

100.0 %

0.32 [ 0.01, 7.73 ]

Yost 2003

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 17.7. Comparison 17 Corticosteroids vs placebo, Outcome 7 Low birthweight.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 7 Low birthweight

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

7/56

5/54

100.0 %

1.35 [ 0.46, 4.00 ]

56

54

100.0 %

1.35 [ 0.46, 4.00 ]

Yost 2003

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 7 (Corticosteroids), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable

0.1 0.2

0.5

1

Favours corticosteroids

2

5

10

Favours placebo

Analysis 17.8. Comparison 17 Corticosteroids vs placebo, Outcome 8 Small-for-gestational age.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 8 Small-for-gestational age

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

1/12

1/12

100.0 %

1.00 [ 0.07, 14.21 ]

12

12

100.0 %

1.00 [ 0.07, 14.21 ]

Nelson-Piercy 2001

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable

0.002

0.1

Favours corticosteroids

1

10

500

Favours placebo

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

Analysis 17.9. Comparison 17 Corticosteroids vs placebo, Outcome 9 Preterm birth.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 9 Preterm birth

Study or subgroup

Corticosteroids

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Nelson-Piercy 2001

2/12

4/12

42.4 %

0.50 [ 0.11, 2.23 ]

Yost 2003

7/56

4/54

57.6 %

1.69 [ 0.52, 5.44 ]

68

66

100.0 %

1.01 [ 0.31, 3.28 ]

Total (95% CI)
Total events: 9 (Corticosteroids), 8 (Placebo)

Heterogeneity: Tau2 = 0.27; Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 17.10. Comparison 17 Corticosteroids vs placebo, Outcome 10 Intervention side effects.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 10 Intervention side effects

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

Risk Ratio

Weight

Duggar 2001

1/14

1/11

100.0 %

0.79 [ 0.06, 11.20 ]

Total (95% CI)

14

11

100.0 %

0.79 [ 0.06, 11.20 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 17.11. Comparison 17 Corticosteroids vs placebo, Outcome 11 Women requiring additional
antiemetic drugs.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 11 Women requiring additional antiemetic drugs

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

5/12

9/12

100.0 %

0.56 [ 0.26, 1.17 ]

12

12

100.0 %

0.56 [ 0.26, 1.17 ]

Nelson-Piercy 2001

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 5 (Corticosteroids), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 17.12. Comparison 17 Corticosteroids vs placebo, Outcome 12 Decision to terminate the
pregnancy.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 17 Corticosteroids vs placebo
Outcome: 12 Decision to terminate the pregnancy

Study or subgroup

Corticosteroids

Placebo

n/N

n/N

0/12

1/12

100.0 %

0.33 [ 0.01, 7.45 ]

12

12

100.0 %

0.33 [ 0.01, 7.45 ]

Nelson-Piercy 2001

Total (95% CI)

Risk Ratio

Weight

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 0 (Corticosteroids), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 ACTH vs placebo, Outcome 1 Reduction or cessation in nausea/vomiting.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 18 ACTH vs placebo
Outcome: 1 Reduction or cessation in nausea/vomiting

Study or subgroup

ACTH

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

Ylikorkala 1979

16

9.4 (3.4)

16

8.8 (3.1)

Total (95% CI)

16

Mean
Difference

Weight

IV,Fixed,95% CI

IV,Fixed,95% CI

16

100.0 %

0.60 [ -1.65, 2.85 ]

100.0 %

0.60 [ -1.65, 2.85 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 18.2. Comparison 18 ACTH vs placebo, Outcome 2 Weight gain (kg).
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 18 ACTH vs placebo
Outcome: 2 Weight gain (kg)

Study or subgroup

ACTH

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

Ylikorkala 1979

16

2.5 (0.9)

16

1.5 (1)

Total (95% CI)

16

Weight

IV,Fixed,95% CI

Mean
Difference
IV,Fixed,95% CI

16

100.0 %

1.00 [ 0.34, 1.66 ]

100.0 %

1.00 [ 0.34, 1.66 ]

Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Not applicable

-10

-5

Favours placebo
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Analysis 18.3. Comparison 18 ACTH vs placebo, Outcome 3 Hospital readmission.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 18 ACTH vs placebo
Outcome: 3 Hospital readmission

Study or subgroup

ACTH

Placebo

n/N

n/N

Risk Ratio

Weight

Ylikorkala 1979

2/16

2/16

100.0 %

1.00 [ 0.16, 6.25 ]

Total (95% CI)

16

16

100.0 %

1.00 [ 0.16, 6.25 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 2 (ACTH), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable

0.005

0.1

1

Favours ACTH

10

200

Favours placebo

Analysis 18.4. Comparison 18 ACTH vs placebo, Outcome 4 Spontaneous abortion.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 18 ACTH vs placebo
Outcome: 4 Spontaneous abortion

Study or subgroup

ACTH

Placebo

n/N

n/N

Risk Ratio

Weight

Ylikorkala 1979

1/16

1/16

100.0 %

1.00 [ 0.07, 14.64 ]

Total (95% CI)

16

16

100.0 %

1.00 [ 0.07, 14.64 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (ACTH), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable

0.005

0.1

Favours ACTH

1

10

200

Favours placebo
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Analysis 18.5. Comparison 18 ACTH vs placebo, Outcome 5 Preterm birth.
Review:

Interventions for treating hyperemesis gravidarum

Comparison: 18 ACTH vs placebo
Outcome: 5 Preterm birth

Study or subgroup

ACTH

Placebo

n/N

n/N

Risk Ratio

Weight

Ylikorkala 1979

1/16

0/16

100.0 %

3.00 [ 0.13, 68.57 ]

Total (95% CI)

16

16

100.0 %

3.00 [ 0.13, 68.57 ]

M-H,Fixed,95% CI

Risk Ratio
M-H,Fixed,95% CI

Total events: 1 (ACTH), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable

0.002

0.1

Favours ACTH

1

10

500

Favours placebo

APPENDICES
Appendix 1. Cochrane Complementary and Alternative Therapies Field Register search
Searched by the Information Specialist (20 September 2014) and then via The Cochrane Register of Studies (CRSO) (20 December
2015)
(pregnan* OR antenatal OR prenatal) AND (nause* OR sickness OR vomit* OR emesis OR hyperemisis OR antiemetic)

WHAT’S NEW
Last assessed as up-to-date: 20 December 2015.

Date

Event

Description

19 May 2016

Amended

We have edited the plain language title to include a plain language description of hyperemesis gravidarum
- severe nausea and vomiting during pregnancy
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
We edited one of our primary outcomes from ’Reduction or cessation in nausea/vomiting’ to ’Severity, reduction or cessation in nausea/
vomiting’ because it was found that this was often what was reported.
We edited one of our secondary outcomes from ’Number of antiemetics required’ to ’Number of women requiring additional antiemetics,’ again because this outcome was more often reported than number of antiemetics.

Interventions for treating hyperemesis gravidarum (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

